KR810000355B1 - Preparation for pharmacologically active compounds - Google Patents

Preparation for pharmacologically active compounds Download PDF

Info

Publication number
KR810000355B1
KR810000355B1 KR7701808A KR770001808A KR810000355B1 KR 810000355 B1 KR810000355 B1 KR 810000355B1 KR 7701808 A KR7701808 A KR 7701808A KR 770001808 A KR770001808 A KR 770001808A KR 810000355 B1 KR810000355 B1 KR 810000355B1
Authority
KR
South Korea
Prior art keywords
methyl
furanyl
thio
dimethylamino
ethyl
Prior art date
Application number
KR7701808A
Other languages
Korean (ko)
Inventor
죤 프라이스 바리
왓트슨 트리더로우 죤
브라드셔 죤
Original Assignee
아롤드 월터 마틴
알렌 앤드 한버리스 리밋티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB32465/76A priority Critical patent/GB1565966A/en
Priority to CY1277A priority patent/CY1077A/en
Priority to FI772264A priority patent/FI72318C/en
Priority to GB28187/78A priority patent/GB1565967A/en
Priority to IE1536/77A priority patent/IE45456B1/en
Priority to US05/818,762 priority patent/US4128658A/en
Priority to SE7708521A priority patent/SE437373B/en
Priority to DK337977A priority patent/DK148258C/en
Priority to NZ184759A priority patent/NZ184759A/en
Priority to NZ191383A priority patent/NZ191383A/en
Priority to DE2760097A priority patent/DE2760097C2/de
Priority to DE2734070A priority patent/DE2734070C2/en
Priority to DE2759959A priority patent/DE2759959C2/de
Priority to CH938077A priority patent/CH642072A5/en
Priority to CA283,694A priority patent/CA1099268A/en
Priority to PT66874A priority patent/PT66874B/en
Priority to AU27519/77A priority patent/AU515628B2/en
Priority to BE179834A priority patent/BE857388A/en
Priority to PH20057A priority patent/PH13540A/en
Priority to YU1911/77A priority patent/YU40006B/en
Priority to LU77911A priority patent/LU77911A1/en
Priority to ES461334A priority patent/ES461334A1/en
Priority to IT50551/77A priority patent/IT1126759B/en
Priority to NLAANVRAGE7708601,A priority patent/NL178320C/en
Application filed by 아롤드 월터 마틴, 알렌 앤드 한버리스 리밋티드 filed Critical 아롤드 월터 마틴
Priority to JP52093722A priority patent/JPS5840956B2/en
Priority to KR7701808A priority patent/KR810000355B1/en
Priority to FR7724021A priority patent/FR2360587B1/en
Priority to AT0574077A priority patent/AT375931B/en
Priority to CH1229/84A priority patent/CH651560A5/en
Priority to FR7814251A priority patent/FR2384753B1/en
Priority to FR7814250A priority patent/FR2384765B1/en
Priority to ES470836A priority patent/ES470836A1/en
Priority to US05/951,025 priority patent/US4279819A/en
Priority to US05/951,024 priority patent/US4169855A/en
Priority to US05/951,026 priority patent/US4255440A/en
Priority to JP3601580A priority patent/JPS55153761A/en
Priority to JP3601680A priority patent/JPS55153779A/en
Priority to AT0322880A priority patent/AT381937B/en
Priority to KE3080A priority patent/KE3080A/en
Priority to HK557/80A priority patent/HK55780A/en
Application granted granted Critical
Publication of KR810000355B1 publication Critical patent/KR810000355B1/en
Priority to MY172/81A priority patent/MY8100172A/en
Priority to FI821570A priority patent/FI80687C/en
Priority to NLAANVRAGE8202659,A priority patent/NL184219C/en
Priority to CH509282A priority patent/CH641176A5/en
Priority to YU2000/82A priority patent/YU40088B/en
Priority to DK427282A priority patent/DK149813C/en
Priority to DK427182A priority patent/DK149812C/en
Priority to SE8205533A priority patent/SE454882B/en
Priority to SE8205962A priority patent/SE8205962L/en
Priority to SE8206061A priority patent/SE8206061D0/en
Priority to SE8206556A priority patent/SE454883B/en
Priority to DK416384A priority patent/DK149952C/en
Priority to IT48437/85A priority patent/IT1221058B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40Radicals substituted by oxygen atoms
    • C07D307/46Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03BMANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B37/00Manufacture or treatment of flakes, fibres, or filaments from softened glass, minerals, or slags
    • C03B37/07Controlling or regulating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Manufacturing & Machinery (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surface Treatment Of Glass Fibres Or Filaments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Title compds. (I; R1 and R2 are same or not, H, lower alkyl, cycloalkyl, lower alkenyl, aralkyl; R3 = H, lower alkyl, lower alkenyl or alkoxyalkyl; X = -CH2, O or S; Y = =S, =O, =NR5 or CHR6; Alk = C1-6 alkylene; R5 = H, nitro, cyano, lower alkyl, aryl, alkylsulfonyl or arylsulfonyl; R6 = nitro, arylsulfonyl, alkylsulfonyl; m = 2-4; n = 1-2) were prepd. by the reaction of compd. II(A = H or IV(P = separating group; Q = =NR5 or -CHR6; or A and B are =CS) and III(Z = H, Z' = H or IV; or Z and Z' are =CO or =CS).

Description

아미노 알킬푸란 유도체의 제조방법Method for preparing amino alkylfuran derivative

본 발명은 히스타민 접수체에 선택적으로 작용하는 신규한 아미노알킬푸란 유도체를 제조하는 방법에 관한 것이다.The present invention relates to a process for the preparation of novel aminoalkylfuran derivatives which selectively act on histamine acceptors.

에쉬와 쉴드씨 및 블랙씨등은 히스타민 접수체(H-접수체)를 H1-접수체와 H2-접수체로 세분하였다.Ash, Shield, Black, etc. subdivided histamine receptors (H-receptors) into H 1 -receptors and H 2 -receptors.

(에쉬와 쉴드끼에 의한 분류는 「Brit.J.Pharmacol. Chemother, 1966,

Figure kpo00001
, 427」을 참고로 하고, 블랙씨등에 의한 분류는 「Nature 1972,
Figure kpo00002
, 385」를 참고로 할 것.)(Classification by Ash and the shield `` Brit. J. Pharmacol. Chemother, 1966,
Figure kpo00001
427 '', and the classification by Mr. Black is `` Nature 1972,
Figure kpo00002
, 385 ”.)

기관지와 위장평활근의 자극은 H1-접수체를 통해서 조정되며 이러한 영향은 메피라진 같은 종래의 히스타민 길항제에 의해서 예방될수 있었다. 위산분비나 심박동수의 자극은 H2-접수체를 통해서 조정되는데 이러한 영향은 메피라진으로는 완화되지 않고 메티아미드 같은 H2-길항제에 의해서 예방되거나 사라지게 된다. 히스타민은 H1-접수체와 H2-접수체를 자극한다.Stimulation of bronchial and gastrointestinal smooth muscle is regulated through the H 1 -receptor and this effect could be prevented by conventional histamine antagonists such as mepyrazine. Stimulation of gastric acid secretion or heart rate is controlled through H 2 -receptors, which are not alleviated by mepyrazine but are prevented or eliminated by H 2 -antagonists such as metiamide. Histamine stimulates H 1 -receptors and H 2 -receptors.

본 발명인은, 몇몇 새로운 아미노알킬푸란 유도체들이 선택적인 H2-길항제로서 작용을 하기 때문에 히스타민 H2-접수체들이 위산의 분비를 자극할때에는 본 발명의 아미노알킬푸란 유도체들이 위산의 분비를 방해한다는 사실을 발견하였다.The inventors have found that the aminoalkylfuran derivatives of the present invention interfere with the secretion of gastric acid when the histamine H 2 -receptors stimulate the secretion of gastric acid because some new aminoalkylfuran derivatives act as selective H 2 -antagonists. I found the facts.

히스타민 H2-접수체들이 위산의 분비를 자극할 때 위산의 분비를 방해하는 이들의 능력은 고쉬와 쉴드가 기술한 방법(Brit.J.Pharmacol. 1958

Figure kpo00003
54)을 후술하는 바와같이 수정해서 사용함으로써 관류(灌流, perfuse)된 쥐의 위장에서 증명되고, 블랙씨 등이 기술한 동일한 방법(Nature 1972 236,385)을 사용하여 하이덴하인 소위가 장치된 의식이 있는 개에서 증명될수 있다.Their ability to interfere with gastric acid secretion when histamine H 2 -receptors stimulate gastric acid secretion is described by Gash and Shield (Brit. J. Pharmacol. 1958).
Figure kpo00003
54, which is demonstrated in the perfused rat's stomach by using a modified version, as described below, and equipped with the so-called HEIDENHAIN using the same method described by Mr. Black et al. (Nature 1972 236,385). It can be proved in dogs.

본 발명에 의한 화합물은 분리된 위장평활근의 수축으로 유발되는 히스타민을 조절하지 않는다.The compounds according to the invention do not modulate histamine caused by contraction of isolated gastrointestinal smooth muscle.

히스타민 H2-차단작용을 하는 화합물은 위궤양이나 소화성궤양 같이 위산이 과도로 분비되는 상태를 치료할때나 또는 히스타민이 공지된 조정기로서 작용하는 알레르기 상태를 치료할 때 사용될수 있다. 이들 화합물은 단독으로 사용되거나 또는 다른 활성성분과 혼합된 상태로 사용되어서 담미진 같은 알레르기성 또는 염증성 상태를 치료할수도 있다.Histamine H 2 -blocking compounds can be used to treat conditions where gastric acid is secreted excessively, such as gastric ulcers or peptic ulcers, or when treating allergic conditions where histamine acts as a known regulator. These compounds may be used alone or in combination with other active ingredients to treat an allergic or inflammatory condition such as dense.

따라서 본 발명은 일반식(Ⅰ)의 화합물과 생리학적으로 허용된 이들의 염 및 N-산화물과 수화물 등을 제조하는 방법을 제공한다.Accordingly, the present invention provides a method for preparing a compound of formula (I), physiologically acceptable salts thereof, N-oxides and hydrates, and the like.

Figure kpo00004
Figure kpo00004

일반식(Ⅰ)에서 R1과 R2는 동일하거나 상이한 것으로서 수소, 저급알킬, 시클로알킬, 저급알케닐, 아랄킬이거나 또는 산소원자나

Figure kpo00005
기로 가로막힌 저급알킬을 나타낸다;R 1 and R 2 in formula (I) are the same or different and are hydrogen, lower alkyl, cycloalkyl, lower alkenyl, aralkyl or oxygen atom.
Figure kpo00005
Lower alkyl blocked with groups;

(R4는 수소나 저급알킬)또는 R1과 R2가 질소원자에 서로 부착되어서 산소와

Figure kpo00006
중에서 선택된 다른 이종원자를 함유하는 헤테로고리를 형성할 수도 있다;(R 4 is hydrogen or lower alkyl) or R 1 and R 2 are attached to the nitrogen atom to oxygen and
Figure kpo00006
It is also possible to form a hetero ring containing another hetero atom selected from among;

R3는 수소, 저급알킬, 저급알케닐, 또는 알콕시 알킬이며;R 3 is hydrogen, lower alkyl, lower alkenyl, or alkoxy alkyl;

X는 -CH2-, O, S이고;X is -CH 2- , O, S;

Y는 =S, =O, =NR5또는 =CHR6를 나타내며;Y represents = S, = O, = NR 5 or = CHR 6 ;

Alk는 곧은사슬 또는 축쇄형태를 이루는 C1-C6알킬렌을 나타낸다;Alk represents C 1 -C 6 alkylene which is straight or condensed;

R5는 H, 니트로, 시아노, 저급알킬, 아릴, 알킬술포닐, 아릴술포닐이며;R 5 is H, nitro, cyano, lower alkyl, aryl, alkylsulfonyl, arylsulfonyl;

R6는 니트로, 아릴술포닐, 알킬술포닐을 나타내고;R 6 represents nitro, arylsulfonyl, alkylsulfonyl;

m은 2-4의 정수이고;m is an integer from 2-4;

n은 1또는 2인데 X가 =S나 -CH2-인 경우에 n은 0.1 또는 2이다.n is 1 or 2, where n is 0.1 or 2 when X is = S or -CH 2- .

"저급"이란 용어가 알킬기에 사용될때는 가급적 1-8개의 탄소원자를 갖는 알킬기를 뜻하며, 알케닐기에 사용될 때는 가급적 3-6개의 탄소원자를 갖는 알케닐기를 뜻한다.When used in an alkyl group, the term "lower" means an alkyl group having 1-8 carbon atoms, and when used in an alkenyl group, an alkenyl group having 3-6 carbon atoms is preferably used.

"아릴"이란 용어는 가급적 페닐이거나 또는 알킬, 알콕시, 할로겐으로 치환된 페닐기를 나타내거나 또는 이러한 기의 일부를 나타낸다.The term "aryl" denotes a phenyl group, preferably phenyl or substituted by alkyl, alkoxy, halogen, or represents part of such a group.

본 발명에 의한 화합물들은 쉽게 구할수 있는 출발물질로부터 쉽게 제조할수 있는 잇점이 있다.The compounds according to the invention have the advantage of being easily prepared from readily available starting materials.

구조식(Ⅰ)의 모든 화합물은 토오토메리 현상을 나타내며 이 구조식은 모든 토오토머를 포함한다. Alk가 측쇄알킬렌기를 나타낼 때는 광학이성질체가 존재하며 이때 이 구조식은 부분입체 이성질체와 광학적인 거울상 이성질체를 망라한 것이 된다.All compounds of formula (I) exhibit autotomerism, which includes all the tautomers. When Alk represents a branched alkylene group, an optical isomer exists, and this structural formula encompasses diastereomers and optical enantiomers.

본 발명에 의한 화합물의 보다 나은 부류는 다음과 같은 기를 갖는 것이다:A better class of compounds according to the invention is those having the following groups:

R1과 R2는 수소, 알킬, 페닐알킬, 디알킬아미노알킬을 나타내거나 또는 R1과 R2모두가 질소원자를 가지고 5-나 6-각형의 포화 헤테로고리 즉, 몰포리노, 피페리디노, 피롤리디노, N-알킬피페라지노 등을 형성한다.R 1 and R 2 represent hydrogen, alkyl, phenylalkyl, dialkylaminoalkyl, or both R 1 and R 2 have nitrogen atoms and are 5- or hexagonal saturated heterocycles, ie morpholino, piperidino , Pyrrolidino, N-alkylpiperazino and the like.

Alk는 곧은 사슬의 C1-C4알킬렌을 나타내며,Alk represents straight chain C 1 -C 4 alkylene,

Y는 =O, =S, =CHNO2이거나 또는 R5가 수소, 니트로, 시아노, 저급알킬, 알킬술포닐, 벤젠술포닐인 =NR5이다.Y is = O, = S, = CHNO 2 or or R 5 is a NR 5 = hydrogen, nitro, cyano, lower alkyl, alkylsulfonyl, benzenesulfonyl.

X,m,n과 R3는 상술한 바와같은 것으로 이루어진다.X, m, n and R 3 are made as described above.

본 발명에 의한 화합물로서 특히 좋은 부류는 다음과 같은 기를 갖는 것이다:A particularly good class of compounds according to the invention is those having the following groups:

R1과 R2는 수소, C1-C3알킬, 펜에틸을 나타내거나 또는 R1과 R2가 모두가 질소원자를 가지고 피롤리딘 고리를 형성한다.R 1 and R 2 represent hydrogen, C 1 -C 3 alkyl, phenethyl or R 1 and R 2 both have a nitrogen atom to form a pyrrolidine ring.

Alk는 C1-C3알킬렌사슬을 나타내고,Alk represents a C 1 -C 3 alkylene chain,

Y는 =S, =CHNO2이거나 또는 R5가 니트로, 시아노, 메틸술포닐, 벤젠술포닐인 =NR5이며,Y is = S, = CHNO 2 or = NR 5 where R 5 is nitro, cyano, methylsulfonyl, benzenesulfonyl,

R3는 수소, C1-C3알킬, 프로페닐 또는 C3알콕시알킬이며,R 3 is hydrogen, C 1 -C 3 alkyl, propenyl or C 3 alkoxyalkyl,

n+m은 3 또는 4이고,n + m is 3 or 4,

X는 위에서 규정한 바와같다.X is as defined above.

본 발명에 의한 화합물로서 또 다른 좋은 것으로는,As another good compound according to the present invention,

R1과 R2가 H, C1-C3알킬, 펜에틸이거나 또는 R1과 R2모두가 질소원자를 가지고 피롤리딘 고리를 형성하며,R 1 and R 2 are H, C 1 -C 3 alkyl, phenethyl or both R 1 and R 2 have a nitrogen atom to form a pyrrolidine ring,

Alk는 C1-C3알킬렌기를 나타내고,Alk represents a C 1 -C 3 alkylene group,

Y는 =S, =CHNO3이거나 또는 R5가 니트로, 시아노 메틸술포닐, 벤젠술포닐인 =NR5이며,Y is = S, = CHNO 3 or = NR 5 where R 5 is nitro, cyano methylsulfonyl, benzenesulfonyl,

X는 S나 -CH2-이고,X is S or -CH 2- ,

R3는 수소, 메틸, 메톡시에틸이며,R 3 is hydrogen, methyl, methoxyethyl,

n가 1이고 m이 2 또는 3인 것이다.n is 1 and m is 2 or 3.

또한 본 발명에 의한 화합물로서 특별히 좋은 것으로는In addition, as the compound according to the present invention, particularly good ones

R1이 수소, 메틸, 에틸이고,R 1 is hydrogen, methyl, ethyl,

R2는 메틸, 에틸이며,R 2 is methyl, ethyl,

Alk는 메틸렌기를 나타내고,Alk represents a methylene group,

Y는 =NCN, =NNO2, =CHNO2이며,Y is = NCN, = NNO 2 , = CHNO 2 ,

R3가 수소, 메틸이고,R 3 is hydrogen, methyl,

X가 S나 -CH2-이며,X is S or -CH 2-

n이 1이고 m이 2인 것이다.n is 1 and m is 2.

특별히 좋은 화합물의 실시예는;Examples of particularly good compounds are;

N-(2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]메틸]-N'-메틸티오우레아N- (2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] methyl] -N'-methylthiourea

N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸]-N"-메틸 구아니딘.N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] -thio] ethyl] -N'-methyl guanidine.

N-[2-[[[5-(디메틸아미노)메틸-2- 푸라닐] 메틸] 티오] 에틸]-N'-메틸-2-니트로-1,1-에텐디아민.N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro-1,1-ethenediamine.

N-시아노-N'-[2-[[[5-(메틸아미노)메틸-2-푸라닐] 메틸] 티오]-에틸]-N"-메틸구아다딘.N-cyano-N '-[2-[[[5- (methylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N'-methylguadadine.

N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐] 메틸] 티오] 에틸]-N'-메틸-2-니트로-1,1-에텐디아민.N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro-1,1-ethenediamine.

N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐] 메틸] 티오] 에틸]-N'-(2-메톡시에틸)-2-니트로-1,1-에텐디아민.N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N '-(2-methoxyethyl) -2-nitro-1,1-ethenediamine.

N-[2-[[[5-(메틸아미노)메틸-2-푸라닐] 메틸] 티오] 에틸]-N'-메틸-2-니트로-1,1-에텐디아민.N- [2-[[[5- (methylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro-1,1-ethenediamine.

N-[3-[[[5-(디메틸아미노)메틸-2-푸라닐] 메틸] 티오] 프로필]-N'-메틸-2-니트로-1,1-에텐디아민.N- [3-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] propyl] -N'-methyl-2-nitro-1,1-ethenediamine.

N-[2-[[[5-(에틸메틸아미노)메틸-2-푸라닐] 메틸] 티오] 에틸]-N'-2-니트로-1,1-에텐디아민.N- [2-[[[5- (ethylmethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-2-nitro-1,1-ethenediamine.

N-[2-[[[5-(디메틸아미노) 메틸-2-푸라닐] 메틸] 티오] 에틸]-N'-니트로구아니딘.N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-nitroguanidine.

N-[2-[[[5-(디메틸아미노) 메틸-2-푸라닐] 메틸] 티오] 에틸]-N'-메탄술포닐-N"-메틸 구아니딘.N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methanesulfonyl-N'-methyl guanidine.

N-[4-[5-(디메틸아미노)메틸-2-푸라닐]부틸]-N'-메틸-티오우레아.N- [4- [5- (dimethylamino) methyl-2-furanyl] butyl] -N'-methyl-thiourea.

N-벤젠술포닐-N'-[2-[[[5-(디메틸아미노) 메틸-2-푸라닐] 메틸] 티오] 에틸]-N"-메틸구아니딘.N-benzenesulfonyl-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methylguanidine.

N-[5-[5-(디메틸아미노) 메틸-2-푸라닐] 펜틸]-N'-메틸-2-니트로-1,1-에텐디아민.N- [5- [5- (dimethylamino) methyl-2-furanyl] pentyl] -N'-methyl-2-nitro-1,1-ethenediamine.

N-시아노-N'-[5-[5-(디메틸아미노)메틸-2-푸라닐] 펜틸]-N'-메틸구아니딘.N-cyano-N '-[5- [5- (dimethylamino) methyl-2-furanyl] pentyl] -N'-methylguanidine.

N-[4-[5-(디메틸아미노) 메틸-2-푸라닐]-부틸]-N'-메틸-2-니트로-1,1-에텐디아민.N- [4- [5- (dimethylamino) methyl-2-furanyl] -butyl] -N'-methyl-2-nitro-1,1-ethenediamine.

N-시아노-N'-[4-[5-(디메틸아미노)메틸-2-푸라닐] 부틸]-N"-메틸구아니딘.N-cyano-N '-[4- [5- (dimethylamino) methyl-2-furanyl] butyl] -N'-methylguanidine.

N-[2-[[[5-[3-(디메틸아미노) 프로필]-2-푸라닐] 메틸] 티오]-N'-메틸-2-니트로-1,1-에텐디아민.N- [2-[[[5- [3- (dimethylamino) propyl] -2-furanyl] methyl] thio] -N'-methyl-2-nitro-1,1-ethenediamine.

N-[2-[[[5-[[2-(디메틸아미노)에틸] 아미노] 메틸-2-푸라닐] 메틸] 티오] 에틸]-N'-메틸-2-니트로-1,1-에텐디아민.N- [2-[[[5-[[2- (dimethylamino) ethyl] amino] methyl-2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro-1,1-ethene Diamine.

본 발명에 의한 화합물은 생리학적으로 허용된 염을 쉽게 형성한다. 이러한 염은 염산염, 취화수소산의 부가염, 황산염 같이 무기 또는 유기산으로된 염이다.Compounds according to the invention readily form physiologically acceptable salts. Such salts are salts of inorganic or organic acids, such as hydrochloride, addition salts of hydrochloric acid, sulfates.

특히 유기산의 염으로 유용한 것은 아세트산염, 말레산염 및 푸마르산염 같이 지방족의 모노- 디-카르복시산으로된 염이다. 이 화합물들은 수화물을 형성할수도 있다. 지적한 바와같이 본 발명에 의한 화합물은 R1과 R2모두가 수소가 아닌 N-산화물도 포함한다.Particularly useful as salts of organic acids are salts of aliphatic mono-di-carboxylic acids such as acetates, maleates and fumarates. These compounds may form hydrates. As pointed out, the compounds according to the invention also comprise N-oxides in which both R 1 and R 2 are not hydrogen.

본 발명에 의한 화합물은 경구적이나 국소적으로 또는 비경구적이나 좌약형태로 투여될수 있지만 보다 나은 투여방법은 경구적인 투여법이다. 또한 이들은 염기나 혹은 생리학적으로 용인된 염의 형태로 사용될수도 있다. 일반적으로, 이들 화합물은 제약적으로 용인된 매개체나 희석제와 함께 혼합되어서 제약조성물을 제공하게 된다.The compounds according to the invention can be administered orally or topically or parenterally or in the form of suppositories, but a better method of administration is oral administration. They may also be used in the form of bases or physiologically tolerated salts. Generally, these compounds are mixed with pharmaceutically acceptable mediators or diluents to provide pharmaceutical compositions.

본 발명에 의한 화합물은 만일 필요하다면 종래의 항히스타민제 같은 다른 활성성분과 혼합되어져서 투여될수 있다. 경구투여시에 제약조성물은 대개 캡슐제나 정제의 형태로서 투여되는 것이 편리하며 정제는 완용성 정제(slow release tablet)로 될수도 있다. 이 조성물은 당의정이나 시럽제의 형태로 될수도 있고 적당한 국소제로는 연고, 로우션, 크림, 분말 또는 분무제 등이 있다. 경구투여시에 적당한 1일 투여량은 투약단위당 20-200㎎을 함유하는 유약단위의 형태로 1일에 100㎎-1.2g 정도이다. 완용성 정제의 경우에 적당한 양생법은 1일에 2-3회 복용하는 것이다.The compounds according to the invention can be administered in admixture with other active ingredients such as conventional antihistamines if necessary. In oral administration, pharmaceutical compositions are usually conveniently administered in the form of capsules or tablets, and the tablets may be slow release tablets. The composition may be in the form of dragees or syrups and suitable topical agents include ointments, lotions, creams, powders or sprays. A suitable daily dosage for oral administration is about 100 mg-1.2 g per day in the form of a glazing unit containing 20-200 mg per dosage unit. In the case of a soluble tablet, a suitable curing method is two to three times a day.

비경구적 투여는 일정한 간격으로 주사하거나 지속주입법으로 행하여지며 주사액은 활성성분을 10-100㎎/㎖함유한다.Parenteral administration may be by regular intervals or by continuous infusion and the injection may contain 10-100 mg / ml of active ingredient.

국소제로는 분무제, 연고, 크림이나 로우션 등이 사용되며 이들 조성물은 활성성분을 유효량만큼 함유하는데 무게로 전체 조성물의 1.5-2%를 활성성분이 차지하게 된다.Topical agents include sprays, ointments, creams or lotions, and these compositions contain an effective amount of the active ingredient, and the active ingredient comprises 1.5-2% of the total composition by weight.

본 발명에 의해서, 구조식(Ⅱ)의 1급 아민과

Figure kpo00007
기를 도입할수 있는 화합물을 반응시켜 구조식(Ⅰ)의 화합물을 제조할수 있다.According to the present invention, the primary amine of the formula (II)
Figure kpo00007
The compound of formula (I) may be prepared by reacting a compound capable of introducing a group.

Figure kpo00008
Figure kpo00008

구조식(Ⅱ)에서 R1과 R2, n, X, m은 전술한 바와같으며,

Figure kpo00009
기에서 R3와 Y도 전술한 바와같다.In formula (II) R 1 and R 2 , n, X, m are as described above,
Figure kpo00009
R 3 and Y in the group are as described above.

이 아민은 유리염기나 아세트산 같은 약산의 염 형태로 사용된다. 또한

Figure kpo00010
기를 도입할수 있는 화합물은 R3NCO 이소시안산염, R3NCS 이소티오시안산염이나 구조식
Figure kpo00011
또는
Figure kpo00012
의 화합물로서 P는 이탈기이다.This amine is used in the form of a salt of a weak acid such as free base or acetic acid. Also
Figure kpo00010
Compounds capable of introducing groups include R 3 NCO isocyanate, R 3 NCS isothiocyanate,
Figure kpo00011
or
Figure kpo00012
P is a leaving group.

이소시안산염이나 이소티오시안산염의 경우에 반응은, 아민과 이소시안산염이나 이소티오시안산염을 아세토 니트릴 같은 용매에서 방치시킴으로 일어나며,

Figure kpo00013
의 경우에 반응은, 반응물을 섭씨 100-120도의 고온에서 용융시킴으로 일어나게 된다. 또한 아민(Ⅱ)와
Figure kpo00014
의 반응은 질산은 이 존재하는 가운데 고온에서 아세토니트릴 같은 용매중에서 일어날수도 있으며, 아민(Ⅱ)와
Figure kpo00015
를 실온에서 수용액 중에 교반시킴으로 일어날수도 있다.In the case of isocyanates or isothiocyanates, the reaction occurs by leaving the amine and isocyanate or isothiocyanate in a solvent such as acetonitrile,
Figure kpo00013
In the case of the reaction occurs by melting the reactants at a high temperature of 100-120 degrees Celsius. Also with amine (II)
Figure kpo00014
The reaction can occur in solvents such as acetonitrile at high temperatures in the presence of silver nitrate.
Figure kpo00015
It can also occur by stirring in an aqueous solution at room temperature.

R3가 수소일때는 알칼리 금속의 시안산염과 티오시안산염이 사용된다. 이탈기는 할로겐, 티오메틸, 3,5-디메틸피라조릴이나 알콕시인데 가급적 티오메틸이 좋다.When R 3 is hydrogen, cyanates and thiocyanates of alkali metals are used. The leaving group is halogen, thiomethyl, 3,5-dimethylpyrazoryl or alkoxy, preferably thiomethyl.

또한

Figure kpo00016
기의 도입은 먼저 아민(Ⅱ)와 다음 구조식의 화합물을 반응시킴으로 효과적일수도 있다.Also
Figure kpo00016
The introduction of the group may be effective by first reacting the amine (II) with a compound of the structure

Figure kpo00017
Figure kpo00017

여기서 P는 전술한바와 같은 이탈기이다. 이 반응은 주위 온도에서 에테르나 아세토니트릴 같은 용매중에서 환류시킴으로 효과적이 된다. 생성된 구조식(Ⅲ)의 화합물을 주위 온도에서 환류시키며 1급 아민 R3NH2로 처리하면 소정의 최종 생성물을 수득할수 있다.Where P is a leaving group as described above. This reaction is effective by refluxing in a solvent such as ether or acetonitrile at ambient temperature. The resulting compound of formula III is refluxed at ambient temperature and treated with primary amine R 3 NH 2 to afford the desired final product.

Figure kpo00018
Figure kpo00018

구조식(Ⅲ)에서

Figure kpo00019
는 =NR5나 =CHR6를 나타낸다.In structural formula (III)
Figure kpo00019
Represents = NR 5 or = CHR 6 .

Y가 황인 생성물을 제조하는 또 다른 방법으로는, 아민(Ⅱ)를 이황화탄소와 함께 가열한 다음 클로로포름산에틸 같은 클로로포름산 에스테르와 반응시켜서 형성된 이소티오시안산염(Ⅳ)를 가급적 에탄올 같은 알칸올 용매 중에서 아민 R3NH2와 반응시킨다.Another method for preparing a product wherein Y is sulfur is isothiocyanate (IV) formed by heating an amine (II) with carbon disulfide and then reacting with a chloroformate ester such as ethyl chloroformate, preferably an alkanol solvent such as ethanol. In an amine R 3 NH 2 .

Figure kpo00020
Figure kpo00020

또 다른 방법으로, X가 황이고 n이 1이며 R1과 R2모두가 수소이고 Y가 =CHNO2가 아닌 화합물은 구조식(Ⅴ) 또는 구조식(Ⅵ)의 출발물질로부터 제조할수 있다.Alternatively, compounds wherein X is sulfur, n is 1, both R 1 and R 2 are hydrogen and Y is not = CHNO 2 can be prepared from starting materials of formula (V) or formula (VI).

Figure kpo00021
Figure kpo00021

구조식(Ⅴ)에서 R7은 수소나 또는 아세틸 같은 아실기나 P-니트로벤조일기이다.R 7 in formula (V) is an acyl group such as hydrogen or acetyl or a P-nitrobenzoyl group.

만일 생성물 중에서 R1과 R2모두가 수소일 경우에, 생성물은 구조식(Ⅴ)의 화합물내에서 프탈이미도기로서 보호를 받게 된다. 따라서 상기 화합물을 구조식(Ⅶ)의 티올과 함께 반응시킨 다음 적당한 단계에서 보호기를 이탈시킨다.If both R 1 and R 2 in the product are hydrogen, the product is protected as a phthalimido group in the compound of formula (V). Therefore, the compound is reacted with thiol of structural formula and then leaves the protecting group in a suitable step.

Figure kpo00022
Figure kpo00022

구조식(Ⅴ)의 화합물이 사용될 때 반응은 가급적 진한 염산과 함께 섭씨 0도에서 반응시키는 것이 좋으며, 구조식(Ⅵ)의 화합물이 사용될 때 반응은 실온에서 디메틸포름아미드 같은 유지용매중에서 실시한다.When the compound of formula (V) is used, the reaction is preferably carried out at 0 degrees Celsius with concentrated hydrochloric acid. When the compound of formula (VI) is used, the reaction is carried out in a holding solvent such as dimethylformamide at room temperature.

클로로메틸 화합물(Ⅵ)은 염화티오닐이나 진환 염산을 사용해서 유사한 알코올로부터 제조될수 있다.Chloromethyl compound (VI) can be prepared from similar alcohols using thionyl chloride or cyclohydrochloric acid.

Y가 NCN기인 생성물은 Y가 황인 구조식(Ⅰ)의 화합물을 은, 납, 카드뮴이나 수은같은 중급속의 시안아미드와 함께 가급적 수용액 중에서 가열함으로 제조될수 있다.Products in which Y is an NCN group may be prepared by heating the compound of formula (I) in which Y is sulfur, in an aqueous solution, preferably with an intermediate rate of cyanamide such as silver, lead, cadmium or mercury.

또한 Y가 =NR5이고 Alk 가 메틸렌기나 또는 측쇄의 알킬렌기인 화합물은 적당한 알데히드와 2급 아민 또는 1급 아민이나 2급 아민의 염을 사용해서 만니히반응(Mannich)에 의하여 구조식(Ⅷ)의 화합물로부터 제조할수 있다.In addition, compounds in which Y is NR 5 and Alk is a methylene group or a branched alkylene group may be formed by a Mannich reaction using a suitable aldehyde and a secondary amine or a salt of a primary amine or a secondary amine. It can be prepared from the compound of.

Figure kpo00023
Figure kpo00023

예를들면, 디메틸아민과 포름알데히드를 사용해서 (CH3)2NCH2-기를 도입할 수가 있다. 이 반응은 아민염과 구조식(Ⅷ)의 화합물을 포름알데히드 수용액과 함께 반응시키거나 또는 아민염과 구조식(Ⅷ)의 화합물을 파라포름알데히드와 함께 환류시킴으로 실시될수 있다.For example, (CH 3 ) 2 NCH 2 -groups can be introduced using dimethylamine and formaldehyde. This reaction can be carried out by reacting the amine salt with the compound of formula with aqueous solution of formaldehyde or refluxing the amine salt with the compound of formula with paraformaldehyde.

본 발명에 의한 화합물을 제조하는데 유효한 방법을 상술한 과정에서 구조식(Ⅱ)의 1급 아민을 논의한바 있다. 이들 화합물은 신규한 것으로서 본 발명은 이들 화합물을 제조하는 방법도 포함한다. 이들 중간체들은 다음과 같은 여러 방법에 의해서 제조될수 있다.In the course described above the effective methods for preparing the compounds according to the invention have been discussed the primary amines of formula (II). These compounds are novel and the present invention also includes a method for producing these compounds. These intermediates can be prepared by several methods, such as:

X가 S이고 n이 1인 구조식(Ⅱ)의 아민은 구조식(Ⅸ)의 푸르푸릴티올과 구조식(X)의 ω-브로모 알킬 프탈이미드를 반응시켜서 제조할수 있다.An amine of formula (II) wherein X is S and n is 1 may be prepared by reacting furfurylthiol of formula (VII) with ω-bromo alkyl phthalimide of formula (X).

Figure kpo00024
Figure kpo00024

만니히 반응에 의해서

Figure kpo00025
기를 생성된 구조식(ⅩⅠ)의화합물 안으로 도입시킨다.By the Mannich reaction
Figure kpo00025
Is introduced into the compound of formula (XI).

Figure kpo00026
Figure kpo00026

그런 다음 히드라진 수화물과 함께 반응시켜 보호기를 제거하면 구조식(Ⅱ)의 아민이 생성된다.Reaction with hydrazine hydrate is then removed to form the amine of formula (II).

X가 S이고 n이 1인 구조식(Ⅱ)의 아민을 제조하는 또 다른 방법에서는 염화 2-푸르푸릴이 출발물질로 사용될수 있다.In another method for preparing amines of formula II wherein X is S and n is 1, 2-furfuryl chloride can be used as starting material.

아민기가 프탈이미드(ⅩⅡ)로서 보호되는 ω-아미노알킬티올과 염화푸르푸릴을 반응시키면 구조식(ⅩⅠ)의 중간체가 생성된다. 이것을 상술한 바와같이 처리하면 구조식(Ⅱ)의 아민을 수득할수 있다.Reaction of ω-aminoalkylthiol in which the amine group is protected as phthalimide (XII) with furfuryl chloride forms an intermediate of formula (XI). Treatment of this as described above gives an amine of formula (II).

Figure kpo00027
Figure kpo00027

X가 S이고 n이 1인 아민(Ⅱ)를 제조하는 다른 방법에서는 구조식(ⅩⅢ)의 출발물질이 사용된다.In another method for preparing amine (II) wherein X is S and n is 1, the starting material of formula (XIII) is used.

Figure kpo00028
Figure kpo00028

이 화합물 산성 상태에서 ω-아미노알킬티올로 처리한다. 이때 만일 원한다면 아민기를 보호할수도 있다.This compound is treated with ω-aminoalkylthiol in an acidic state. If desired, the amine group may be protected.

또는 구조식(ⅩⅢ)의 화합물을 ω-아미노알킬티올과 함께 반응시키기 전에 염기성 상태에서 유사한 아세트산염으로 전환시킬수도 있다.Alternatively, the compound of formula (XIII) may be converted into a similar acetate salt in the basic state before reacting with ω-aminoalkylthiol.

구조식(Ⅱ)의 1급 아민은 (X=S이고 n=0인 것은 제외) 푸란을 리튬 부틸과 함께 반응시켜 리티오 유도체(ⅩⅣ)을 제조한 다음, 계속해서 α,ω-디할로-화합물 Hal(CH2) N X(CH2)m Hal(Hal은 염소, 브롬, 요오드)과 반응시키고 (ⅰ)프탈이미드화 칼륨으로 처리해서 (ⅱ)생성된 반응 생성물인 구조식(ⅩⅤ)의 화합물을 만니히 반응 시키고 히드라진 수화물과 반응시켜 보호기를 제거함으로써 제조된다.The primary amine of formula (II) (except X = S and n = 0) reacts furan with lithium butyl to produce a thiothio derivative (IV), followed by α, ω-dihalo-compound Hal (CH 2 ) NX (CH 2 ) m Hal (Hal is reacted with chlorine, bromine, iodine) and treated with (i) potassium phthalimide to give (ii) the reaction product of formula (VV). Prepared by reacting with Mannich and reacting with hydrazine hydrate to remove the protecting group.

Figure kpo00029
Figure kpo00029

X가 S이고 n이 0인 중간체는 R1과 R2가 수소가 아닌 구조식(ⅩⅥ)의 푸란을 리튬 및 황원자와 반응시키고 w-브로모알킬프탈이미드(X)과 반응시킨 다음 생성된 구조식(ⅩⅦ)의 화합물을 히드라진 수화물과 반응시켜 보호기를 제거함으로써 제조할수 있다.Intermediates in which X is S and n is 0 react with the furan of the structural formula (XVI) in which R 1 and R 2 are not hydrogen with lithium and sulfur atoms and with w-bromoalkylphthalimide (X) The compound of (iii) can be prepared by reacting with hydrazine hydrate to remove the protecting group.

Figure kpo00030
Figure kpo00030

X가 산소원자이고 n이 1인 중간체를 제조하려면, 디메틸포름 아미드 같은 용매 중에서 특히 3급 부톡시화 칼륨 같은 염기가 존재하는 가운데 Hal 이 할로겐 원자, 가급적 염소를 나타내는 Hal(CH2)m NH2화합물을 구조식(ⅩⅢ)의 알코올과 반응시키면 된다.In order to prepare an intermediate in which X is an oxygen atom and n is 1, a Hal (CH 2 ) m NH 2 compound in which Hal represents a halogen atom, preferably chlorine, in the presence of a base such as tertiary potassium butoxide in a solvent such as dimethylformamide What is necessary is just to react with alcohol of a structural formula (XIII).

m이 2이고 X가 황 또는 산소인 구조식(Ⅱ)의 중간체는 에틸렌이민을 구조식(ⅩⅢ)의 화합물이나 등비용티올과 반응시킴으로서 제조할수 있다.Intermediates of formula (II) wherein m is 2 and X is sulfur or oxygen can be prepared by reacting ethyleneimine with a compound of formula (XIII) or an isotropic thiol.

또한, 구조식(Ⅱ)의 아민은 n과 m, X가 전술한 바와같은 구조식(ⅩⅧ)의 화합을 출발물질로 해서 제조할수 있다.In addition, the amine of the formula (II) can be prepared using the compound of the formula (n) in which n, m, and X have been described as starting materials.

Figure kpo00031
Figure kpo00031

이 니트릴 화합물을 만니히 반응시키고 LiAlH4로 환원하여 구조식(Ⅱ)의 화합물을 제조한다. 만니히 반응을 사용할 때, 적당한 단계에서

Figure kpo00032
기를 도입할수도 있으나 가급적 이 반응은 구조식(ⅩⅨ)이나 (ⅩⅩ)의 화합물을 가지고 행하는 것이 좋다.The nitrile compound was reacted with Mannich and reduced with LiAlH 4 to prepare a compound of formula II. When using the Mannich reaction,
Figure kpo00032
A group may be introduced, but preferably this reaction is carried out with a compound of formula (VII) or (VII).

Figure kpo00033
Figure kpo00033

적당한 알데히드와 아민을 사용하는 만니히 반응은 Alk가 메틸렌기나 측쇄알킬렌기를 나타내는 화합물을 제조할 때 사용되며 특히 Alk가 메틸렌일때는 포름알데히드를 사용한다.The Mannich reaction using suitable aldehydes and amines is used to prepare compounds in which Alk represents methylene or branched alkylene groups, especially formaldehyde when Alk is methylene.

Alk가 메틸렌인 화합물을 제조하는 다른 방법에서는, 출발물질로서 푸란-2-카르복시산을 사용한다. 이것을 구조식 R1R2NH의 아민과 함께 반응시켜서 생성된 구조식(ⅩⅩⅠ)의 아미드를 LiAlH4로 환원하여 구조식(ⅩⅩⅡ)의 화합물을 제조한다.In another method for preparing compounds wherein Alk is methylene, furan-2-carboxylic acid is used as starting material. This compound is reacted with an amine of the formula R 1 R 2 NH to reduce the amide of the formula (XI) to LiAlH 4 to prepare a compound of the formula (XI).

Figure kpo00034
Figure kpo00034

구조식(ⅩⅩⅡ)의화합물을 구조식(ⅩⅢ)의 화합물로 전환시키기 위해서 포름알데히드와 아세트산을 사용하여 히드록시메틸기를 도입시킨다.In order to convert the compound of formula (XII) into the compound of formula (XIII), hydroxymethyl group is introduced using formaldehyde and acetic acid.

만일 R1과 R2모두가 수소일 경우에, 아미노기는 히드록시메틸화가 일어나는 동안 포탈아미드로서 보호되어진다.If both R 1 and R 2 are hydrogen, the amino group is protected as a portalamide during hydroxymethylation.

실제로 탈 보호기 반응은 히드라진 수화물을 사용하므로서 효과적이다.Indeed the deprotection reaction is effective by using hydrazine hydrate.

R1과 R2모두가 수소가 아닌 경우에 히드록시메틸화는 리듐부틸을 사용하고 포름알데히드를 가함으로써 효과적이 된다.In the case where both R 1 and R 2 are not hydrogen, hydroxymethylation is effective by using lithium butyl and by adding formaldehyde.

Alk가 C2이상의 곧은사슬 알킬렌기일 경우에는 다음의 두 방법이 적당하다.When Alk is a C 2 or higher straight chain alkylene group, the following two methods are suitable.

편리한 한가지 방법은 푸란-2-카르복시산 대신에 카르복시산(ⅩⅩⅢ)을 사용해서 상기의 메틸렌 유도체와 유사한 에틸렌 유도체를 제조하는데 사용된다.One convenient method is used to prepare ethylene derivatives similar to the methylene derivatives above using carboxylic acids (XIII) instead of furan-2-carboxylic acids.

Figure kpo00035
Figure kpo00035

알킬렌사슬 즉, Alk가 C2이상인 경우에, 구조식(ⅩⅣ)의 리티오 유도체를 Hal 이 염소나 브롬 또는 요오드인 구조식 Hal Alk Hal의 디할로알칸으로 처리하고 (ⅰ)아민 R1R2NH 로 처리해서 (ⅱ)Alk가 C3-C6인 구조식(ⅩⅥ)의 화합물을 제조한다.When the alkylene chain, i.e., Alk is C 2 or more, the thiothio derivative of structure (XIV) is treated with dihaloalkane of the structure Hal Alk Hal wherein Hal is chlorine, bromine or iodine and (iii) amine R 1 R 2 NH (Ii) to prepare a compound of formula (XIV) wherein Alk is C 3 -C 6 .

R1과 R2가 수소일 때 아민 R1R2NH는 상기 두 개의 반응에서 프탈이미드화 칼륨으로 치환된다. 양쪽 반응의 생성물을 상술한 바와같이 히드록시메틸화시키고 적당한 단계에서 보호기를 이탈시켜 구조식(ⅩⅢ)의 화합물을 제조한다.When R 1 and R 2 are hydrogen, the amine R 1 R 2 NH is substituted with potassium phthalimide in both reactions. The product of both reactions is hydroxymethylated as described above, leaving the protecting group in a suitable step to prepare a compound of formula (XIII).

만일 R1가 R2가 수소가 아닌 화합물을 얻고저 한다면, 포름알데히드와 프롬산을 사용해서 에쉬와일러-크라크(Eschweiler Clarke)법에 의하여 유리아미노 화합물을 적당한 치환된 아미노기로 전환시켜 디메틸아미노 화합물을 수득할수도 있으나 반응 중 적당한 단계에서 치환된 아민을 사용하는 것이 바람직하다.If R 1 is intended to yield a compound in which R 2 is not hydrogen, the dimethylamino compound is converted to an appropriate substituted amino group by the Eschweiler Clarke method using formaldehyde and phlomic acid. May be obtained but it is preferred to use substituted amines at appropriate stages of the reaction.

n이 2인 구조식(Ⅱ)의 아민은 Z가 이탈기 즉, 토시록시, 메시록시나 브롬인 구조식(ⅩⅩⅣ)의 화합물을 출발물질로 사용함으로서 제조될수 있다.An amine of formula II wherein n is 2 can be prepared by using as a starting material a compound of formula IV wherein Z is a leaving group, i.e., tosioxy, mesoxyoxy or bromine.

Figure kpo00036
Figure kpo00036

이 화합물을 구조식(ⅩⅡ)의 ω-프탈이미도-알킬티올과 함께 반응시켜서 생성된 화합물을 만니히 반응시키고 보호기를 이탈시켜 원하는 구조식(Ⅱ)의 아민을 제조해 낸다.The compound is reacted with the ω-phthalimido-alkylthiol of the structural formula (XIII) to react with the resulting compound and leaving the protecting group to produce an amine of the desired structural formula (II).

본 발명의 화합물들을 제조하는 중에, 구조식(Ⅴ)의 화합물을 Y가 특별히 =CHNO2인 구조식(Ⅶ)의 티올과 함께 반응시킬수 있다.During the preparation of the compounds of the invention, compounds of formula (V) can be reacted with thiols of formula (VII) wherein Y is = CHNO2.

Y가 =CHNO2이고 m이 2인 구조식(Ⅶ)의 화합물은 구조식(ⅩⅩⅤ)의 티아졸리딘 중간체를 아민 R3NH2와 반응시킴으로서 제조할수 있다. 티아졸리딘(ⅩⅩⅤ)는 시스테아민과 비스메틸티오 화합물(ⅩⅩⅥ)로부터 제조된다.The compound of formula IV wherein Y = CHNO 2 and m is 2 may be prepared by reacting the thiazolidine intermediate of formula IV with the amine R 3 NH 2 . Thiazolidine (XV) is prepared from cysteamine and bismethylthio compound (XVI).

Figure kpo00037
Figure kpo00037

Y가 =CHNO2이고 m이 2인 구조식(Ⅶ)의 티올은 신규한 화합물로서 본 발명은 이들 화합물을 제조하는 방법도 포함한다.Thiols of formula (VII) wherein Y is = CHNO 2 and m is 2 are novel compounds and the present invention also includes methods for preparing these compounds.

본 발명을 보다 잘 이해하기 위해서 다음의 실시예를 설명한다. 제조방법 1-4는 출발물질을 제조하는 방법을 기술한 것이고, 실시예 A-L은 구조식(Ⅱ)의 아민 및 관련된 중간체를 제조하는 방법의 예이며, 실시예 1-32는 구조식(Ⅰ)의 화합물의 제조법을 기술한 것이고 실시예 33은 제약조성물의 제조예이다.In order to better understand the present invention, the following examples are described. Preparation Methods 1-4 describe methods for preparing starting materials, Example AL is an example of a method for preparing amines of formula (II) and related intermediates, and Examples 1-32 are compounds of formula (I). The preparation method of is described and Example 33 is an example of preparation of a pharmaceutical composition.

[제조방법 1][Manufacturing Method 1]

(a) 5-(메틸아미노)메틸-2-푸란메탄올(a) 5- (methylamino) methyl-2-furanmethanol

2-푸란메탄올(49g), 염산메틸아민(51.5g)과 36%-포름알데이드용액(50㎖)의 혼합물을 섭씨 0-3도에서 3시간 동안 교반하고 16시간 동안 정치시켰다. 과량의 탄산나트륨을 여기에 가하고 이 슬러리를 아세트산에틸로 추출시켰다.A mixture of 2-furanmethanol (49 g), methylamine hydrochloride (51.5 g) and 36% formaldehyde solution (50 mL) was stirred at 0-3 degrees Celsius for 3 hours and allowed to stand for 16 hours. Excess sodium carbonate was added thereto and the slurry was extracted with ethyl acetate.

용매를 제거한 후에 잔류물을 증류해서 5-(메틸아미노)메틸-2-푸란메탄올(36.2g)을 수거하였다.After removing the solvent, the residue was distilled off to collect 5- (methylamino) methyl-2-furanmethanol (36.2 g).

비점 ; 섭씨 111-113도(0.2mmHg).Boiling point; 111-113 degrees Celsius (0.2 mmHg).

2-푸란메탄올과 유사한 염산아민으로부터 다음의 물질을 동일한 방법으로 제조하였다.From the amine hydrochloride similar to 2-furanmethanol the following materials were prepared in the same manner.

(b) 5-[(2-페닐에틸) 아미노] 메틸 -2-푸란메탄올. 기름.(b) 5-[(2-phenylethyl) amino] methyl-2-furanmethanol. Oil.

Rf ; 0.45(실리카/아세톤)Rf; 0.45 (silica / acetone)

NMR(CCl4)7.29, br.s(4H) ; 6.8s(2H) ; 6.40s(2H) ; 5.62s(2H) ; 4.0br(2H) ; 2.87s(5H).NMR (CCl 4 ) 7.29, br. S (4H); 6.8 s (2H); 6.40 s (2H); 5.62 s (2H); 4.0 br (2H); 2.87 s (5H).

(c) 5-[(1-메틸에틸)아미노]메틸-2-푸란메탄올. 기름.(c) 5-[(1-methylethyl) amino] methyl-2-furanmethanol. Oil.

Rf ; 0.55(실리카/메탄올)Rf; 0.55 (silica / methanol)

분석실측치 ; C, 63.55 ; H,8/78 ; N,8.09.Analysis measured value; C, 63.55; H, 8/78; N, 8.09.

C9H15NO2의 계산치 ; C,63.88 ; H,8.94 ; N,8.28%.Calculated C 9 H 15 NO 2 ; C, 63.88; H, 8.94; N, 8.28%.

(d) 5-(에틸메틸아미노)메틸-2-푸란메탄올.(d) 5- (ethylmethylamino) methyl-2-furanmethanol.

Rf ; 0.32(실리카/아세톤)Rf; 0.32 (silica / acetone)

NMR(CDCl3) 8.93t(3H) ; 7.80s(2H) ; 7.55q(2H) ; 6.05s(2H) ; 6.33br. s(1H) ; 5.47s(2H) ; 3.80(2H).NMR (CDCl 3 ) 8.93t (3H); 7.80 s (2H); 7.55q (2H); 6.05 s (2H); 6.33br. s (1H); 5.47 s (2H); 3.80 (2 H).

(e) 5[[(2-디메틸아미노)에틸]아미노]메틸-2-푸란-메탄올 비스말레산염.(e) 5 [[(2-dimethylamino) ethyl] amino] methyl-2-furan-methanol bismaleate.

융점 ; 섭씨 119-121도Melting point; 119-121 degrees celsius

[제조방법 2][Manufacturing Method 2]

5-[2-(N,N-디메틸아미노)에틸]-2-푸란메탄올5- [2- (N, N-dimethylamino) ethyl] -2-furanmethanol

N,N-디메틸-2-푸란에탄아민(9.8g), 포름알데히드 30% 수용액(17.5g), 빙초산(18㎖)를 섭씨 70도의 온도에서 5시간 동안 가열하였다. 반응물을 냉각시키고 수산화나트륨을 가해서 염기성으로 만들어 에테르로 추출했다. 유기추출물을 증류해서 기름상의 상기 물질을 수거하였다.N, N-dimethyl-2-furanethanamine (9.8 g), 30% aqueous formaldehyde solution (17.5 g) and glacial acetic acid (18 ml) were heated at a temperature of 70 degrees Celsius for 5 hours. The reaction was cooled, basified by addition of sodium hydroxide and extracted with ether. The organic extract was distilled off to collect the oily material.

비점 ; 섭씨 90-100도Boiling point; 90-100 degrees centigrade

분석실측치 ; C,64.C ; H,8.9 ; N, 8.0Analysis measured value; C, 64.C; H, 8.9; N, 8.0

C9H15NO2의 계산치 ; C, 63.9 ; H, 8.9 ; N, 8.2%Calculated C 9 H 15 NO 2 ; C, 63.9; H, 8.9; N, 8.2%

[제조방법 3][Manufacturing Method 3]

2[1-(4-브로모부틸)]푸란2 [1- (4-bromobutyl)] furan

헥산중에 1.6M 용해된 n-리튬부틸(375㎖)를 푸란(40.8g)을 함유하는 건성 테트라히드로푸란(375㎖) 용액에 가했다. 이 혼합물을 섭씨 40도에서 3시간 동안 교반한 다음 1,4-디브로모부탄(129.6g)을 섭씨-30도에서 가하고 반응물을 실온에서 4시간 동안 교반하였다. 여기에 물을 가하고 혼합물을 아세트산에틸로 추출하였다. 얻어진 추출물을 증류해서 투명한 무색액체를 수득하였다.N-lithium butyl (375 mL) dissolved 1.6 M in hexane was added to a dry tetrahydrofuran (375 mL) solution containing furan (40.8 g). The mixture was stirred at 40 degrees Celsius for 3 hours, then 1,4-dibromobutane (129.6 g) was added at -30 degrees Celsius and the reaction was stirred at room temperature for 4 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The obtained extract was distilled off to obtain a clear colorless liquid.

비점 ; 섭씨 60-62도(0.5mmHg)Boiling point; 60-62 degrees Celsius (0.5mmHg)

N,N-디메틸-4-(2-푸라닐) 부탄아민N, N-dimethyl-4- (2-furanyl) butanamine

2-[1-(4-브로모부틸)]푸란(82g)을 함유하는 톨루엔(500㎖)용액에 디메틸아민(56g)을 가했다. 이용액을 실온에서 2일 동안 교반하고 염산을 가해서 산성으로 만들었다.Dimethylamine (56 g) was added to a toluene (500 mL) solution containing 2- [1- (4-bromobutyl)] furan (82 g). The solution was stirred at room temperature for 2 days and made acidic by addition of hydrochloric acid.

산층이 분리되면 에테르로 세척하고 수산화나트륨을 가해서 염기성으로 한다음 에테르로 추출하였다. 에테르성 추출물을 증류해서 무색투명한 기름상의 상기물질을 얻었다.The acid layer was separated, washed with ether, made basic by addition of sodium hydroxide and extracted with ether. The ethereal extract was distilled off to obtain a colorless transparent oily substance.

비점 ; 섭씨 55-58도(0.8mmHg)Boiling point; 55-58 degrees Celsius (0.8mmHg)

염산염의 융점 ; 섭씨 133-136도Melting point of hydrochloride; 133-136 degrees celsius

분석 실측치 ; C, 59.01 ; H,9.02 ; N,6.87Analysis observed; C, 59.01; H, 9.02; N, 6.87

C10H17NO·HCl의 계산치 ; C, 58.96 ; H,8.91 ; N, 6.88%Calcd for C 10 H 17 NO · HCl; C, 58.96; H, 8.91; N, 6.88%

5-[4-(디메틸아미노)부틸]-2-푸란메탄올5- [4- (dimethylamino) butyl] -2-furanmethanol

(a) n-헥산중에 1.6몰 용해된 n-리튬부틸(125㎖)를 N,N-디메틸-4-(2푸라닐)부탄아민(33.4g)을 함유하는 건성 테트라히드로푸란(125㎖)의 한냉용액에 가했다.(a) Dry tetrahydrofuran (125 ml) containing 1.6 mol of n-lithium butyl (125 ml) dissolved in n-hexane containing N, N-dimethyl-4- (2furanyl) butanamine (33.4 g) Cold solution was added.

이 혼합물을 실온에서 4시간동안 교반하고 파라포름알데히드(6.0g)을 여기에 가한다음 이 혼합물을 1시간동안 더 교반하였다. 반응물을 수냉시키고 클로로포름으로 추출한 다음 유지추출물을 증류해서 무색투명한 기름상의 상기 화합물을 수거하였다.The mixture was stirred at room temperature for 4 hours, paraformaldehyde (6.0 g) was added thereto, and the mixture was further stirred for 1 hour. The reaction was cooled with water, extracted with chloroform, and the oil and fat extract was distilled to collect the colorless transparent oily compound.

비점 ; 섭씨 100-105도(0.1mmHg).Boiling point; 100-105 degrees Celsius (0.1 mmHg).

융점 ; 섭씨 26-28.5도Melting point; 26-28.5 degrees Celsius

분석실측치 ; C, 67.09 ; H, 10.01 ; N, 7.06Analysis measured value; C, 67.09; H, 10.01; N, 7.06

C11H19NO2의 계산치 ; C,66.97 ; H,9.71 ; N, 7.10%Calcd for C 11 H 19 NO 2 ; C, 66.97; H, 9.71; N, 7.10%

동일한 방법으로 제조된 것으로는;Prepared in the same manner;

(b) 5-[3-(디메틸아미노)프로필]-2-푸란메탄올(b) 5- [3- (dimethylamino) propyl] -2-furanmethanol

비점 ; 섭씨 160도(0.08mmHg)Boiling point; 160 degrees Celsius (0.08mmHg)

융점 ; 섭씨 24도Melting point; 24 degrees celsius

분석 실측치 ; C, 64.66 ; H, 9.36 ; N, 7.39Analysis observed; C, 64.66; H, 9. 36; N, 7.39

C10H17NO2, 1/5H2O의 계산치 ; C, 64.28; H,9.39 ; N, 7.50%Calcd for C 10 H 17 NO 2 , 1 / 5H 2 O; C, 64.28; H, 9.39; N, 7.50%

[제조방법 4][Manufacturing Method 4]

아세트산[5-[4-N,N-디메틸아미노]부틸]-2-푸라닐메틸Acetic acid [5- [4-N, N-dimethylamino] butyl] -2-furanylmethyl

5-[4-(디메틸아미노)부틸]-2-푸란메탄올 (4.9g)과 무수아세트산(25g), 용융 분말상의 아세트산 나트륨(10g), 벤젠(25㎖)의 혼합물을 실온에서 24시간 동안 교반하였다.A mixture of 5- [4- (dimethylamino) butyl] -2-furanmethanol (4.9 g), acetic anhydride (25 g), molten powdered sodium acetate (10 g), and benzene (25 mL) was stirred at room temperature for 24 hours. It was.

반응물을 물(100㎖)로 희석하고 아세트산에틸로 추출하였다. 추출물을 증류해서 무색 투명한 기름상의 상기 물질을 수거하였다.The reaction was diluted with water (100 mL) and extracted with ethyl acetate. The extract was distilled off to collect the colorless transparent oily material.

비점 ; 섭씨 100도(0.5mmHg)Boiling point; 100 degrees Celsius (0.5mmHg)

분석 실측치 ; C, 65.72 ; H, 9.03 ; N,5.95Analysis observed; C, 65.72; H, 9.03; N, 5.95

C13H21NO3의 계산치 ; C,65.24 ; H,8.85 ; N,5.85%Calcd for C 13 H 2 1NO 3 ; C, 65.24; H, 8.85; N, 5.85%

[실시예 A]Example A

(a) 2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에탄아민(a) 2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethanamine

염산시스테아민 (11.36g)을 함유하는 진한 염산 (40㎖) 빙냉 용액에 5-(디메틸아미노)-메틸-2-푸란 메탄올(15.5g)을 적하 하면서 교반하였다.It was stirred while dropping 5- (dimethylamino) -methyl-2-furan methanol (15.5 g) into concentrated hydrochloric acid (40 mL) ice-cooled solution containing cysteamine hydrochloride (11.36 g).

섭씨 0도에서 18시간 동안 정치시킨 후에 과량의 무수탄산나트륨을 여기에 가하고 생성된 고체를 디에틸에테르로 추출하였다. 잔류물을 증류해서 용매를 제거하여 2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에탄아민(11.6g)을 수거하였다.After standing for 18 hours at 0 degrees Celsius, excess anhydrous sodium carbonate was added thereto and the resulting solid was extracted with diethyl ether. The residue was distilled off to remove the solvent, and 2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethanamine (11.6 g) was collected.

비점 ; 섭씨 104-106도(0.1mmHg)Boiling point; 104-106 degrees Celsius (0.1mmHg)

피크르산염의 융점 ; 섭씨 142-144도Melting point of pictrates; 142-144 degrees celsius

유사한 푸란메탄올과 염산시스테아민으로부터 동일하게 제조된 것으로는;Identically prepared from similar furanmethanol and cysteamine hydrochloride;

(b) 2-[[[5-(메틸아미노)메틸-2-푸라닐]메틸]티오]-에탄아민(b) 2-[[[5- (methylamino) methyl-2-furanyl] methyl] thio] -ethanamine

모노프크르산염의 융점 ; 섭씨 142-144도Melting point of monofractate; 142-144 degrees celsius

(c) 2-[[[5-(1-메틸에틸)아미노]메틸-2-푸라닐]메틸]티오]-에탄아민. 기름.(c) 2-[[[5- (1-methylethyl) amino] methyl-2-furanyl] methyl] thio] -ethanamine. Oil.

Rf ; 0.4(실리카/메탄올 : 0.880암모니아 79:1)Rf; 0.4 (Silica / Methanol: 0.880 Ammonia 79: 1)

(d) 2-[[[5-(디에틸아미노메틸)-2-푸라닐]메틸]티오]-에탄아민.(d) 2-[[[5- (diethylaminomethyl) -2-furanyl] methyl] thio] -ethanamine.

비점 ; 섭씨 134-135도(1mmHg)Boiling point; 134-135 degrees Celsius (1mmHg)

(e) 2-[[[5-(1-피페리디닐)메틸-2-푸라닐]메틸]티오]-에탄아민. 기름.(e) 2-[[[5- (1-piperidinyl) methyl-2-furanyl] methyl] thio] -ethanamine. Oil.

Rf ; 0.37(실리카/메탄올 : 0.880암모니아 79:1)Rf; 0.37 (silica / methanol: 0.880 ammonia 79: 1)

(f) 2-[[[5-(아미노메틸)-2-푸라닐]메틸]티오]-에탄아민.(f) 2-[[[5- (aminomethyl) -2-furanyl] methyl] thio] -ethanamine.

중염산염의 융점 ; 섭씨 222-224도(분해).Melting point of dihydrochloride; 222-224 degrees Celsius (decomposition).

(g) N[-5-[[[(2-아미노에틸)티오] 메틸]-2-푸라닐]메틸]- 벤젠 에탄아민 기름.(g) N [-5-[[[(2-aminoethyl) thio] methyl] -2-furanyl] methyl]-benzene ethanamine oil.

Rf ; 0.33 (실리카/메탄올 : 0.880 암모니아 79:1)Rf; 0.33 (silica / methanol: 0.880 ammonia 79: 1)

(h) 2-[[[5-(2-디메틸아미노)에틸]-2-푸라닐]메틸]티오]-에탄아민.(h) 2-[[[5- (2-dimethylamino) ethyl] -2-furanyl] methyl] thio] -ethanamine.

비점 ; 섭씨 150-155도(0.44mmHg)Boiling point; 150-155 degrees Celsius (0.44mmHg)

(i) 2-[[[5-(3-디메틸아미노)프로필]-2-푸라닐]메틸]티오]-에탄아민.(i) 2-[[[5- (3-dimethylamino) propyl] -2-furanyl] methyl] thio] -ethanamine.

비점 ; 섭씨 150도(0.05mmHg)Boiling point; 150 degrees Celsius (0.05mmHg)

(j) 2-[[[5-(에틸메틸아미노)메틸]-2-푸라닐]메틸]티오]-에탄아민.(j) 2-[[[5- (ethylmethylamino) methyl] -2-furanyl] methyl] thio] -ethanamine.

Rf ; 0.34(실리카/메탄올 : 0.880 암모니아 79: 1)Rf; 0.34 (silica / methanol: 0.880 ammonia 79: 1)

(k) 2-[[[5-(2-디메틸아미노에틸)이미노]메틸-2-푸라닐]-메틸]티오]에탄아민.(k) 2-[[[5- (2-dimethylaminoethyl) imino] methyl-2-furanyl] -methyl] thio] ethanamine.

트리말레산염의 융점 ; 섭씨 132-135도Melting point of trimaleate; 132-135 degrees celsius

(l) 2-[[[5-(1-피롤리디노]메틸-2-푸라닐]메틸]티오]-에탄아민.(l) 2-[[[5- (1-pyrrolidino] methyl-2-furanyl] methyl] thio] -ethanamine.

비스옥살산염의 융점 ; 섭씨 136.5-138.5 도Melting point of bisoxalate; 136.5-138.5 degrees Celsius

[실시예 B]Example B

2-[[[5-(4-디메틸아미노)부틸-2-푸라닐]메틸]티오]-에탄아민2-[[[5- (4-dimethylamino) butyl-2-furanyl] methyl] thio] -ethanamine

칼륨-3급-부톡시화물(8.98g)을 함유하는 건성 디메틸포름아미드 (125㎖)냉용액에 염산시스테아민(4.5g)을 가했다. 이 혼합물을 20분동안 교반한 다음 아세트산 [5-[4-(디메틸아미노)부틸]-2-푸라닐] 메틸(9.6g)을 가했다. 이 반응물을 섭씨 90도에서 4시간 동안 가열한 다음 얼음과 물의 혼합물에 쏟아붓고 클로로포름으로 추출하여 얻어진 유기 추출물을 증류해서 황색기름을 얻었다. 용리액으로 메탄올/0.880 암모니아(9 : 1)을 사용하여 실리카 상에서 관크로마토그래피한 다음 더욱 더 증류해서 무색의 기름을 수득하였다.Cysteamine hydrochloride (4.5 g) was added to a dry dimethylformamide (125 mL) cold solution containing potassium tert-butoxide (8.98 g). The mixture was stirred for 20 minutes and then acetic acid [5- [4- (dimethylamino) butyl] -2-furanyl] methyl (9.6 g) was added. The reaction was heated at 90 ° C. for 4 hours, poured into a mixture of ice and water, and extracted with chloroform to distill the organic extract to give yellow oil. Tube chromatography on silica using methanol / 0.880 ammonia (9: 1) as eluent was followed by further distillation to give a colorless oil.

비점 ; 섭씨 140도(0.05mmHg)Boiling point; 140 degrees Celsius (0.05mmHg)

분석 실측치 ; C,60.81 ; H, 9.86 ; N,10.44Analysis observed; C, 60.81; H, 9. 86; N, 10.44

C13H24N2OS의 계산치 ; C, 60.91; H,9.44; N,10.93%Calcd for C 13 H 24 N 2 OS; C, 60.91; H, 9.94; N, 10.93%

[실시예 C]Example C

2-[[2-(2-푸라닐)에틸]티오]에틸-1H-이소인돌-1,3(2H)디온2-[[2- (2-furanyl) ethyl] thio] ethyl-1H-isoindole-1,3 (2H) dione

2-프탈아미도-에탄올(1.03g)을 함유하는 건성 디메틸포름아미드 용액에 80%의 수소화나트륨(0.115g)을 섭씨 0도에서 적하하였다. 20분후에, 2-푸란에탄올과 4-메틸벤젠술푼산염(1.33g)을 함유하는 건성 디메틸포름아미드 용액을 여기에 적하하고 이 용액을 실온에서 하룻밤 동안 교반하였다. 이 혼합물을 얼음-물 용액에 쏟자 백색 고체인 2-[[2-(2-푸라닐)에틸]티오]에틸-1H-이소인돌-1,3(2H)-디온(1.3g)이 분리되었다.To a dry dimethylformamide solution containing 2-phthalamido-ethanol (1.03 g), 80% sodium hydride (0.115 g) was added dropwise at 0 degrees Celsius. After 20 minutes, a dry dimethylformamide solution containing 2-furanethanol and 4-methylbenzenesulfonate (1.33 g) was added dropwise thereto and the solution was stirred overnight at room temperature. The mixture was poured into an ice-water solution to separate white solid 2-[[2- (2-furanyl) ethyl] thio] ethyl-1H-isoindole-1,3 (2H) -dione (1.3 g). .

융점 ; 섭씨 53-55도Melting point; 53-55 degrees celsius

[실시예 D]Example D

(a) 2-[2-[[(2-푸라닐)메틸]티오]에틸-1H-이소인돌-1,3(2H)- 디온(a) 2- [2-[[(2-furanyl) methyl] thio] ethyl-1H-isoindole-1,3 (2H) -dione

푸르푸릴메르캅탄(6g)을 함유하는 건성 디메틸포름아미드(50㎖)용액에 80%의 수소화나트륨(1.58g)을 적하하였다. 30분 후에 2-브로모에틸 프탈아미드(16.71g)용액을 건성 디메틸포름아미드(65㎖)에 가하고 이 용액을 섭씨 100도에서 2일동안 가열하였다.80% sodium hydride (1.58 g) was added dropwise to a dry dimethylformamide (50 mL) solution containing furfuryl mercaptan (6 g). After 30 minutes, 2-bromoethyl phthalamide (16.71 g) solution was added to dry dimethylformamide (65 mL) and the solution was heated at 100 degrees Celsius for 2 days.

용매를 제거한 후에 잔류물을 물로 세척하고 아세트산 에틸로 추출하였다.After removal of the solvent the residue was washed with water and extracted with ethyl acetate.

얻어진 아세트산에틸 추출물에서 용매를 제거하고 잔류물을 시클로헥산에서 재결정하여 2-[2-[[(2-푸라닐)메틸]티오]에틸-1H-이소인돌-1,3(2H)-디온(7.8g)을 얻었다.The solvent was removed from the obtained ethyl acetate extract and the residue was recrystallized from cyclohexane to give 2- [2-[[(2-furanyl) methyl] thio] ethyl-1H-isoindole-1,3 (2H) -dione ( 7.8 g) was obtained.

융점 ; 섭씨 62-63도Melting point; 62-63 Celsius

ω-브로모알킬프탈이미드와 프루프릴메르캅탄으로부터 동일하게 제조된 것으로는;those prepared identically from ω-bromoalkylphthalimide and frucrylmercaptan;

(b) 2-[3-[[(2-푸라닐)메틸]티오]프로필]-1H-이소인돌-1,3(2H)-디온(b) 2- [3-[[(2-furanyl) methyl] thio] propyl] -1 H-isoindole-1,3 (2H) -dione

NMR(CDCl3) 7.7-8.3m(2H); 7.2-7.7m(2H); 6.29s(2H); 6.23t(2H); 3.7m(2H); 2.7m(1H); 2.4m(4H).NMR (CDCl 3 ) 7.7-8.3 m (2H); 7.2-7.7 m (2H); 6.29 s (2H); 6.23 t (2H); 3.7 m (2H); 2.7 m (1 H); 2.4 m (4 H).

(c) 2-[4-[[(2-푸라닐)메틸]티오]부틸]-1H-이소인돌-1,3(2H)-디온,(c) 2- [4-[[(2-furanyl) methyl] thio] butyl] -1 H-isoindole-1,3 (2H) -dione,

NMR(CDCl3) 8-8.5m(4H); 7.49t(2H); 6.33m(4H); 3.7n(2H); 2.7m(1H); 2.3m(4H).NMR (CDCl 3 ) 8-8.5 m (4H); 7.49 t (2H); 6.33 m (4 H); 3.7n (2H); 2.7 m (1 H); 2.3 m (4H).

[실시예 E]Example E

(a) 2-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오-에틸-1H-이소인돌-1,3(2H)-디온. 36% 포름알데히드 용액(3㎖)를 함유하는 아세트산(50㎖)와 2-[2-[[(2-푸라닐)메틸]티오]에틸]-1H-이소인돌-1,3(2H)-디온 (10g), 염화디메틸 암모늄(3.1g)의 혼합물을 수증기탕 위에서 9시간 동안 가열하였다.(a) 2- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio-ethyl-1H-isoindole-1,3 (2H) -dione. Acetic acid (50 mL) with 36% formaldehyde solution (3 mL) and 2- [2-[[(2-furanyl) methyl] thio] ethyl] -1 H-isoindole-1,3 (2H)- A mixture of dione (10 g), dimethyl ammonium chloride (3.1 g) was heated on a steam bath for 9 hours.

이 용액을 냉각하고 용매는 진공속에서 제거하였다. 잔류물에 5N의 수산화나트륨을 가해서 염기성으로 만들어 아세트산에틸로 추출하였다. 유기상을 활성탄으로 처리하고 건조시킨 다음 증발시켜서 관크로마토그래피(실리카/에탄올 : 아세트산에틸 1 : 1)로 정제하여 기름(5.7g)을 수거하였다.The solution was cooled and the solvent removed in vacuo. 5N sodium hydroxide was added to the residue to make basic and extracted with ethyl acetate. The organic phase was treated with activated charcoal, dried and evaporated to purify by column chromatography (silica / ethanol: ethyl acetate 1: 1) to collect oil (5.7 g).

Rf ; 0.4Rf; 0.4

NMR(DCDl3/DMSO) 7.71s(6H); 7.22t(2H); 6.52s(2H); 6.2s(2H); 6.1t(2H); 3.8m(2H); 2.2m(4H).NMR (DCDL 3 / DMSO) 7.71 s (6H); 7.22 t (2H); 6.52 s (2H); 6.2 s (2H); 6.1 t (2H); 3.8 m (2H); 2.2 m (4 H).

2-[ω-[[[(2-푸라닐)메틸]티오]-알킬]-1H-이소인돌-1,3-디온과 유사한 아민, 포름알데히드로부터 동알히게 제조된 것으로는;Amines similar to 2- [ω-[[[(2-furanyl) methyl] thio] -alkyl] -1H-isoindole-1,3-dione, which are prepared equivalently from formaldehyde;

(b) 2-[2-[[[5-(1-피롤리디닐)메틸]-2-푸라닐]메틸]티오]-에틸-1H-이소인돌-1,3(2H)-디온.(b) 2- [2-[[[5- (1-pyrrolidinyl) methyl] -2-furanyl] methyl] thio] -ethyl-1H-isoindole-1,3 (2H) -dione.

NMR(CDCl3) 8-8.4m(4H); 7-7.6m(6H) 6-6.5m(6H); 3.7-4.0m(2H); 2-2.4m(4H).NMR (CDCl 3 ) 8-8.4 m (4H); 7-7.6 m (6H) 6-6.5 m (6H); 3.7-4.0 m (2H); 2-2.4 m (4H).

(c) 2-[3-[[[5-디메틸아미노)메틸-2-푸라닐]메틸]티오]-프로필-1H-이소인돌-1,3(2H)-디온.(c) 2- [3-[[[5-dimethylamino) methyl-2-furanyl] methyl] thio] -propyl-1H-isoindole-1,3 (2H) -dione.

Rf ; 0.45(실리카/메탄올)Rf; 0.45 (silica / methanol)

(d) 2-[4-[[[5-디메틸아미노)메틸-2-푸라닐]메틸]티오]-부틸]-1H-이소인돌-1,3(2H)-디온(d) 2- [4-[[[5-dimethylamino) methyl-2-furanyl] methyl] thio] -butyl] -1 H-isoindole-1,3 (2H) -dione

Rf ; 0.26(실리카/메탄올)Rf; 0.26 (silica / methanol)

(e) 2-[2-[[[5-(4-메틸-1-피페라지닐]메틸]-2-푸라닐]-메틸]티오]에틸]-1H-이소인돌-1,3(2H)-디온.(e) 2- [2-[[[5- (4-methyl-1-piperazinyl] methyl] -2-furanyl] -methyl] thio] ethyl] -1 H-isoindole-1,3 (2H ) -Dion.

NMR(CDCl3)7.75s(3H); 7.52s(8H); 7-7.5m(2H); 6.5s(2H) 6-6.3m (4H); 3.85m (2H); 2-2.4m(4H).NMR (CDCl 3 ) 7.75 s (3H); 7.52 s (8H); 7-7.5 m (2H); 6.5 s (2H) 6-6.3 m (4H); 3.85 m (2 H); 2-2.4 m (4H).

(f) 2-[2-[[[5-(4-몰포리닐)메틸]-2-푸라닐]메틸]티오]-에틸]-1H-이소인돌-1,3(2H)-디온(f) 2- [2-[[[5- (4-morpholinyl) methyl] -2-furanyl] methyl] thio] -ethyl] -1H-isoindole-1,3 (2H) -dione

NMR(CDCl3) 7.54m (4H); 7.24m (2H); 6.50s (2H); 6.22m (6H); 3.8m (2H); 2.0-2.4m(4H).NMR (CDCl 3 ) 7.54 m (4H); 7.24 m (2 H); 6.50 s (2H); 6.22 m (6 H); 3.8 m (2H); 2.0-2.4 m (4H).

[실시예 F]Example F

2-[2-[[2-[5-(디메틸아미노)메틸-2-푸라닐]에틸]티오]에틸]-1H-이소인돌-1,3(2H)-디온2- [2-[[2- [5- (dimethylamino) methyl-2-furanyl] ethyl] thio] ethyl] -1 H-isoindole-1,3 (2H) -dione

2-[[2-(2-푸라닐)에틸]티오-1H-이소인돌-1,3(2H)-디온(0.5g), 염산디메틸아민(0.27g)과 파라포름알데히드(0.102g)을 에탄올중에서 환류하며 가열했다.2-[[2- (2-furanyl) ethyl] thio-1H-isoindole-1,3 (2H) -dione (0.5 g), dimethylamine hydrochloride (0.27 g) and paraformaldehyde (0.102 g) Heated under reflux in ethanol.

5시간 후에, 염산디메틸아민(0.27g)과 파라포름알데히드(0.102g)을 여기에 더가하고 16시간동안 계속 해서 가열했다. 용매를 제거한 다음 잔류물을 염기성으로 만들고 아세트산 에틸로 추출하여 기름을 얻었다. 이것을 관크로마토그라피(실리카/메탄올)해서 담색기름인 2-[2-[5-(디메틸아미노)메틸-2-푸라닐]에틸]티오-에틸]-1H-이소인돌-1,3(2H)-디온(0.43g)을 수거하였다.After 5 hours, dimethylamine hydrochloride (0.27 g) and paraformaldehyde (0.102 g) were added thereto and heating continued for 16 hours. The solvent was removed and the residue was made basic and extracted with ethyl acetate to give an oil. This was subjected to tube chromatography (silica / methanol) to give 2- [2- [5- (dimethylamino) methyl-2-furanyl] ethyl] thio-ethyl] -1H-isoindole-1,3 (2H) as a pale oil. Dione (0.43 g) was collected.

분석 실측치 ; C, 61.48; H, 6.13; N, 7.63Analysis observed; C, 61.48; H, 6. 13; N, 7.63

C19H22N2O3S.3/4H2O의 계산치; C,61.35; H, 6.37; N, 7.53%Calcd. For C 19 H 22 N 2 O 3 S.3 / 4H 2 O; C, 61.35; H, 6. 37; N, 7.53%

[실시예 G]Example G

2-[[5-(디메틸아미노)메틸-2-푸라닐]메톡시]에탄아민2-[[5- (dimethylamino) methyl-2-furanyl] methoxy] ethanamine

방법(ⅰ)Method

메탄술폰산 (11.6g)을 함유하는 테트라히드로푸란(40㎖)를 5-(디메틸아미노)메틸-2-푸란메탄올(6.2g)과 에틸렌아민(2.82g)을 함유하는 건성 테트라히드로푸란 용액에 가하였다. 이 용액을 증발시킨 다음 유성(油性)잔류물을 섭씨 98-100도에서 10분동안 가열했다.Tetrahydrofuran (40 ml) containing methanesulfonic acid (11.6 g) was added to a dry tetrahydrofuran solution containing 5- (dimethylamino) methyl-2-furanmethanol (6.2 g) and ethyleneamine (2.82 g). It was. The solution was evaporated and the oily residue was heated at 98-100 degrees Celsius for 10 minutes.

18시간 후에, 5N의 수산화나트륨(60㎖)를 가하고 2시간 후에 이 서스펜션을 여과한 다음 탈색 활성탄으로 처리하고 증발시켰다.After 18 hours, 5N sodium hydroxide (60 mL) was added and after 2 hours the suspension was filtered, treated with decolorized activated carbon and evaporated.

생성된 기름을 먼저 메탄올-암모니아 0.88을 79: 1로해서 크로마토그래피하여 용출액은 버리고, 다음으로 메탄올-암모니아 0.88을 19 : 1로 해서 크로마토그래피한 용출액은 증발시켜서 기름을 얻고 이 기름으로부터 2-[[5-(디메틸아미노)메틸-2-푸라닐]메톡시]-에탄아민의 비스-옥살산염(에탄올에서 수득)0.2g을 얻었다.The resulting oil was chromatographed first with methanol-ammonia 0.88 at 79: 1 and the eluate was discarded. Next, the eluate chromatographed with methanol-ammonia 0.88 at 19: 1 was evaporated to obtain an oil. 0.2 g of bis-oxalate (obtained from ethanol) of [5- (dimethylamino) methyl-2-furanyl] methoxy] -ethanamine was obtained.

융점; 섭씨 125-128도Melting point; 125-128 degrees celsius

방법(ⅱ)Method (ii)

칼륨-3급-부톡시화물(8.96g)과 5-(디메틸-아미노)메틸-2-푸란메탄올(12.4g)을 함유하는 건성 디메틸포름아미드 냉용액을 교반하면서 여기에 염산 2-클로로에틸아민(6.25g)을함유하는 건성디메틸 포름아미드 용액을 적하하였다.2-chloroethylamine hydrochloride while stirring dry dimethylformamide cold solution containing potassium tert-butoxide (8.96 g) and 5- (dimethyl-amino) methyl-2-furanmethanol (12.4 g) (6.25 g) was added dropwise a dry dimethyl formamide solution.

2시간 후에 용매를 제거하고 잔류물을 염기성으로 만들어서 아세트산에틸로 추출하였다. 용매를 제거한 후에 에탄올 중에서 잔류물을 에탄올성 옥살산으로 처리하였다.After 2 hours the solvent was removed and the residue was made basic and extracted with ethyl acetate. After removal of the solvent the residue was treated with ethanol oxalic acid in ethanol.

생성된 결정성염을 에탄올에서 재결정하여 2-[[5-(디메틸아미노)메틸-2-푸란)메톡시 에탄아민(3.05g)을 수득하였다.The resulting crystalline salt was recrystallized in ethanol to give 2-[[5- (dimethylamino) methyl-2-furan) methoxy ethanamine (3.05 g).

비스옥살산염의 융점; 섭씨 130-133도Melting point of bisoxalate; 130-133 degrees celsius

방법(ⅱ)에 의해서 동일하게 제조된것으로는;Prepared identically by method (ii);

(b)2-[[5-(메틸아미노)메틸-2-푸란]메톡시]에탄아민,(b) 2-[[5- (methylamino) methyl-2-furan] methoxy] ethanamine,

비스옥살산염의 융점; 섭씨 162-164도Melting point of bisoxalate; 162-164 degrees Celsius

[실시예 H]Example H

(a) 2-[4-(2-푸라닐)부틸]-1H-이소인돌-1,3(2H)-디온(a) 2- [4- (2-furanyl) butyl] -1 H-isoindole-1,3 (2H) -dione

2[1-(4-브로모부틸)]푸란 (406㎎)과 프탈이미드화 칼륨(370㎎)을 건성 디메틸포름아미드 중에서 하룻밤 동안 실온에서 교반하였다.2 [1- (4-bromobutyl)] furan (406 mg) and potassium phthalimide (370 mg) were stirred in dry dimethylformamide overnight at room temperature.

이 용액을 얼음-물에 쏟아붓고 생성된 백색고체를 여과, 건조시킨 다음 클로로포름/석유 에텔(비점 섭씨 60-80도)중에서 재결정하여 백색의 미(微)결정체인 2-[4-(2-푸라닐)부틸]-1H-이소인돌-1,3(2H)-디온 (430㎎)을 수득하였다.The solution was poured into ice-water, the resulting white solid was filtered and dried, and then recrystallized in chloroform / petroleum ether (60-80 degrees C. boiling point) to give a white microcrystalline 2- [4- (2- Furanyl) butyl] -1H-isoindole-1,3 (2H) -dione (430 mg) was obtained.

융점 ; 섭씨 61-63도Melting point; 61-63 Celsius

동일한 방법으로 제조된 것으로는;Prepared in the same manner;

(b) 2-[5-(2-푸라닐)펜틸]-1H-인소인돌-1,3(2H)-디온(b) 2- [5- (2-furanyl) pentyl] -1 H-phosphoindole-1,3 (2H) -dione

융점; 섭씨 54-56도Melting point; 54-56 degrees celsius

[실시예 I]Example I

(a)2-[4-(5-(디메틸아미노)메틸-2-푸라닐-부틸]-1H-이소인돌-1,3(2H)-디온(a) 2- [4- (5- (dimethylamino) methyl-2-furanyl-butyl] -1 H-isoindole-1,3 (2H) -dione

2-[4-(2-푸라닐)부틸]-1H-이소인돌-1,3(2H)-디온(5.38g), 파라포름 알데히드(1.2g)과 염산 디메틸아민(3.26g)을 무수에탄올(100㎖)중에서 환류시켰다. 6시간 후에 파라포름알데히드 (0.6g)과 염산 디메틸아민(1.6g)을 더가하고 20시간동안 계속해서 가열하였다.2- [4- (2-furanyl) butyl] -1H-isoindole-1,3 (2H) -dione (5.38 g), paraformaldehyde (1.2 g) and dimethylamine hydrochloride (3.26 g) It was refluxed in (100 mL). After 6 hours, paraformaldehyde (0.6 g) and dimethylamine hydrochloride (1.6 g) were added and heating continued for 20 hours.

용매를 증발시키고 잔류물에 5N의 수산화나트륨을 가해서 강염기성으로 만들어 아세트산에틸로 추출한 다음 유기층을 증발시켰다. 조생성물을 관크로마토그래피로 정제해서 호박색 기름(3.25g)을 수득하였다.The solvent was evaporated and 5N sodium hydroxide was added to the residue to make it highly basic, extracted with ethyl acetate, and the organic layer was evaporated. The crude product was purified by tube chromatography to give amber oil (3.25 g).

Rf ; 0.4(실리카/메탄올)Rf; 0.4 (silica / methanol)

NMR(CDCl3)8-8.6m(4H); 7.75s (6H); 7.3m (2H); 6.55S(2H); 6.3m(2H) ; 1.9-2.4m (4H).NMR (CDCl 3 ) 8-8.6 m (4H); 7.75 s (6 H); 7.3 m (2H); 6.55 S (2 H); 6.3 m (2H); 1.9-2.4 m (4H).

동일한 방법으로 제조된 것으로로는;As prepared in the same manner;

(b) 2-[5-[5-(디메틸아미노)메틸-2-푸라닐]펜틸-1H-이소인돌-1,3(2H)-디온(b) 2- [5- [5- (dimethylamino) methyl-2-furanyl] pentyl-1H-isoindole-1,3 (2H) -dione

TLC Rf ; 0.4(실리카/메탄올)TLC Rf; 0.4 (silica / methanol)

NMR 8.0-8.8m (6H); 7.70m (6H); 7.37t (2H); 6.52s (2H); 6.30t (2h); 4.0m (2H); 2.2m (4H).NMR 8.0-8.8 m (6H); 7.70 m (6 H); 7.37 t (2 H); 6.52 s (2H); 6.30 t (2 h); 4.0 m (2H); 2.2 m (4 H).

[실시예 J]Example J

5-(디메틸아미노)메틸-2-푸란프로판아민5- (dimethylamino) methyl-2-furanpropanamine

푸란프로피오니트릴 (1.21g), 염산디메틸아민(1.62g), 파라포름알데히드(0.7g), 에탄올(20㎖)를 환류하면서 24시간 동안 가열하였다.Furanpropionitrile (1.21 g), dimethylamine hydrochloride (1.62 g), paraformaldehyde (0.7 g) and ethanol (20 mL) were heated to reflux for 24 hours.

용매를 제거하고, 잔류물을 pH12로 만들어서 아세트산에틸로 추출했다. 용매를 제거한 후에 잔류된 기름을 관크로마토그래피(실리카/메탄올)로 정제해서 5-(디메틸아미노)-메틸-2-푸란프로피오니트릴(0.6g)을 분리하였다.The solvent was removed and the residue was brought to pH 12 and extracted with ethyl acetate. After the solvent was removed, the remaining oil was purified by column chromatography (silica / methanol) to separate 5- (dimethylamino) -methyl-2-furanpropionitrile (0.6 g).

Rf ; 0.55(실리카/메탄올).Rf; 0.55 (silica / methanol).

니트릴(6.0g)을 함유하는 건성 에테르(40㎖)를 수소화리튬알루미늄(2.0g)을 함유하는 에테르에 적하하면서 섭씨 0도에서 교반하였다. 물을 가하고 용매를 제거해서 관크로마토그래피한 후에 담색기름인 5-(디메틸아미노)-메틸-2-푸란프로판아민(3.33g)을 얻었다.Dry ether (40 ml) containing nitrile (6.0 g) was added dropwise to ether containing lithium aluminum hydride (2.0 g) and stirred at 0 degrees Celsius. Water was added, the solvent was removed, and the residue was subjected to column chromatography to give 5- (dimethylamino) -methyl-2-furanpropanamine (3.33 g) as a pale oil.

NMR(CDCl3) 8.2m (2H); 7.6br (2H); 7.75s (6H); 7.30m (4H); 6.60s (2H); 4.0m (2H).NMR (CDCl 3 ) 8.2 m (2H); 7.6 br (2H); 7.75 s (6 H); 7.30 m (4 H); 6.60 s (2 H); 4.0 m (2 H).

[실시예 K]Example K

2-[3-[[[5-(디메틸아미노)메틸-2-푸라닐]티오]프로필]]-1H-이소인돌-1,3(2H)-디온2- [3-[[[5- (dimethylamino) methyl-2-furanyl] thio] propyl]]-1H-isoindole-1,3 (2H) -dione

N,N-디메틸푸란 메탄아민(75g)의 리티오 유도체 용액에 황(1.9g)을 섭씨 -40도에서 적하하였다. 혼합물을 섭씨-10도에서 20분동안 교반하고 2-(3-브로모프로필)-1H-이소인돌-1,3(2H)-디온(16g)을 가했다. 이 혼합물을 섭씨 0도에서 하룻밤 방치하고 용매를 진공에서 제거한 다음 아세트산에틸중의 잔류물을 여과해서 2N의 황산으로 추출하였다. 수성층을 염기화하고 아세트산 에틸로 재추출한 후 유기층을 건조시켰다. 용매를 제거해서 얻어진 결정상 고체를 에탄올(활성탄)에서 재결정하여 2-[3-[[5-(디메틸아미노)-메틸-2-푸라닐]티오]프로필]]-1H-이소인돌-1,3(2H)-디온(7.59g)을 수득하였다.Sulfur (1.9 g) was added dropwise at -40 degrees Celsius to a solution of a thio derivative of N, N-dimethylfuran methaneamine (75 g). The mixture was stirred at -10 degrees Celsius for 20 minutes and 2- (3-bromopropyl) -1H-isoindole-1,3 (2H) -dione (16 g) was added. The mixture was left overnight at 0 degrees Celsius, the solvent was removed in vacuo and the residue in ethyl acetate was filtered off and extracted with 2N sulfuric acid. The aqueous layer was basified, reextracted with ethyl acetate and the organic layer was dried. The crystalline solid obtained by removing the solvent was recrystallized from ethanol (activated carbon) to give 2- [3-[[5- (dimethylamino) -methyl-2-furanyl] thio] propyl]]-1H-isoindole-1,3 (2H) -dione (7.59 g) was obtained.

융점 ; 섭씨 64-65도Melting point; 64-65 degrees celsius

[실시예 L]Example L

(a) 4-[5-(디메틸아미노)메틸-2-푸라닐]부탄아민(a) 4- [5- (dimethylamino) methyl-2-furanyl] butanamine

2-[[4-(5-디메틸아미노)메틸-2-푸라닐]부틸-1H-이소인돌-1,3(2H)-디온(2.9g)과 히드라진 수화물(0.5㎖)를 에탄올 중에서 6시간 동안 환류하였다. 용매를 제거해서 얻어진 결정상 잔류물을 5N의 수산화나트륨 용액에 용해하고 이것을 아세트산에틸로 추출한 다음 용매를 제거해서 황색 모빌유(1.68g)을 수득하였다. Rf값이 0.15인 위치에서 단일점이 나타났다. (TLC 실리카/메탄올)2-[[4- (5-dimethylamino) methyl-2-furanyl] butyl-1H-isoindole-1,3 (2H) -dione (2.9 g) and hydrazine hydrate (0.5 mL) in ethanol for 6 hours At reflux. The crystalline residue obtained by removing the solvent was dissolved in 5N sodium hydroxide solution, which was extracted with ethyl acetate, and then the solvent was removed to give a yellow mobile oil (1.68 g). A single point appeared at the position where the R f value was 0.15. (TLC Silica / Methanol)

NMR(CDCl3) 8.0-8.8m (4H); 7.7s(6H); 7.6br(2H); 7.3m (4H); 6.548s(2H); 4.0m (2H).NMR (CDCl 3 ) 8.0-8.8 m (4H); 7.7 s (6H); 7.6 br (2H); 7.3 m (4H); 6.548 s (2H); 4.0 m (2 H).

유사한 프탈이미드로부터 동일하게 제조된 것으로는;Identically prepared from similar phthalimides;

(b) 5-[5-(디메틸아미노)메틸-2-푸라닐]펜탄아민(b) 5- [5- (dimethylamino) methyl-2-furanyl] pentanamine

NMR(CDCl3) 8.0-8.8m (6H); 7.75s(6H); 7.0-7.6m(2H); 4.0m (2H).NMR (CDCl 3 ) 8.0-8.8 m (6H); 7.75 s (6 H); 7.0-7.6 m (2H); 4.0 m (2 H).

(c) 5-[[[(3-아미노프로필)티오]메틸]-N,N-디메틸푸란-2-메탄아민(c) 5-[[[(3-aminopropyl) thio] methyl] -N, N-dimethylfuran-2-methanamine

MNR(CDCl3) 8-8.5m (2H); 7.57s(6H); 7.42t(2H); 7.25m (2H); 6.58s(2H); 6.3s(2H); 3.88s(2H).MNR (CDCl 3 ) 8-8.5 m (2H); 7.57 s (6H); 7.42 t (2H); 7.25 m (2 H); 6.58 s (2H); 6.3 s (2H); 3.88 s (2H).

[실시예 1]Example 1

(a) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N'-메틸티오우레아(a) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N'-methylthiourea

2-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸-1H-이소인돌-1,3(2H)-디온(5.3g)과 히드라진 수화물(0.85g)을 에탄올 중에서 30분 동안 환류했다. 용매를 증발해서 2[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에탄아민의 프탈히드라지드염을 수득하였다.2- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl-1H-isoindole-1,3 (2H) -dione (5.3 g) with hydrazine hydrate (0.85 g) was refluxed in ethanol for 30 minutes. The solvent was evaporated to give the phthalhydrazide salt of 2 [[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethanamine.

이 염(1g)을 아세토니트릴에 부유시키고 이소티오시안산 메틸(0.21g)을 가했다. 이 서스펜션을 실온에서 5시간동안 교반하고 섭씨 60도에서 2시간 동안 교반한 다음 여과하고 증발시켜서 얻은 기름을 관크로마토그래피(실리카/메탄올)로 정제하여 담색 기름인 N-2-[[[5-디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸-N'-메틸티오우레아(0.3g)을 분리시켰다.This salt (1 g) was suspended in acetonitrile and methyl isothiocyanate (0.21 g) was added. The suspension was stirred for 5 hours at room temperature, stirred for 2 hours at 60 degrees Celsius, filtered and evaporated, and the oil obtained by purification was purified by tube chromatography (silica / methanol) to give a pale oil, N-2-[[[5- Dimethylamino) methyl-2-furanyl] methyl] thio] ethyl-N'-methylthiourea (0.3 g) was isolated.

분석 실측치 ; C, 49.68; H, 7.52; N, 14.22Analysis observed; C, 49.68; H, 7.52; N, 14.22

C12H21N3OS2의 계산치 ; C,50.14; H,7.37; N,14.62%Calcd for C 12 H 21 N 3 OS 2 ; C, 50.14; H, 7.37; N, 14.62%

동일하게 제조된 것으로는;To be prepared in the same way;

(b) N-메틸-N'-[2-[[[5-(1-피롤리디닐)메틸-2-푸라닐]메틸]티오]에틸]티오우레아(b) N-methyl-N '-[2-[[[5- (1-pyrrolidinyl) methyl-2-furanyl] methyl] thio] ethyl] thiourea

분석 실측치 ; C, 52.33; H, 7.12 ; N,13.17Analysis observed; C, 52.33; H, 7. 12; N, 13.17

C14H23N3OS2·1/2H2O의 계산치 ; C, 52.14; H, 7.50; H,13.03%Calcd for C 14 H 23 N 3 OS 2 1 / 2H 2 O; C, 52.14; H, 7. 50; H, 13.03%

(c) N-[4-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]부틸]-N'-메틸티오우레아(c) N- [4-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] butyl] -N'-methylthiourea

분석 실측치 ; C, 51.69; H, 8.53 ; N,12.83Analysis observed; C, 51.69; H, 8.53; N, 12.83

C14H25N3OS2의 계산치 ; C, 51.82; H, 8.08; N,12.95%Calcd for C 14 H 25 N 3 OS 2 ; C, 51.82; H, 8.08; N, 12.95%

(d) N-[3-[[5-(디메틸아미노)메틸-2-푸라닐]티오프로필]-N'-메틸티오우레아(d) N- [3-[[5- (dimethylamino) methyl-2-furanyl] thiopropyl] -N'-methylthiourea

분석 실측치 ; C, 49.71; H, 7.33 ; N,14.35Analysis observed; C, 49.71; H, 7.33; N, 14.35

C12H21N3OS2의 계산치 ; C, 50.10; H, 7.30; N,14.62%Calcd for C 12 H 21 N 3 OS 2 ; C, 50.10; H, 7. 30; N, 14.62%

(e) N-메틸-N'-[2-[[[5-(4-몰포리닐)메틸]-2-푸라닐]메틸]티오]에틸]티오우레아(e) N-methyl-N '-[2-[[[5- (4-morpholinyl) methyl] -2-furanyl] methyl] thio] ethyl] thiourea

분석 실측치 ; C, 51.26; H, 7.08 ; N,12.51Analysis observed; C, 51.26; H, 7.08; N, 12.51

C14H23N3O2S2의 계산치 ; C, 51.03; H, 7.04; N,12.75%Calcd for C 14 H 23 N 3 O 2 S 2 ; C, 51.03; H, 7.04; N, 12.75%

(f) N-메틸-N'-[2-[[[5-[(4-몰포리닐)메틸]-2-푸라닐]메틸]티오]에틸]티오우레아(f) N-methyl-N '-[2-[[[5-[(4-morpholinyl) methyl] -2-furanyl] methyl] thio] ethyl] thiourea

분석 실측치 ; C, 50.93; H, 7.74 ; N,15.82Analysis observed; C, 50.93; H, 7. 74; N, 15.82

C15H26N4OS2의 계산치 ; C, 51.25; H, 8.03; N,15.94%Calcd for C 15 H 26 N 4 OS 2 ; C, 51.25; H, 8.03; N, 15.94%

(g) N-[2-[[2-[5-(디메틸아미노)메틸-2-푸라닐]에틸]티오]에틸]-N'-메틸티오우레아(g) N- [2-[[2- [5- (dimethylamino) methyl-2-furanyl] ethyl] thio] ethyl] -N'-methylthiourea

분석 실측치 ; C, 50.19; H, 7.20 ; N,13.18Analysis observed; C, 50.19; H, 7. 20; N, 13.18

C13H23N3O2O·1/2H2O의 계산치 ; C, 50.32; H, 7.74; N,13.54%Calcd for C 13 H 23 N 3 O 2 O · 1 / 2H 2 O; C, 50.32; H, 7. 74; N, 13.54%

[실시예 2]Example 2

(a) N-[5-[5-(디메틸아미노)메틸-2-푸라닐]펜틸]-N'-메틸티오우레아(a) N- [5- [5- (dimethylamino) methyl-2-furanyl] pentyl] -N'-methylthiourea

5-[5-(디메틸아미노)메틸-2-푸라닐]펜탄아민(0.5g)과 이소티오시안산메틸(0.25g)을 아세토니트릴 중에서 24시간 동안 실온에서 교반하였다. 용매를 제거하고 생성물을 관크로마토그래피(실리카/메탄올)로 정제한 후 에테르와 함께 분쇄해서 혼백색 결정인 N-5-[5-(디메틸아미노)메틸-2-푸라닐]펜틸]-N'-메틸티오우레아를 수득하였다.5- [5- (dimethylamino) methyl-2-furanyl] pentanamine (0.5 g) and methyl isothiocyanate (0.25 g) were stirred in acetonitrile at room temperature for 24 hours. The solvent was removed and the product was purified by column chromatography (silica / methanol) and triturated with ether to give the off-white crystals N-5- [5- (dimethylamino) methyl-2-furanyl] pentyl] -N '. -Methylthiourea was obtained.

융점; 섭씨 66-69도Melting point; 66-69 degrees Celsius

유사한 아민과 이소티오시안산메틸로부터 동일하게 제조된 것으로는;Identically prepared from similar amines and methyl isothiocyanate;

(b) N-[3-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-프로필]-N'-메틸티오우레아(b) N- [3-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -propyl] -N'-methylthiourea

분석 실측치 ; C, 51.38; H, 7.93 ; N,13.41Analysis observed; C, 51.38; H, 7.93; N, 13.41

C13H23N2OS2의 계산치 ; C, 51.79; H, 7.69; N,13.94%Calcd for C 13 H 23 N 2 OS 2 ; C, 51.79; H, 7.69; N, 13.94%

(c) N-[4-[5-(디메틸아미노)메틸-2-푸라닐]부틸]-N'-메틸티오우레아(c) N- [4- [5- (dimethylamino) methyl-2-furanyl] butyl] -N'-methylthiourea

NMR(CDCl3) 8-8.6m (4H) 7.22 S(6H); 7.35t (2H); 6.98 d(3H); 6.2-6.8m (4H); 4.0d(2H); 3-3.8m (2H).NMR (CDCl 3 ) 8-8.6 m (4H) 7.22 S (6H); 7.35 t (2 H); 6.98 d (3 H); 6.2-6.8 m (4H); 4.0d (2H); 3-3.8 m (2 H).

(d) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메톡시]에틸]-N'-메틸티오우레아(d) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methoxy] ethyl] -N'-methylthiourea

분석 실측치 ; C, 51.91; H, 8.14 ; N,14.98Analysis observed; C, 51.91; H, 8.14; N, 14.98

C12H21N3O2S.1/2H2O의 계산치 ; C, 51.40; H, 7.91; N,14.99%Calcd for C 12 H 21 N 3 O 2 S.1 / 2H 2 O; C, 51.40; H, 7.91; N, 14.99%

[실시예 3]Example 3

(a) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N'-(2-메톡시에틸)티오우레아 )(a) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N '-(2-methoxyethyl) thiourea)

1-(이소티오시아나토)-2-메톡시에탄(1.17g)과 2-[[[(5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에탄아민(2.14g)을 아세토니트릴중에서 하룻밤 방치하였다. 용매를 제거하고 잔류기름을 크로마토그래피(실리카/메탄올)해서 담색기름인 N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸-N'-(2-메톡시에틸)티오우레아를 수득하였다.1- (isothiocyanato) -2-methoxyethane (1.17 g) and 2-[[[(5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethanamine (2.14 g) The solvent was removed and the residual oil was chromatographed (silica / methanol) to give N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] as a pale oil. Ethyl-N '-(2-methoxyethyl) thiourea was obtained.

Rf : 0.45Rf: 0.45

분석 실측치 ; C, 50.64; H, 7.51; N,12.69Analysis observed; C, 50.64; H, 7.51; N, 12.69

C14H25N3O2S2의 계산치 ; C, 50.75; H, 7.55; N,12.68%Calcd for C 14 H 25 N 3 O 2 S 2 ; C, 50.75; H, 7.55; N, 12.68%

유사한 이소티오시안산염과 2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에탄아민으로부터 동일하게 제조된 것으로는;Prepared identically from similar isothiocyanates and 2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethanamine;

(b) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N'-(2-프로페닐)티오우레아(b) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N '-(2-propenyl) thiourea

분석 실측치 ; C, 52.68; H, 7.58 ; N,13.16Analysis observed; C, 52.68; H, 7. 58; N, 13.16

C14H23N3OS2·1/2H2O의 계산치 ; C, 52.14; H, 7.50; H,13.03%Calcd for C 14 H 23 N 3 OS 2 1 / 2H 2 O; C, 52.14; H, 7. 50; H, 13.03%

(c) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N-(1-메틸에틸)티오우레아(c) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N- (1-methylethyl) thiourea

분석 실측치 ; C, 51.84; H, 7.88 ; N,13.00Analysis observed; C, 51.84; H, 7.88; N, 13.00

C14H25N3OS2·1/2H2O의 계산치 ; C, 51.90; H, 8.09; N,12.97%Calcd for C 14 H 25 N 3 OS 2 1 / 2H 2 O; C, 51.90; H, 8.09; N, 12.97%

[실시예 4]Example 4

N-[2-[[[5-(메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N'-메틸우레아N- [2-[[[5- (methylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N'-methylurea

2-[[[5-(메틸아미노)메틸-2-푸라닐]메틸]티오]에탄아민(1.5g)을 함유하는 아세토니트릴(24㎖)용액을 교반하면서 여기에 이소시안산메틸(0.45g)을 함유하는 아세토니트릴(15㎖)용액을 적하하였다. 30분후에 이 용액을 건조될때까지 증발시켜 얻어진 기름을 먼저 실리카/메탄올 : 0.88 암모니아 79 : 1상에서 판크로마토그래피하고 다음으로 알루미나/메탄올상에서 관크로마토그래피하여 N-[2-[[[5-(메틸아미노)메틸-2-푸라닐]-메틸]티오]에틸]-N'-메틸우레아(0.25g)으로 이루어지는 기름을 수득하였다.Acetonitrile (24 mL) solution containing 2-[[[5- (methylamino) methyl-2-furanyl] methyl] thio] ethanamine (1.5 g) was added thereto while stirring with methyl isocyanate (0.45 g). Acetonitrile (15 mL) solution containing d) was added dropwise. After 30 minutes, the solution was evaporated to dryness. The oil obtained was first chromatographed on silica / methanol: 0.88 ammonia 79: 1 phase and then tube chromatography on alumina / methanol to give N- [2-[[[5- ( An oil consisting of methylamino) methyl-2-furanyl] -methyl] thio] ethyl] -N'-methylurea (0.25 g) was obtained.

분석 실측치 ; C,51.00; H,7.38; N,15.91Analysis observed; C, 51.00; H, 7.38; N, 15.91

C11H19N3O2S의 계산치 ; C,51.33; H,7.44; N,16.33%Calcd for C 11 H 19 N 3 O 2 S; C, 51.33; H, 7.44; N, 16.33%

[실시예 5]Example 5

(a) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N'-메틸우레아(a) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N'-methylurea

2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에탄아민과, 프탈히드라지드착물(2g)을 함유하는 아세토니트릴(50㎖)의 서스펜션에 이소시안산메틸(0.33g)을 가하였다. 2시간후에 이 용액을 여과하고 여액을 증발시켜서 얻어진 기름을 관크로마크로피(실리카/메탄올)로 정제해서 N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N'-메틸우레아를 수득하였다.Methyl isocyanate in the suspension of acetonitrile (50 mL) containing 2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethaneamine and phthalhydrazide complex (2 g) (0.33 g) was added. After 2 hours, the solution was filtered and the filtrate was evaporated. The oil obtained was purified by tube chromatography (silica / methanol) and purified by N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl]. Thio] ethyl] -N'-methylurea was obtained.

분석 실측치 ; C, 52.38; H, 77.61 ; N,15.25Analysis observed; C, 52.38; H, 77.61; N, 15.25

C12H21N3O2S·1/4H2O의 계산치 ; C, 52.24; H, 7.76; N,15.32%Calcd for C 12 H 21 N 3 O 2 S · 1 / 4H 2 O; C, 52.24; H, 7.76; N, 15.32%

동일하게 제조된 것으로는;To be prepared in the same way;

(b) N-메틸-N'-[2-[[[5-(1-피롤리디닐)메틸-2-푸라닐]-메틸]티오]에틸]우레아(b) N-methyl-N '-[2-[[[5- (1-pyrrolidinyl) methyl-2-furanyl] -methyl] thio] ethyl] urea

분석 실측치 ; C, 54.70; H, 7.33 ; N,14.07Analysis observed; C, 54.70; H, 7.33; N, 14.07

C14H23N3O2S·1/2H2O의 계산치 ; C, 54.87; H, 7.89; N,13.71%Calcd for C 14 H 23 N 3 O 2 S · 1 / 2H 2 O; C, 54.87; H, 7.89; N, 13.71%

[실시예 6]Example 6

(a) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸-N'-(1-메틸에틸)우레아(a) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl-N '-(1-methylethyl) urea

2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에탄아민(2.14g)과 이소시안산이소프로필(0.89g)을 아세토니트릴에 용해하고 하룻밤동안 정치하였다. 용매를 제거하고 잔류물을 메탄올 : 에테르에서 재결정하여 결정체인 N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N'-(1-메틸에틸)우레아(2.8g)을 수득하였다.2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethanamine (2.14 g) and isopropyl isocyanate (0.89 g) were dissolved in acetonitrile and allowed to stand overnight. The solvent was removed and the residue was recrystallized from methanol: ether to give the crystals N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N '-(1-methyl Ethyl) urea (2.8 g) was obtained.

융점 ; 섭씨 65-67도Melting point; 65-67 degrees Celsius

동일하게 제조된 것으로는;To be prepared in the same way;

(b) N-[3-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]프로필]-N'-메틸우레아(b) N- [3-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] propyl] -N'-methylurea

융점 ; 섭씨 69-69.5도Melting point; 69-69.5 degrees Celsius

[실시예 7]Example 7

N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]우레아N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] urea

중염산 2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에탄아민(2.8g)과 시안산칼륨(3.75g), 물(50㎖)를 수증기 탕위에서 8시간동안 가열하였다. 과량의 탄산나트륨 고체를 가하고 유기물질을 디에틸에테르로 연속 추출하였다. 추출물을 증발시키고 잔류물을 관크로마토그래피하여 납(蠟)같은 고체의 N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]우레아(1.28g)을 얻었다.Dihydrochloric acid 2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethanamine (2.8 g), potassium cyanate (3.75 g) and water (50 mL) for 8 hours on a steam bath Heated. Excess sodium carbonate solid was added and the organics were extracted successively with diethyl ether. The extract was evaporated and the residue was chromatographed to give a lead-like solid N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] urea (1.28 g). Got.

분석 실측치 ; C,48.22; H,7.50; N,15.61Analysis observed; C, 48.22; H, 7.50; N, 15.61

C11N19N3O2S.H2O의 계산치 ; C, 48.00; H, 7.63; N, 15.27%Calcd for C 11 N 19 N 3 O 2 SH 2 O; C, 48.00; H, 7.63; N, 15.27%

[실시예 8]Example 8

N-[2-[[[5-디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N'-니트로구아니딘N- [2-[[[5-dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N'-nitroguanidine

2-[[[5-(디메틸아미노)메틸-2-푸라닐]-메틸]티오]에탄아민 (2.14g)과 S-메틸-N-니트로이소티오우레아(1.5g), 에탄올(10㎖)를 섭씨 40도에서 5분동안 가열하였다. 생성된 침전물을 여과하고 아세르산에틸과 석유에테르(비점; 섭씨 80-100도)에서 재결정하여 N-[2-[[[5-디메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸-N'-니트로구아니딘을 수득했다.2-[[[5- (dimethylamino) methyl-2-furanyl] -methyl] thio] ethanamine (2.14 g), S-methyl-N-nitroisothiourea (1.5 g), ethanol (10 mL) Heated at 40 degrees Celsius for 5 minutes. The resulting precipitate was filtered and recrystallized from ethyl acetate and petroleum ether (boiling point; 80-100 degrees Celsius) to give N- [2-[[[5-dimethylamino) methyl-2-furanyl] methyl] -thio]. Ethyl-N'-nitroguanidine was obtained.

융점 ; 섭씨 103-104도Melting point; 103-104 degrees celsius

[실시예 9]Example 9

(a) N-시아노-N'-[2-[[[5-(메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸-N"-메틸구아니딘(a) N-cyano-N '-[2-[[[5- (methylamino) methyl-2-furanyl] methyl] -thio] ethyl-N'-methylguanidine

2-[[[5-(메틸아미노)메틸-2-푸라닐]-메틸]-티오] 에탄아민(2.0g)과 N-시아노-N'-메틸카르밤이미도-티오산, 메틸에스테르(1.25g)을 수증기탕 위에서 6.5시간동안 가열했다. 일정한 간격으로 진공상태를 만들어서 메탄티올을 제거하고 조생성물을 관크로마토그래피로 정제하여 N-시아노-N'-[2-[[[5-(메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N"-메틸구아니딘(1.05g)을 수득했다.2-[[[5- (methylamino) methyl-2-furanyl] -methyl] -thio] ethanamine (2.0 g), N-cyano-N'-methylcarbamimido-thio acid, methyl ester (1.25 g) was heated on a steam bath for 6.5 hours. Vacuum was removed at regular intervals to remove methanethiol and the crude product was purified by column chromatography to obtain N-cyano-N '-[2-[[[5- (methylamino) methyl-2-furanyl] methyl]. Thio] ethyl] -N'-methylguanidine (1.05 g) was obtained.

Rf ; 0.65(실리카/메탄올 : 암모니아 79 : 1)Rf; 0.65 (silica / methanol: ammonia 79: 1)

융점 ; 섭씨 81-85도Melting point; 81-85 degrees Celsius

유사한 아민과 N-시아노-N'-메틸카르밤이미도티오산, 메틸에스테르로부터 동일하게 제조된 것으로는Similarly prepared from similar amines and N-cyano-N'-methylcarbamimidiothioic acid, methyl ester

(b) N-시아노-N'-[2-[[[5-(1-메틸에틸)아미노]메틸-2-푸라닐]메틸]티오]에틸]-N"-메틸구아니딘(b) N-cyano-N '-[2-[[[5- (1-methylethyl) amino] methyl-2-furanyl] methyl] thio] ethyl] -N'-methylguanidine

분석 실측치 ; C, 54.73; H, 7.82 ; N,22.31Analysis observed; C, 54.73; H, 7. 82; N, 22.31

C14H23N5OS의 계산치 ; C, 54.34; H, 7.49; N,22.64%Calcd for C 14 H 23 N 5 OS; C, 54.34; H, 7. 49; N, 22.64%

(c) N-시아노-N'-[2-[[[5-(디에틸아미노)메틸-2-푸라닐]-메틸]티오]에틸]-N"-메틸구아니딘(c) N-cyano-N '-[2-[[[5- (diethylamino) methyl-2-furanyl] -methyl] thio] ethyl] -N'-methylguanidine

분석 실측치 ; C, 53.54; H, 7.82 ; N,20.65Analysis observed; C, 53.54; H, 7. 82; N, 20.65

C15H25N5OS·3/4H2O의 계산치 ; C, 53.46; H, 7.70; N,20.78%Calcd for C 15 H 25 N 5 OS · 3 / 4H 2 O; C, 53.46; H, 7. 70; N, 20.78%

(d) N-시아노-N'-[2-[[[5-(1-피롤리디닐)메틸-2-푸라닐]-메틸]티오]에틸]-N"-메틸구아니딘(d) N-cyano-N '-[2-[[[5- (1-pyrrolidinyl) methyl-2-furanyl] -methyl] thio] ethyl] -N'-methylguanidine

분석 실측치 ; C, 53.97; H, 6.87 ; N,21.06Analysis observed; C, 53.97; H, 6.87; N, 21.06

C15H23N5OS·3/4H2O의 계산치 ; C, 53.79; H, 7.37; N,20.91%Calcd for C 15 H 23 N 5 OS · 3 / 4H 2 O; C, 53.79; H, 7. 37; N, 20.91%

(e) N-시아노-N'-[3-[[[5-(디메틸아미노)메틸-2-푸라닐]-메틸]티오]프로필-N"-메틸구아니딘(e) N-cyano-N '-[3-[[[5- (dimethylamino) methyl-2-furanyl] -methyl] thio] propyl-N'-methylguanidine

분석 실측치 ; C, 52.86; H, 7.49 ; N,20.64Analysis observed; C, 52.86; H, 7. 49; N, 20.64

C14H23N5OS·3/4H2O의 계산치 ; C, 52.80; H, 7.59; N,21.20%Calcd for C 14 H 23 N 5 OS · 3 / 4H 2 O; C, 52.80; H, 7.59; N, 21.20%

[실시예 10]Example 10

N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸]-N"-메틸구아니딘N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] -thio] ethyl] -N'-methylguanidine

2-[[[5-(디메틸아미노) 메틸-2-푸라닐]-메틸]티오]에탄아민(10.7g)용액에 탄산칼륨(20.7g)이 부유되어 있는 서스펜션과, N-시아노-N'-메틸카르밤-이미도티오산메틸에스테르(7.1g)을 함유하는 아세토니트릴(107㎖)를 교반하면서 여기에 질산은 (9.35g)을 함유하는 아세토니트릴(20㎖)용액을 섭씨 70도에서 1시간동안 가했다. 이 혼합물을 16시간 동안 교반하고 고체성분을 여과한 다음 여액을 건조될 때 까지 증발시켰다. 잔류물을 아세트산에틸(250㎖)에 용해하고 이것의 일부(10.5㎖)를 물(6㎖)로 씻은 다음 아세트산에틸층을 증발시켜서 얻은 고체를 아세트산이소프로필(1.75㎖)에서 결정화하여 N"-시아노-N-[2-[[[5-(디메틸아미노메틸)-2-푸라닐]-메틸]티오]에틸]-N'-메틸구아니딘(0.35g)을 수득하였다.Suspension in which potassium carbonate (20.7 g) is suspended in a 2-[[[5- (dimethylamino) methyl-2-furanyl] -methyl] thio] ethanamine (10.7 g) solution, and N-cyano-N While stirring acetonitrile (107 ml) containing '-methylcarbam-imidothioic acid methyl ester (7.1 g), acetonitrile (20 ml) solution containing silver nitrate (9.35 g) was added at 70 degrees Celsius. Added for hours. The mixture was stirred for 16 h, the solids were filtered off and the filtrate was evaporated to dryness. The residue was dissolved in ethyl acetate (250 mL), a portion of this (10.5 mL) was washed with water (6 mL), and the solid obtained by evaporation of the ethyl acetate layer was crystallized in isopropyl acetate (1.75 mL) to give N "-. Cyano-N- [2-[[[5- (dimethylaminomethyl) -2-furanyl] -methyl] thio] ethyl] -N'-methylguanidine (0.35 g) was obtained.

융점 ; 섭씨 79-81.5도Melting point; 79-81.5 degrees Celsius

위에서, 잔류물을 아세트산에틸에 용해한 나머지 용액 중(225㎖)에 세바스산(9.09g)을 함유하는 에탄올(30㎖)를 가하고 이를 여과해서 세바스산염(13.74g)을 수득하였다.Above, the residue was dissolved in ethyl acetate and ethanol (30 mL) containing sebacic acid (9.09 g) was added to the remaining solution (225 mL) and filtered to give sebacate (13.74 g).

융점 ; 섭씨 92.5-94도Melting point; 92.5-94 degrees Celsius

분석실측치 ; C, 54.91; H, 7.94; N, 14.02.Analysis measured value; C, 54.91; H, 7.94; N, 14.02.

C13H21N5OS·C10H8O4의 계산치 ; C, 55.51; H, 7.90; N, 14.07%Calcd for C 13 H 21 N 5 OS · C 10 H 8 O 4 ; C, 55.51; H, 7.90; N, 14.07%

[실시예11]Example 11

N-시아노-N'-(2-메톡시에틸)카르밤이미도티오산, 메틸에스테르N-cyano-N '-(2-methoxyethyl) carbamimidothioic acid, methyl ester

나트륨(2.3g)을 함유하는 무수에탄올 용액을 교반하면서 여기에 분말상의 시안아미드(4.2g)을 가했다. 30분후에 이소티오시안산메톡시에틸(11.7g)을 함유하는 무수에탄올 용액을 상기 냉용액을 가하고 또 1시간이 지난 후에 실온에서 황산디메틸(12.66g)을 30분 동안 가한 다음 혼합물을 하룻밤 동안 교반했다. 용매를 제거하고 잔류하고 고체를 물로 잘 씻어서 백색 결정상 고체인 N-시아노-N'-2(메톡시에틸)카르밤이미도-티오산, 메틸에스테르(12.37g)을 수득하였다.Powdered cyanamide (4.2 g) was added to this, stirring the anhydrous ethanol solution containing sodium (2.3 g). After 30 minutes, anhydrous ethanol solution containing methoxyethyl isothiocyanate (11.7 g) was added to the cold solution, and after 1 hour, dimethyl sulfate (12.66 g) was added at room temperature for 30 minutes, and the mixture was overnight. Stirred. The solvent was removed and the residue was washed well with water to give N-cyano-N'-2 (methoxyethyl) carbamimido-thio acid, methyl ester (12.37 g) as a white crystalline solid.

융점 ; 섭씨 94.5-95.5도Melting point; 94.5-95.5 degrees Celsius

동일하게 제조된 것으로는;To be prepared in the same way;

N-시아노-N'-(2-프로페닐) 카르밤이미도티오산, 메틸에스테르N-cyano-N '-(2-propenyl) carbamimidothioic acid, methyl ester

융점 ; 섭씨 109-110도Melting point; 109-110 degrees celsius

(a) N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸]-N"-(2-메톡시에틸)구아니딘(a) N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] -thio] ethyl] -N'-(2-methoxyethyl) guanidine

2-[[[5-(디메틸아미노)메틸-2-푸라닐]-메틸]티오]에탄아민(2.14g)과 N-시아노-N'-(2-메톡시에틸)-카르밤이미도티오산, 메틸에스테르(1.73g)등의 혼합물을 수증기탕 위에서 6.5시간동안 가열했다. 가끔씩 진공상태를 만들어 메탄티올을 제거하고 조생성물을 크로마토그래피(실리카겔/메탄올)로 정제하여 N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N"-(2-메톡시에틸)구아니딘(1.4g)을 수거했다.2-[[[5- (dimethylamino) methyl-2-furanyl] -methyl] thio] ethanamine (2.14 g) with N-cyano-N '-(2-methoxyethyl) -carbamididoti A mixture of OH, methyl ester (1.73 g) and the like were heated on a steam bath for 6.5 hours. Occasionally, vacuum was removed to remove methanethiol, and the crude product was purified by chromatography (silica gel / methanol) to give N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl]. Methyl] thio] ethyl] -N '-(2-methoxyethyl) guanidine (1.4 g) was collected.

분석실측치 ; C, 50.51; H, 7.20; N, 19.41Analysis measured value; C, 50.51; H, 7. 20; N, 19.41

C15H25N5O2S·H2O의 계산치; C,50.42; H,7.50; N, 19.60%Calcd. For C 15 H 25 N 5 O 2 S.H 2 O; C, 50.42; H, 7.50; N, 19.60%

2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에탄아민과 유사한 N-알킬-N'-시아노카르밤이미도티오산, 메틸에스테르로부터 동일하게 제조된 것으로는;Similarly prepared from N-alkyl-N'-cyanocarbamimidiothioic acid, methyl ester, similar to 2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethanamine ;

(b) N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]-메틸]티오]에틸]-N"-(2-프로페닐)구아니딘(b) N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] -methyl] thio] ethyl] -N'-(2-propenyl) guanidine

분석 실측치 ; C, 53.33; H, 7.01 ; N,20.70Analysis observed; C, 53.33; H, 7.0 1; N, 20.70

C15H23N5OS·H2O의 계산치 ; C, 53.09; H, 7.37; N,20.64%Calculated values of C 15 H 23 N 5 OS · H 2 O; C, 53.09; H, 7. 37; N, 20.64%

(c) N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]-메틸]티오]에틸]-N"-(1-메틸에틸)구아니딘(c) N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] -methyl] thio] ethyl] -N'-(1-methylethyl) guanidine

분석 실측치 ; C, 52.97; H, 7.70 ; N,20.57Analysis observed; C, 52.97; H, 7. 70; N, 20.57

C15H25H5OS·H2O의 계산치 ; C, 52.78; H, 7.91; N,20.52%Calcd for C 15 H 25 H 5 OS · H 2 O; C, 52.78; H, 7.91; N, 20.52%

[실시예 12]Example 12

(a) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N'-메틸구아니딘(a) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N'-methylguanidine

2-[[[5-(디메틸아미노)메틸-2-푸라닐]-메틸]티오]에탄아민(2.14g)과 요오드화 N,S-디메틸이소티오우로늄의 혼합물을 수증기탕 위에서 3시간 동안 가열하였다. 메탄올 중에 존재하는 잔류물을 앰버리스트 A26이온교환수지로부터 용리해 내서 호박색 기름인 N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]-메틸]티오]에틸]-N'-메틸구아니딘(1.5g)을 수득하였다.A mixture of 2-[[[5- (dimethylamino) methyl-2-furanyl] -methyl] thio] ethanamine (2.14 g) and iodide N, S-dimethylisothiouronium was heated over a steam bath for 3 hours It was. The residue present in methanol is eluted from Amberlyst A26 ion exchange resin to give amber oil N- [2-[[[5- (dimethylamino) methyl-2-furanyl] -methyl] thio] ethyl] -N '-Methylguanidine (1.5 g) was obtained.

분석 실측치 ; C, 50.92; H, 8.23 ; N,19.90Analysis observed; C, 50.92; H, 8.23; N, 19.90

C12H22N4OS·3/4H2OC 12 H 22 N 4 OS, 3 / 4H 2 O

의 계산치 ; C, 50.76; H, 8.34; N,19.74%Calculated value; C, 50.76; H, 8.34; N, 19.74%

동일하게 제조된 것으로는;To be prepared in the same way;

(b) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N',N"-디메틸구아니딘(b) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N ', N'-dimethylguanidine

NMR(CDCl3) 7.75 s(6H); 6.8-7.3m(8H); 6.5m(4H); 6.22s (2H); 3.80m(2H); 2.0-3.5br(2H)NMR (CDCl 3 ) 7.75 s (6H); 6.8-7.3 m (8H); 6.5 m (4H); 6.22 s (2 H); 3.80 m (2 H); 2.0-3.5 br (2H)

[실시예 13]Example 13

N-메틸-1-메틸티오-2-니트로에탄아민N-methyl-1-methylthio-2-nitroethanamine

1,1-비스메틸티오-2-니트로-에덴(99.0g, 0.6몰)을 함유하는 이염화에틸렌(1.51)용액을 교반하면서 여기에 메틸아민을 함유하는 에탄올/이염화에틸렌(33%의 에탄올성 메틸아민 112.5㎖를 함유하는 이염화에틸렌 0.8ℓ:0.94몰)용액을 섭씨 70도에서 5시간 30분 동안 가했다.Ethylene dichloride (1.51) solution containing 1,1-bismethylthio-2-nitro-edene (99.0 g, 0.6 mole) while stirring, ethanol / ethylene dichloride (33% ethanol) containing methylamine Ethylene dichloride 0.8 L: 0.94 mol) containing 112.5 ml of methyl methylamine was added at 70 degrees Celsius for 5 hours 30 minutes.

이용액을 끊을때까지 가열하고 용매 0.7ℓ를 증류해서 제거한 다음 냉각시킨 용액을 2N-염산(0.25ℓ)로 씻고 소금물(0.25ℓ)로 씻었다. 용매를 제거시키고 그 잔류물을 아세트산 이소프로피(0.5ℓ)에서 결정화한 다음 뜨거운 용액을 활성탄(10.0g)으로 처리해서 노란색 주형의 생성물(35.0g)을 수득하였다.The solution was heated until it was stopped, 0.7 L of the solvent was distilled off, and the cooled solution was washed with 2N hydrochloric acid (0.25 L) and brine (0.25 L). The solvent was removed and the residue was crystallized in isopropacetic acid (0.5 L) and the hot solution was treated with activated charcoal (10.0 g) to give a yellow template product (35.0 g).

융점 ; 섭씨 114도Melting point; 114 degrees celsius

염산 N-[2-[[[5-(메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N'-메틸-2-니트로-1, 1-에덴디아민Hydrochloric acid N- [2-[[[5- (methylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro-1, 1-edendiamine

2-[[[5-(메틸아미노)-메틸-2-푸라닐]메틸]티오]에탄아민(10g, 0.05몰) 용액과, N-메틸-1-메틸티오-2-니트로에렌아민(7.4g)을 함유하는 물(25㎖)를 섭씨 50도에서 2시간 동안 교반했다. 여기에 아세톤(350㎖)를 가하고 유출물이 275㎖가 될 때까지 용매를 대기압에서 증류시켜 제거한 다음 이 잔류물에 에탄올성 염화수소(2몰 ; 275㎖)를 가하고 이 용액을 실온에서 하룻밤 교반하였다. 융점이 섭씨 161도인 생성물(11.0g)을 수거해서 에탄올로부터 재결정하여 무색의 미정질(微晶質)고체(10.1g)을 수득하였다.2-[[[5- (methylamino) -methyl-2-furanyl] methyl] thio] ethanamine (10 g, 0.05 mole) solution and N-methyl-1-methylthio-2-nitroeramine (7.4 Water (g) containing g) was stirred at 50 degrees Celsius for 2 hours. Acetone (350 mL) was added thereto, and the solvent was distilled off at atmospheric pressure until the effluent became 275 mL, and then ethanol hydrogen chloride (2 mol; 275 mL) was added to the residue, and the solution was stirred overnight at room temperature. . The product having a melting point of 161 degrees Celsius (11.0 g) was collected and recrystallized from ethanol to give a colorless microcrystalline solid (10.1 g).

융점; 섭씨 162도Melting point; 162 degrees celsius

분석실측치 ; C, 42.6; H, 6.3; N16.4Analysis measured value; C, 42.6; H, 6.3; N16.4

C12H20N4O3S·HCl의 계산치 ; C, 42.8; H,6.2; N, 16.6% C 12 H 2 0N 4 O 3 S · HCl Calcd of; C, 42.8; H, 6.2; N, 16.6%

[실시예 14]Example 14

(a) N-[2-[[[5-(메틸아미노)메틸-2-푸라닐]메틸]티오]-N'-메틸-2-니트로-1,1-에텐디아민(a) N- [2-[[[5- (methylamino) methyl-2-furanyl] methyl] thio] -N'-methyl-2-nitro-1,1-ethenediamine

2-[[[5-(메틸아미노)메틸-2-푸라닐]메틸]티오]에탄아민(0.9g)과 N-메틸-1-메틸티오-2-니트로-에텐아민의 혼합물을 양수압(water pump pressure)중에서 30분 동안 섭씨 100-120도에서 가열하였다. 잔류물을 관크로마토그래피(실리카/메탄올 : 0.88 암모니아)로 정제하고 아세토니트릴에서 결정화하여 N-[2-[[[5-(메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N'-메틸]-2-니트로1,1-에텐디아민 (0.65g)을 수득하였다.A mixture of 2-[[[5- (methylamino) methyl-2-furanyl] methyl] thio] ethanamine (0.9 g) and N-methyl-1-methylthio-2-nitro-ethenamine was mixed with positive pressure ( heated at 100-120 degrees Celsius for 30 minutes under water pump pressure. The residue was purified by column chromatography (silica / methanol: 0.88 ammonia) and crystallized in acetonitrile to give N- [2-[[[5- (methylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N'-methyl] -2-nitro1,1-ethenediamine (0.65 g) was obtained.

융점 ; 섭씨 106-108도Melting point; 106-108 degrees Celsius

동일한 방법으로 제조된 것으로는;Prepared in the same manner;

(b) N-[2-[[[5-[(1-메틸에틸)아미노]메틸-2-푸라닐]-메틸]티오]에틸-N'-메틸-2-니트로-1,1-에텐디아민(b) N- [2-[[[5-[(1-methylethyl) amino] methyl-2-furanyl] -methyl] thio] ethyl-N'-methyl-2-nitro-1,1-ethene Diamine

분석실측치 ; C, 49.75; H, 7.21; N, 16.36Analysis measured value; C, 49.75; H, 7. 21; N, 16.36

C14H24N4O3S·1/2H2O의 계산치 ; C, 49.83; H, 7.47; N, 16.06%Calcd for C 14 H 24 N 4 O 3 S · 1 / 2H 2 O; C, 49.83; H, 7.47; N, 16.06%

(c) N-메틸-2-니트로-N'-[2-[[[5-[(2-페닐에틸)아미노]메틸-2-푸라닐]-메틸]티오]에틸-1,1-에텐디아민(c) N-methyl-2-nitro-N '-[2-[[[5-[(2-phenylethyl) amino] methyl-2-furanyl] -methyl] thio] ethyl-1,1-ethene Diamine

분석실측치 ; C, 57.19; H, 6.53; N, 13.83Analysis measured value; C, 57.19; H, 6.53; N, 13.83

C19H26N4O3S·1/2H2O의 계산치 ; C, 57.12; H, 6.81; N, 14.02%Calcd for C 19 H 26 N 4 O 3 S · 1 / 2H 2 O; C, 57.12; H, 6.81; N, 14.02%

(d) N-메틸-2-니트로-N'-[2-[[[5-[(1-피페리디닐)메틸]-2-푸라닐]-메틸]티오]에틸]-1,1-에텐디아민(d) N-methyl-2-nitro-N '-[2-[[[5-[(1-piperidinyl) methyl] -2-furanyl] -methyl] thio] ethyl] -1,1- Ethendiamine

분석실측치 ; C, 53.36; H, 7.51; N, 14.23Analysis measured value; C, 53.36; H, 7.51; N, 14.23

C16H26N4O3S·1/4H2O의 계산치 ; C, 53.33; H, 7.44; N, 15.61%Calcd for C 16 H 26 N 4 O 3 S. 1 / 4H 2 O; C, 53.33; H, 7. 44; N, 15.61%

(e) N-[2-[[[5-[(2-디메틸아미노)에틸]-2-푸라닐]메틸]티오]-에틸]-N'-메틸-2-니트로-1,1-에텐디아민(e) N- [2-[[[5-[(2-dimethylamino) ethyl] -2-furanyl] methyl] thio] -ethyl] -N'-methyl-2-nitro-1,1-ethene Diamine

융점 ; 섭씨 95.5-96도Melting point; 95.5-96 degrees Celsius

(f) N-[2-[[[5-[3-(디메틸아미노)프로필]-2-푸라닐]메틸]-티오]에틸]-N'-메틸-2-니트로-1,1-에텐디아민(f) N- [2-[[[5- [3- (dimethylamino) propyl] -2-furanyl] methyl] -thio] ethyl] -N'-methyl-2-nitro-1,1-ethene Diamine

NMR τ(CDCl3) 7.1-8.1m(6H); 7.65s(6H); 7.1 s(3H); 6.5m (2H); 6.28 s(2H); 4.0m(2H); 3.38s(1H)NMR τ (CDCl 3 ) 7.1-8.1 m (6H); 7.65 s (6 H); 7.1 s (3H); 6.5 m (2H); 6.28 s (2 H); 4.0 m (2H); 3.38 s (1 H)

(g) N-[2-[[[5-[4-(디메틸아미노)부틸]-2-푸라닐]-메틸]-티오]에틸]-N-메틸-2-니트로-1,1-에텐디아민(g) N- [2-[[[5- [4- (dimethylamino) butyl] -2-furanyl] -methyl] -thio] ethyl] -N-methyl-2-nitro-1,1-ethene Diamine

납같은 고체의 분석실측치 ; C, 53.90; H, 7.95; N, 15.64Analysis of solids such as lead; C, 53.90; H, 7.95; N, 15.64

C16H28N4O3O3S의 계산치 ; C, 53.91; H, 7.92; N, 15.72%Calcd for C 16 H 28 N 4 O 3 O 3 S; C, 53.91; H, 7.92; N, 15.72%

(h) N-[2-[[[5-[(에틸메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸]-N'-메틸-2-니트로-1,1-에텐디아민(h) N- [2-[[[5-[(ethylmethylamino) methyl-2-furanyl] methyl] -thio] ethyl] -N'-methyl-2-nitro-1,1-ethenediamine

NMR τ(CDCl3) 8.90t(3H); 7.76s(3H); 6.8-7.5m(7H); 6.5br(2H); 6.25s(2H); 3.77s(2H); 3.35s(1H)NMR τ (CDCl 3 ) 8.90t (3H); 7.76 s (3 H); 6.8-7.5 m (7 H); 6.5 br (2H); 6.25 s (2 H); 3.77 s (2H); 3.35 s (1 H)

(i) N-[2-[[[5-[[2-(디메틸아미노)에틸]아미노]메틸-2-푸라닐]메틸]티오]에틸]-N'-메틸-2-니트로-1,1-에텐디아민(i) N- [2-[[[5-[[2- (dimethylamino) ethyl] amino] methyl-2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro-1, 1-ethenediamine

NMR τ(CDCl3) 7.79s(6H); 7-7.76m(10H); 6.6m(2H); 6.26(2H); 6.22s(2H); 3.85m(2H); 3.37s(1H); 2-3.2br(1H); 0.8-0.2br(1H);NMR τ (CDCl 3 ) 7.79 s (6H); 7-7.76 m (10 H); 6.6 m (2H); 6.26 (2H); 6.22 s (2H); 3.85 m (2H); 3.37 s (1 H); 2-3.2 br (1H); 0.8-0.2 br (1 H);

(j) N-[2-[[[5-[[2-(디메틸아미노)메틸-2-푸라닐메톡시]에틸-N'-2-니트로-1,1-에텐디아민(j) N- [2-[[[5-[[2- (dimethylamino) methyl-2-furanylmethoxy] ethyl-N'-2-nitro-1,1-ethenediamine

융점 ; 섭씨 110-112도Melting point; 110-112 degrees celsius

[실시예 15]Example 15

N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N'-메틸-2-니트로-1,1-에텐디아민N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro-1,1-ethenediamine

N-메틸-1-(메틸티오)-2-니트로에텐아민(230g)을 함유하는 물(400㎖)를 교반하면서 섭씨 45-50 도에서 가열하였다. 여기에 2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에탄아민(321g)을 4시간 동안 적하하고 생성된 용액을 3시간 30분간 동안 더 교반하였다. 그런 다음 이용액을 환류하면서 30분동안 가열하고 섭씨 70도로 냉각한후 4-메틸 -펜탄-2-온(2ℓ)를 가했다. 환산압력(260기압) 하에서 함께 끊는 증류(azeotropic distillation)로 물을 제거하고 생성된 용액을 섭씨 50도에서 활성탄(10g)으로 처리했다. 이 용액을 여과하고 섭씨 10도로 냉각한 다음 다시 여과하고 건조시켜서 N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N'-메틸-2-니트로-1,1-에텐디아민(380g)을 수득하였다.Water (400 mL) containing N-methyl-1- (methylthio) -2-nitroethenamine (230 g) was heated at 45-50 degrees Celsius with stirring. 2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethanamine (321 g) was added dropwise thereto for 4 hours, and the resulting solution was further stirred for 3 hours and 30 minutes. The solution was then heated to reflux for 30 minutes, cooled to 70 degrees Celsius and 4-methyl-pentan-2-one (2 L) was added. Water was removed by azeotropic distillation under reduced pressure (260 atm) and the resulting solution was treated with activated carbon (10 g) at 50 degrees Celsius. The solution was filtered, cooled to 10 degrees Celsius, filtered again and dried to form N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N'-methyl- 2-nitro-1,1-ethenediamine (380 g) was obtained.

융점 ; 섭씨 69-70도Melting point; 69-70 degrees Celsius

[실시예 16]Example 16

N-메틸-2-니트로-N'-[2-[[[5-[(1-피롤리디닐)메틸]-2-푸라닐]메틸]팅]에틸-1,1-에텐디아민N-methyl-2-nitro-N '-[2-[[[5-[(1-pyrrolidinyl) methyl] -2-furanyl] methyl] ting] ethyl-1,1-ethenediamine

2-[[[5-(1-피롤리디노)메틸-2-푸라닐]-메틸]티오] 에탄아민 비스옥살산염(2.1g)과 수산화칼륨(1.12g), 및 N-메틸-(1-메틸티오)-2-니트로-에텐아민(0.9g)을 함유하는 물(9㎖)등의 혼합물을 실온에서 18시간 동안 교반하였다.2-[[[5- (1-pyrrolidino) methyl-2-furanyl] -methyl] thio] ethanamine bisoxalate (2.1 g) and potassium hydroxide (1.12 g), and N-methyl- (1 A mixture such as water (9 ml) containing -methylthio) -2-nitro-ethenamine (0.9 g) was stirred at room temperature for 18 hours.

환산압력하에서 물을 증발시켜 제거하고 잔류물은 과량의 무수탄산나트륨이 존재하는 중에 아세트산에틸로 추출하였다. 용매를 증발시켜 얻어진 잔류물을 아세트산 이소프로필에서 결정화하여 백색의 결정상 고체(0.9g)을 수득하였다.Water was removed by evaporation under reduced pressure, and the residue was extracted with ethyl acetate in the presence of excess anhydrous sodium carbonate. The residue obtained by evaporating the solvent was crystallized in isopropyl acetate to give a white crystalline solid (0.9 g).

융점 ; 섭씨 79-82도Melting point; 79-82 degrees Celsius

분석실측치 ; C, 52.78; H, 7.05; N, 16.57Analysis measured value; C, 52.78; H, 7.05; N, 16.57

C15H24N4O3S의 계산치 ; C, 52.92; H, 7.11; N, 16.46%Calcd for C 15 H 24 N 4 O 3 S; C, 52.92; H, 7. 11; N, 16.46%

[실시예 17]Example 17

N-[2-[[[5-(메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N'-메틸우레아N- [2-[[[5- (methylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methylurea

N-[2-(메르캅토메틸]-N'-메틸우레아(2.0g)을 함유하는 진한 염산용액을 교반하면서 여기에 5-(메틸아미노)메틸-2-푸란-메탄올(2.0g)을 함유하는 물(3㎖) 용액을 섭씨 0도에서 적하하였다. 24시간 후에 아세트산에틸(100㎖)와 과량의 무수산나트륨을 가하고 이 서스펜션을 여과해서 얻은 여액을 건조될 때 까지 증발시킨 다음 기름상의 잔류물을 관크로마토그래피(실리카/메탄올 : 0.88 암모니아 79 : 1) 하였다.Concentrate the concentrated hydrochloric acid solution containing N- [2- (mercaptomethyl] -N'-methylurea (2.0 g), while containing 5- (methylamino) methyl-2-furan-methanol (2.0 g) A solution of water (3 ml) was added dropwise at 0 ° C. After 24 hours, ethyl acetate (100 ml) and excess sodium anhydride were added, and the filtrate obtained by filtration was evaporated to dryness and the oily residue remained. Water was subjected to tube chromatography (silica / methanol: 0.88 ammonia 79: 1).

용출액을 건조될때까지 증발해서 실시예 4의 생성물과 동일한 기름(0.42g)을 수득하였다.The eluate was evaporated to dryness to afford the same oil (0.42 g) as the product of Example 4.

NMR(CDCl3)τ 3.85s(2H); 4.3-4.8m(2H); 6.27s(4H); 6.49q(2H); 7.22d 7.32t 7.54s(8H); 8.50brs(1H)NMR (CDCl 3 ) τ 3.85 s (2H); 4.3-4.8 m (2H); 6.27 s (4H); 6.49q (2H); 7.22d 7.32t 7.54s (8H); 8.50 brs (1H)

[실시예 18]Example 18

N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸]-N"-메틸구아니딘N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] -thio] ethyl] -N'-methylguanidine

N-시아노-N'-(2-메르캅토에틸)-N"-메틸구아니딘(1g)을 함유하는 진한 염산용액을 교반하면서 여기에 5-(디메틸아민)-2-푸란메탄올(0.98g)을 섭씨 0도에서 10분동안 적하하였다. 3시간 후에 실온에서 과량의 무수탄산나트륨을 가해서 이 용액을 중화하고 생성된 고체를 아세트산에틸로 추출하였다. 용매를 제거해서 얻은 기름을 관크로마토그래피해서 실시예 10의 화합물과 동일한 생성물을 수득하였다. (0.42g)5- (dimethylamine) -2-furanmethanol (0.98 g) while stirring a concentrated hydrochloric acid solution containing N-cyano-N '-(2-mercaptoethyl) -N'-methylguanidine (1 g) Was added dropwise at 0 degrees Celsius for 10 minutes. After 3 hours excess sodium carbonate was added at room temperature to neutralize the solution and the resulting solid was extracted with ethyl acetate. The oil obtained by removing the solvent was subjected to tube chromatography to obtain the same product as the compound of Example 10. (0.42g)

NMR(CDCl3)τ 3.82s 3.6-4.4brm, (4H); 6.28s(2H); 6.57s 6.63q(4H); 7.15d. 7.30t(5H); 7.65s(6H)NMR (CDCl 3 ) τ 3.82 s 3.6-4.4 brm, (4H); 6.28 s (2 H); 6.57s 6.63q (4H); 7.15d. 7.30 t (5H); 7.65 s (6 H)

[실시예 19]Example 19

N-[2-[[5-(아미노메틸)-2-푸라닐메틸]티오]에틸]-N"-시아노-N'-메틸구아니딘N- [2-[[5- (aminomethyl) -2-furanylmethyl] thio] ethyl] -N'-cyano-N'-methylguanidine

2-(5-클로로메틸-2-푸라닐메틸)-1H-이소인돌-1,3(2H)-디온2- (5-chloromethyl-2-furanylmethyl) -1H-isoindole-1,3 (2H) -dione

2-(5-히드록시메틸-2-푸라닐메틸)-1H-이소인돌-1,3(2H)-디온(10g)을 염화티오닐(15㎖)에 용해하되 천천히 가열하면서 용해시켰다. 이 용액을 건조될때까지 증발시키고 고체잔류물을 시클로헥산-벤젠(1 : 1)과 함께 다시 증발시킨 다음, 잔류물을 에테르에 부유시켜서 얻어진 서스펜션을 여과하고 에테르로 세척한 다음 건조시켜서 2-(5-클로로메틸-2-푸라닐메틸)-1H-이소인돌-1,3(2H)-디온(10.1g)을 수득하였다.2- (5-hydroxymethyl-2-furanylmethyl) -1H-isoindole-1,3 (2H) -dione (10 g) was dissolved in thionyl chloride (15 mL) but dissolved slowly with heating. The solution was evaporated to dryness and the solid residue was evaporated again with cyclohexane-benzene (1: 1), and then the suspension obtained by floating the residue in ether was filtered, washed with ether and dried to give 2- ( 5-Chloromethyl-2-furanylmethyl) -1H-isoindole-1,3 (2H) -dione (10.1 g) was obtained.

융점 ; 섭씨 119-122도(분해)Melting point; 119-122 degrees Celsius (decomposition)

분석실측치 ; C, 61.32; H, 3.71; N, 5.00Analysis measured value; C, 61.32; H, 3.71; N, 5.00

C14H10ClHO4의 계산치 ; C, 60.99; H, 3.66; N, 5.08%Calcd for C 14 H 10 ClHO 4 ; C, 60.99; H, 3. 66; N, 5.08%

N"-시아노-N-[2-[[5-[1,3-디옥소-2H-이소인돌-2-일)메틸]-2-푸라닐메틸]티오]에틸-N'-메틸구아니딘N-cyano-N- [2-[[5- [1,3-dioxo-2H-isoindol-2-yl) methyl] -2-furanylmethyl] thio] ethyl-N'-methylguanidine

N"-시아노-N-(2-메르캅토에틸)-N'-메틸구아니딘(1.0g)과 수소화나트륨(0.152g)을 함유하는 건성 디케틸포름아미드(4㎖)용액을 교반하면서 여기에 2-(5-클로로메틸-2-푸라닐메틸)-1H-이소인돌-1,3(2H)-디온(1.74g)을 함유하는 건성 디메틸포름아미드(8㎖)용액을 실온에서 서시히 가했다. 2시간 동안 교반한 후에 이 용액을 건조될때까지 증발시키고 유성잔류물을 아세트산에틸(25㎖)-물(20㎖) 혼합물에 부유시켰다. 고체잔류물을 여과한 다음 메탄올에서 결정화하여 표제화합물(1.4g)을 수득하였다.Dry diketylformamide (4 ml) solution containing N'cyano-N- (2-mercaptoethyl) -N'-methylguanidine (1.0 g) and sodium hydride (0.152 g) A dry dimethylformamide (8 mL) solution containing 2- (5-chloromethyl-2-furanylmethyl) -1H-isoindole-1,3 (2H) -dione (1.74 g) was added slowly at room temperature. After stirring for 2 hours the solution was evaporated to dryness and the oily residue was suspended in an ethyl acetate (25 mL) -water (20 mL) mixture. The solid residue was filtered and then crystallized in methanol to give the title compound (1.4 g).

융점 ; 섭씨 179-182도Melting point; 179-182 degrees celsius

N-[2-[[5-(아미노메틸)-2-푸라닐메틸]티오]에틸]-N"-시아노-N'-메틸구아니딘N- [2-[[5- (aminomethyl) -2-furanylmethyl] thio] ethyl] -N'-cyano-N'-methylguanidine

메탄올(35㎖)중에 분산되어 있는 N"-시아노-N-[2-[[5-[1,3-디옥소-2H-이소인돌-2-일)메틸]-2-푸라닐메틸]티오]에틸]-N'-메틸-구아니딘(4.45g)과 히드라진수화물(0.6g)의 서스펜션을 건조될 때 까지 증발시키고 잔류물을 섭씨 0도에서 물(15㎖)에 용해한 다음 5N 염산으로 중화하였다. 이 서스펜션을 여과하고 과량의 무수탄산나트륨을 가한 다음 용액을 건조될 때까지 증발시켰다. 잔류물을 무수황산나트륨을 혼합하고, 고체물질을 에탄올로 추출해서 얻은 추출물을 증발시켜서 반-고체물을 수득하였다. 이를 무수황산나트륨과 혼합하고 아세트산에틸로 추출하여 얻은 기름(2.12g)을 관크로마토그래피(실리카/메탄올 : 0,88 암모니아 79.1)한 다음 용출액을 증발시켜서 생성된 기름을 서서히 응고시켜 표제화합물(1.88g)을 수득하였다.N'-cyano-N- [2-[[5- [1,3-dioxo-2H-isoindol-2-yl) methyl] -2-furanylmethyl] dispersed in methanol (35 mL) Suspension of thio] ethyl] -N'-methyl-guanidine (4.45 g) and hydrazine hydrate (0.6 g) is evaporated to dryness and the residue is dissolved in water (15 mL) at 0 degrees Celsius and then neutralized with 5N hydrochloric acid. It was. This suspension was filtered, excess anhydrous sodium carbonate was added and the solution was evaporated to dryness. The residue was mixed with anhydrous sodium sulfate and the extract obtained by extracting the solids with ethanol was evaporated to give a semi-solid. This was mixed with anhydrous sodium sulfate, extracted with ethyl acetate (2.12 g), was subjected to tube chromatography (silica / methanol: 0,88 ammonia 79.1), and the eluate was evaporated to slowly solidify the resulting oil (1.88 g). ) Was obtained.

융점 ; 섭씨 80-82도Melting point; 80-82 degrees celsius

분석실측치 ; C, 49.57; H, 6.66; N, 25.93Analysis measured value; C, 49.57; H, 6. 66; N, 25.93

C11H17N5OS의 계산치; C, 49.41; H, 6.41; N, 26.20%Calculated by C 11 H 17 N 5 OS; C, 49.41; H, 6. 41; N, 26.20%

[실시예 20]Example 20

N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N'-메틸-2-니트로-1,1-에텐디아민N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro-1,1-ethenediamine

2-니트로메틸렌 티아졸리딘2-nitromethylene thiazolidine

염산시스테아민(11.36g), 수산화칼륨(5.61g), 1,1-비스(메틸티오)-2-니트로에텐(16.52g)을 함유하는 물(30㎖)와 에탄올(100㎖)의 혼합물을 환류하면서 1시간 동안 가열하였다. 이 서스펜션을 건조될때까지 증발시키고 잔류물을 물에 부유시킨 다음 이를 여과해서 얻은 잔류물을 메탄올에서 결정화하여 2-니트로에틸렌 티아졸리딘(9.2g)을 수득하였다.Of water (30 mL) and ethanol (100 mL) containing cysteamine hydrochloride (11.36 g), potassium hydroxide (5.61 g), 1,1-bis (methylthio) -2-nitroethene (16.52 g) The mixture was heated at reflux for 1 h. The suspension was evaporated to dryness and the residue was suspended in water and the residue obtained by filtration was crystallized in methanol to give 2-nitroethylene thiazolidine (9.2 g).

융점 ; 섭씨 141-142도Melting point; 141-142 degrees Celsius

분석실측치 ; C, 32.91; H, 4.13; N, 19.10Analysis measured value; C, 32.91; H, 4.13; N, 19.10

C4H6N2O2S의 계산치; C, 32.87; H, 4.14; N, 19.17%Calcd for C 4 H 6 N 2 0 2 S; C, 32.87; H, 4.14; N, 19.17%

N-(2-메르캅토에틸)-N'-메틸-2-니트로-1,1-에텐디아민N- (2-mercaptoethyl) -N'-methyl-2-nitro-1,1-ethenediamine

메틸렌아민 33% 용액과 에탄올(40㎖)중에 함유되어 있는 2-니트로에틸렌 티아졸리딘(5g)용액을 실온에서 65시간 동안 방치하였다. 분리된 고체를 여과하고 에탄올로 세척한 다음 건조시켜서 N-(2-메르캅토-에틸)-N'-메틸-2-니트로-1,1-에텐디아민(4.98g)을 수득하였다.A 33% solution of methyleneamine and a 2-nitroethylene thiazolidine (5 g) solution in ethanol (40 mL) were allowed to stand at room temperature for 65 hours. The separated solid was filtered, washed with ethanol and dried to give N- (2-mercapto-ethyl) -N'-methyl-2-nitro-1,1-ethenediamine (4.98 g).

융점 ; 섭씨 174-175도, 분해 : 섭씨 209-211도Melting point; 174-175 degrees Celsius, decomposition: 209-211 degrees Celsius

분석실측치 ; C, 34.05; H, 5.87; N, 23.85Analysis measured value; C, 34.05; H, 5.87; N, 23.85

C5H11N3O2S의 계산치; C, 33.88; H, 6.26; N, 23.71%Calcd for C 5 H 11 N 3 0 2 S; C, 33.88; H, 6. 26; N, 23.71%

N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N'-메틸-2-니트로-1,1-에텐디아민N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro-1,1-ethenediamine

N-(2-메르캅토에틸)-N'-메틸-2-니트로-1,1-에텐디아민(345㎎)을 함유하는 진한 염산(2㎖)를 섭씨 0도에서 5-(디메틸아미노)메틸-2-푸란메탄올(428㎎)에 적하하였다. 이 용액을 섭씨 0도에서 7일동안 정치시킨 후에 반응물을 물(3㎖)로 희석하고 과량의 탄산칼륨을 가한 다음 고체성분을 아세트산 에틸(50㎖)로 추출했다. 용매를 증발시키고 잔류물을 준비된 층 크로마토그래피로 정제해서 실시예 15와 같은 표제화합물(10㎎)을 수득하였다.Concentrated hydrochloric acid (2 mL) containing N- (2-mercaptoethyl) -N'-methyl-2-nitro-1,1-ethenediamine (345 mg) was dissolved in 5- (dimethylamino) methyl at 0 degrees Celsius. It was dripped at 2-furanmethanol (428 mg). The solution was left at 0 ° C. for 7 days, after which the reaction was diluted with water (3 mL), excess potassium carbonate was added and the solid component was extracted with ethyl acetate (50 mL). The solvent was evaporated and the residue was purified by preparative layer chromatography to give the title compound (10 mg) as in Example 15.

[실시예 21]Example 21

N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N'-메틸-2-니트로-1,1-에텐디아민N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro-1,1-ethenediamine

N,N-디메틸-2-푸란메탄아민(125㎎)을 빙초산(1㎖)에 용해하고 파라포름알데히드(30㎎)을 가했다. N-(2-메르캅토에틸)-N'-메틸-2-니트로-1,1-에텐디아민(354㎎)을 함유하는 진한 염산(1㎖)와 물(30㎖)로 희석하고 탄산칼륨으로 포화시킨 다음 아세트산에틸로 추출하였다. 추출물을 준비된 층 크로마토그래피로 정제해서 실시예 15와 같은 표제화합물(89㎎)을 수득하였다.N, N-dimethyl-2-furanmethane amine (125 mg) was dissolved in glacial acetic acid (1 mL) and paraformaldehyde (30 mg) was added. Dilute with concentrated hydrochloric acid (1 ml) and water (30 ml) containing N- (2-mercaptoethyl) -N'-methyl-2-nitro-1,1-ethenediamine (354 mg), and add potassium carbonate. Saturated and extracted with ethyl acetate. The extract was purified by prepared layer chromatography to give the title compound (89 mg) as in Example 15.

[실시예 22]Example 22

N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸-N"-메틸구아니딘N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] -thio] ethyl-N'-methylguanidine

N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸-티오]에틸]카르밤이미도티오산, 메틸에스테르N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl-thio] ethyl] carbamimidothioic acid, methyl ester

2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에탄아민(1.07g)을 N-시아노이미도-카르바모디티오산, 디멘틸에스테르(0.73g)을 함유하는 에테르 용액에 가하고 하룻밤 동안 교반하였다. 형성된 결정상 고체를 여과하고 에테르로 세척한 다음 건조시켜서 N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-카르밤이미도티오산, 메틸에스테르(1.14g)을 수득하였다.2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethanamine (1.07 g) was replaced with N-cyanoimido-carbamodithioic acid and dimentyl ester (0.73 g). It was added to the containing ether solution and stirred overnight. The crystalline solid formed was filtered off, washed with ether and dried to give N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -carbamimi Dothioic acid and methyl ester (1.14 g) were obtained.

융점 ; 섭씨 78-79도Melting point; 78-79 degrees Celsius

N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸]-N"-메틸구아니딘N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] -thio] ethyl] -N'-methylguanidine

N'-시아노-N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]카르밤이미도티오산, 메틸 에스테르(1.06g)을 함유하는 에탄올성 메틸아민 33% 용액(10㎖)를 실온에서 4시간 동안 교반하였다.N'-cyano-N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] carbamimidothio acid, ethanol containing methyl ester (1.06 g) A 33% solution of methylamine (10 mL) was stirred at rt for 4 h.

이 용액을 건조될때까지 증발시키고 유성잔류물을 아세트산에틸-경우(비점 ; 섭씨 80-100도)에서 결정화해서 표제화합물을 수득하였다.The solution was evaporated to dryness and the oily residue was crystallized in ethyl acetate (boiling point; 80-100 degrees Celsius) to afford the title compound.

융점 ; 섭씨 77-80도Melting point; 77-80 degrees celsius

[실시예 23]Example 23

N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸]-N"-헵틸구아니딘N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] -thio] ethyl] -N'-heptylguanidine

헵틸아민(1.15g)과 N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-카르밤이미도티오산(3.12g)의 혼합물을 유욕(oil bath)상에서 12시간 동안 섭씨 100도에서 가열하였다. 생성물을 크로마토그래피(실리카/메탄올)하여 N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸-N"-헵틸구아니딘 수화물(2.31g)을 수득하였다.Heptylamine (1.15 g) and N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -carbamimidothioic acid (3.12 g) The mixture of was heated at 100 degrees Celsius for 12 hours on an oil bath. The product was chromatographed (silica / methanol) to give N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl-N'-heptylguanidine hydrate ( 2.31 g) was obtained.

Rf ; 0.49Rf; 0.49

분석실측치 ; C, 56.99; H, 8.32; N, 17.53Analysis measured value; C, 56.99; H, 8.32; N, 17.53

C19H33N5OS.H2O의 계산치 ; C, 57.43; H, 8.81; N, 17.63%Calcd for C 19 H 33 N 5 OS.H 2 O; C, 57.43; H, 8.81; N, 17.63%

[실시예 24]Example 24

N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸-N'-메틸-2-니트로-1,1-에테디아민N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl-N'-methyl-2-nitro-1,1-ethedamine

2-[[[5-(디메틸아미노) 메틸-2-푸라닐]메틸]티오]-에탄아민(4.25g)과 1,1-비스(메틸티오)-2-니트로에텐(3.3g)을 아세토니트릴(50㎖)중에서 14시간동안 환류하였다. 용매를 제거하고 잔류물을 35%의 페탄올성 메탄아민(50㎖)에 용해한 다음 이 용액을 8시간 동안 환류하였다.2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethanamine (4.25 g) and 1,1-bis (methylthio) -2-nitroethene (3.3 g) Reflux in acetonitrile (50 mL) for 14 h. The solvent was removed and the residue was dissolved in 35% petanol methaneamine (50 mL) and the solution was refluxed for 8 hours.

용매를 제거하고 메탄올에 함유되어 있는 잔류물을 활성탄으로 처리한 다음 여과한 후 용매를 증발시켜서 실시예 15와 같은 표제화합물(5.0g)을 수득하였다.The solvent was removed, the residue contained in methanol was treated with activated charcoal, filtered and the solvent was evaporated to give the title compound (5.0 g) as in Example 15.

[실시예 25]Example 25

(a) N-[2-[[[5-(디메틸아미노) 메틸-2-푸라닐]메틸]티오]-에틸]-N'-(2-메톡시에틸)-2-니트로-1,1-에텐디아민(a) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N '-(2-methoxyethyl) -2-nitro-1,1 Ethendiamine

2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에탄아민(2.14g)과 1,1-비스(메틸티오)-2-니트로에텐(1.65g)을 아세토니트릴 중에서 8시간 동안 환류시켰다. 용매를 제거하고 2-메톡시에틸아민(0.75g)의 에탄올성 용액을 가한 다음 8시간 동안 더 환류하고 용매를 제거해서 기름을 얻었다. 이것을 관크로마토그래피로 정제해서 N-[2-[[[5-(디메틸아미노) 메틸-2-푸라닐]메틸]티오]에틸]-N'-(2-메톡시에틸)-2-니트로-1,1-에텐디아민(1.0g)을 수득하였다.2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethanamine (2.14 g) and 1,1-bis (methylthio) -2-nitroethene (1.65 g) Reflux in acetonitrile for 8 hours. The solvent was removed and an ethanol solution of 2-methoxyethylamine (0.75 g) was added, followed by further reflux for 8 hours, and the solvent was removed to obtain an oil. This was purified by column chromatography to obtain N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N '-(2-methoxyethyl) -2-nitro- 1,1-ethenediamine (1.0 g) was obtained.

NMRτ(CDCl3) 7.73s(6H); 7-7.5m(2H); 6.2-7m(11H); 6.23s(2H); 3.81s(2H); 3.42s(1H)NMRτ (CDCl 3 ) 7.73 s (6H); 7-7.5 m (2H); 6.2-7 m (11 H); 6.23 s (2H); 3.81 s (2H); 3.42 s (1 H)

동일하게 제조된 것으로는;To be prepared in the same way;

(b) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]2-니트로-1,1-에텐디아민(b) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] 2-nitro-1,1-ethenediamine

융점 ; 섭씨 100-101도Melting point; 100-101 degrees celsius

[실시예 26]Example 26

(a) N-[4-[5-(디메틸아미노)메틸-2-푸라닐]부틸]-N'-메틸-2-니트로-1,1-에텐디아민(a) N- [4- [5- (dimethylamino) methyl-2-furanyl] butyl] -N'-methyl-2-nitro-1,1-ethenediamine

4-[5-(디메틸아미노) 메틸-2-푸라닐] 부탄아민(0.7g)과 1,1-비스(티오메틸)-2-니트로에텐(0.6g)을 함유하는 아세토니트릴(12㎖)를 22시간동안 환류하였다. 용매를 제거하고 잔류물은 33%의 에탄올성 메틸아민중에서 2시시간동안 환류하시켰다. 용매를 제거한 다음 잔유물을 관크로마토그래피(실리카/메탄올)로 정제해서 N-[4-[5-(디메틸아미노)메틸-2-푸라닐]부틸]-N'-메틸-2-니트로-1,1-에텐디아민(310㎎)을 수득하였다.Acetonitrile (12 ml) containing 4- [5- (dimethylamino) methyl-2-furanyl] butanamine (0.7 g) and 1,1-bis (thiomethyl) -2-nitroethene (0.6 g) ) Was refluxed for 22 hours. The solvent was removed and the residue was refluxed for 2 h in 33% ethanol methylamine. The solvent was removed and the residue was purified by column chromatography (silica / methanol) to give N- [4- [5- (dimethylamino) methyl-2-furanyl] butyl] -N'-methyl-2-nitro-1, 1-ethenediamine (310 mg) was obtained.

분석실측치 ; C, 55.54; H, 8.23; N, 17.75Analysis measured value; C, 55.54; H, 8.23; N, 17.75

C14H24N4O31/2H2O의 계산치 ; C, 55.26; H, 8.22; N, 18.42%Calcd for C 14 H 24 N 4 O 3 1 / 2H 2 O; C, 55.26; H, 8.22; N, 18.42%

(b) N-[5-[5-(디메틸아미노)메틸-2-푸라닐]펜틸]-N'-메틸-2-니트로-1,1-에텐디아민(b) N- [5- [5- (dimethylamino) methyl-2-furanyl] pentyl] -N'-methyl-2-nitro-1,1-ethenediamine

분석실측치; C, 56.76; H, 8.36; N, 17.37Analytical observations; C, 56.76; H, 8. 36; N, 17.37

C15H26N4O3H2O의 계산치 ; C, 56.43; H, 8.46; N, 17.55%Calcd for C 15 H 26 N 4 O 3 H 2 O; C, 56.43; H, 8. 46; N, 17.55%

(c) N-[3-[[5-(디메틸아미노)메틸-2-푸라닐]티오]프로필]-N'-메틸-2-니트로-1,1-에텐디아민(c) N- [3-[[5- (dimethylamino) methyl-2-furanyl] thio] propyl] -N'-methyl-2-nitro-1,1-ethenediamine

분석실측치; C, 49.36; H, 7.19; N, 17.45Analytical observations; C, 49.36; H, 7. 19; N, 17.45

C13H22N4O3의 계산치 ; C, 49.66; H, 7.05; N, 17.84%Calcd for C 13 H 22 N 4 O 3 ; C, 49.66; H, 7.05; N, 17.84%

(d) N-[3-[5-(디메틸아미노)메틸-2-푸라닐]프로필]-N'-메틸-2-니트로-1,1-에텐디아민(d) N- [3- [5- (dimethylamino) methyl-2-furanyl] propyl] -N'-methyl-2-nitro-1,1-ethenediamine

분석실측치; C, 55.09; H, 7.84Analytical observations; C, 55.09; H, 7.84

C13H22N4O3의 계산치 ; C, 55.31; H, 7.72%Calcd for C 13 H 22 N 4 O 3 ; C, 55.31; H, 7.72%

(e) N-[2-[[[5-(디에틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N'-메틸-2-니트로-1,1-에텐디아민(e) N- [2-[[[5- (diethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N'-methyl-2-nitro-1,1-ethenediamine

분석실측치; C, 51.38; H, 7.44; N, 15.66Analytical observations; C, 51.38; H, 7. 44; N, 15.66

C15H26N4O3S·1/2H2O의 계산치 ; C, 51.26; H, 7.74; N, 15.94%Calcd for C 15 H 26 N 4 O 3 S. 1 / 2H 2 O; C, 51.26; H, 7. 74; N, 15.94%

(f) N-[3-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]프로필]-N'-메틸-2-니트로-1,1-에텐디아민(f) N- [3-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] propyl] -N'-methyl-2-nitro-1,1-ethenediamine

분석실측치; C, 49.57; H, 7.20; N, 15.59Analytical observations; C, 49.57; H, 7. 20; N, 15.59

C14H24N4O3S·1/2H2O의 계산치 ; C, 49.86; H, 7.47; N, 16.61%Calcd for C 14 H 24 N 4 O 3 S · 1 / 2H 2 O; C, 49.86; H, 7.47; N, 16.61%

[실시예 27]Example 27

(a) N-시아노-N'-[4-[5-(디메틸아미노)메틸-2-푸라닐]부틸]-N"-메틸구아니딘(a) N-cyano-N '-[4- [5- (dimethylamino) methyl-2-furanyl] butyl] -N'-methylguanidine

4-[5-(디메틸아미노)메틸-2-푸라닐]부탄아민(0.4g)과 N-시아노이미도카르바모디티오산, 디메틸에스테르(0.3g)을 에탄올중에서 3시간 동안 실온에서 교반하였다. 그런다음 33%의 메탄이민을 함유하는 에탄올 용액을 가하고 이 혼합물을 2시간 동안 환류하며 가열했다. 용매를 환산압력하에서 제거하고 생성물을 관크로마토그래피(실리카/메탄올)로 정제해서 담황색 기름인 생성물을 수득하였다.4- [5- (dimethylamino) methyl-2-furanyl] butanamine (0.4 g), N-cyanoimidocarbamodithioic acid and dimethyl ester (0.3 g) were stirred in ethanol for 3 hours at room temperature. An ethanol solution containing 33% methaneimine was then added and the mixture was heated to reflux for 2 hours. The solvent was removed under reduced pressure and the product was purified by column chromatography (silica / methanol) to give the product as a pale yellow oil.

NMRτ(CDCl3)8-8.5br(4H); 7.77s(6H); 6.61-7.5m (9H); 4.0m(2H); 2.8-3.7m(2H)NMRτ (CDCl 3 ) 8-8.5 br (4H); 7.77 s (6 H); 6.61-7.5 m (9H); 4.0 m (2H); 2.8-3.7m (2H)

동일한 방법으로 제조된 것으로는Manufactured in the same way

(b) N-시아노-N'-[5-[5-(디메틸아미노)메틸-2-푸라닐]펜틸]-N'-메틸구아니딘(b) N-cyano-N '-[5- [5- (dimethylamino) methyl-2-furanyl] pentyl] -N'-methylguanidine

NMRτ(CDCl3) 8.0-8.7br(6H); 7.68s(6H); 7.32t(2H); 7.10d(3H); 6.7q(2H); 6.48s(2H); 3.8-4.3m(4H)NMRτ (CDCl 3 ) 8.0-8.7 br (6H); 7.68 s (6 H); 7.32 t (2H); 7.10d (3H); 6.7q (2H); 6.48 s (2H); 3.8-4.3 m (4H)

[실시예 28]Example 28

(a) N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]-에틸]-N'-메탄술포닐-N"-메틸구아니딘(a) N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] -ethyl] -N'-methanesulfonyl-N'-methylguanidine

메탄술포닐이미노디티오카르밤산, 디메틸에스테르(1.9g)과 2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오-에탄아민(2.14g)을 에탄올중에서 3시간 동안 실온에서 교반하였다. 여기에 33%의 에탄올성 메틸아민(20㎖)를 가하고 16시간동안 환류시키며 가열하였다. 생성물을 관크로마토그래피(실리카/메탄올)로 정제해서 담색기름인 N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸-N'-메탄술포닐-N"-메틸구아니딘(2.7g)을 수득하였다.Methanesulfonyliminodithiocarbamic acid, dimethyl ester (1.9 g) and 2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio-ethanamine (2.14 g) in ethanol for 3 hours Stir at room temperature. To this was added 33% ethanol methylamine (20 mL) and heated to reflux for 16 h. The product was purified by column chromatography (silica / methanol) to obtain a pale oil, N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl-N'-methanesulfonyl- N'-methylguanidine (2.7 g) was obtained.

분석실측치 ; C, 43.54; H, 7.05; N, 15.48Analysis measured value; C, 43.54; H, 7.05; N, 15.48

C13H24N4O3S2·1/2H2O의 계산치; C, 43.70; H, 7.00; N, 15.69%Calcd. For C 13 H 24 N 4 O 3 S 2 .1 / 2H 2 O; C, 43.70; H, 7.00; N, 15.69%

동일하게 제조된 것으로는;To be prepared in the same way;

(b) N-벤젠술포닐-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸[티오]에틸]-N"-메틸구아니딘(b) N-benzenesulfonyl-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl [thio] ethyl] -N'-methylguanidine

분석실측치 ; C, 50.30; H, 6.25; N, 12.93Analysis measured value; C, 50.30; H, 6. 25; N, 12.93

C18H26N4O3S. H2O의 계산치 ; C, 50.47; H, 6.54; N, 13.08%C 18 H 26 N 4 O 3 S. Calculated value of H 2 O; C, 50.47; H, 6. 54; N, 13.08%

[실시예 29]Example 29

N-시아노-N'-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]-티오]에틸]-N"-메틸구아니딘N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] -thio] ethyl] -N'-methylguanidine

N-시아노-N'-메틸카르밤이미도티오산, 메틸에스테르(6.1g), 트리에틸아민(4.8g)과 2-[[[2-푸라닐]메틸]티오]에탄아민(7.8g)을 함유하는 메탄올(150㎖) 용액에 질산은 (8.25g)을 함유하는 디메틸 포름아미드(50㎖)용액을 적하하였다. 42시간 후에 섭씨 50도에서 이 혼합물을 여과하고 여액을 증발시켰더니 잔류물은 아세트산에틸과 물사이에서 구획되어 있었다. 유기층을 건조시키고 증발시켜서 수득한 기름에서 결정성 N-시아노-N'-[2-[[[2-(푸라닐]메틸]티오]에틸]-N"-메틸구아니딘(3.9g)을 산출해냈다.N-cyano-N'-methylcarbamimidiothioic acid, methyl ester (6.1 g), triethylamine (4.8 g) and 2-[[[2-furanyl] methyl] thio] ethanamine (7.8 g) To a methanol (150 mL) solution containing dimethyl formamide (50 mL) solution containing silver nitrate (8.25 g) was added dropwise. After 42 hours, the mixture was filtered at 50 degrees Celsius and the filtrate was evaporated. The residue was partitioned between ethyl acetate and water. Drying and evaporation of the organic layer yielded crystalline N-cyano-N '-[2-[[[2- (furanyl] methyl] thio] ethyl] -N'-methylguanidine (3.9 g) in oil obtained by drying. I did it.

융점 ; 섭씨 78-82도Melting point; 78-82 degrees Celsius

이 아민(4.5g)과 염산디메틸아민(3.1g), 36%의 포름알데히드수용액(3.16g)의 용액을 에탄올(20㎖) 중에서 60시간동안 섭씨 50도에서 가열하였다. 잔류물은 아세트산에틸과 염기수용액 사이에서 구획되어 있었다. 화합된 유기추출물을 건조, 증발시켜 얻은 기름을 이소프로판올 중에서 세바스산으로 처리하여 표제화합물의 세바스산염(2g)을 수득하였다.A solution of this amine (4.5 g), dimethylamine hydrochloride (3.1 g), and 36% aqueous formaldehyde solution (3.16 g) was heated in ethanol (20 mL) at 50 degrees Celsius for 60 hours. The residue was partitioned between ethyl acetate and aqueous base solution. The combined organic extracts were dried and evaporated and the oil was treated with sebacic acid in isopropanol to give sebacate (2 g) of the title compound.

융점 ; 섭씨 93-94도Melting point; 93-94 Celsius

[실시예 30]Example 30

N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N-메틸티오우레아N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N-methylthiourea

수산화나트륨(0.8g)을 함유하는 냉수(1.7㎖)를 교반하면서 여기에 이황화 탄소(1.52g)을 가했다. 여기에 2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에탄아민(4.28g)을 서서히 가한 다음 이 혼합물을 섭씨 100도에서 2시간 동안 가열하였다.Carbon disulfide (1.52 g) was added thereto while stirring cold water (1.7 mL) containing sodium hydroxide (0.8 g). To this was slowly added 2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethanamine (4.28 g) and then the mixture was heated at 100 degrees Celsius for 2 hours.

혼합물을 섭씨 40도 이하로 냉각한 후에 클로로포름산에틸(ClCOOCH2CH3)(1.94㎖)를 가하고 30분동안 더 계속해서 교반하였다. 약간 된 황색기름을 클로로포름으로 추출하고 건조시킨 다음 증발해서 기름인 N,N-디메틸-5-[[[2-(이소티오시아나토)에틸]티오]메틸]푸란메탄아민을 수득하였다.After cooling the mixture to 40 degrees Celsius or less, ethyl chloroformate (ClCOOCH 2 CH 3 ) (1.94 mL) was added and stirring continued for 30 minutes. The slightly yellow oil was extracted with chloroform, dried and evaporated to give N, N-dimethyl-5-[[[[2- (isothiocyanato) ethyl] thio] methyl] furanmethanamine as an oil.

Rf ; 0.43(실리카/메탄올)Rf; 0.43 (silica / methanol)

조제한 이소티오시안산염(0.46g)을 33%의 에탄올성 메틸아민(25㎖)에 용해하고 하룻밤 정치시켜서, 2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에탄아민과 이소티오시안산메틸로부터 제조된 물질과 동일한 담색기름인 N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸]-N'-메틸오우레아(0.16g)을 분리해냈다.Prepared isothiocyanate (0.46 g) was dissolved in 33% ethanol methylamine (25 mL) and allowed to stand overnight to afford 2-[[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio]. N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl] -N'-methylou, the same pale oil as the material produced from ethanamine and methyl isothiocyanate Lea (0.16 g) was isolated.

[실시예 31]Example 31

N-시아노-N'-[2-[[[5-(디메틸아미노) 메틸-2-푸라닐]메틸]-티오]에틸]-N"-메틸구아니딘N-cyano-N '-[2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] -thio] ethyl] -N'-methylguanidine

N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]-메틸]티오]에틸]-N'-메틸티오우레아(1.3g)을 납시아나미드(1.5g)과 함께 환류하면서 가열했다. 이 용액을 여과하고 여액은 증발시켰으며 잔류물은 이소프로판올 중에서 세바스산용액으로 처리하여 표제화합물의 모노세바스산염(0.7g)을 수득하였다.N- [2-[[[5- (dimethylamino) methyl-2-furanyl] -methyl] thio] ethyl] -N'-methylthiourea (1.3 g) was refluxed with lead cyanamide (1.5 g) While heating. The solution was filtered and the filtrate was evaporated and the residue was treated with a sebacic acid solution in isopropanol to give the mono sebacate of the title compound (0.7 g).

융점 ; 섭씨 90-92도Melting point; 90-92 Celsius

[실시예 32]Example 32

염산 N-2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸-N'-메틸-2-니트로-1,1-에텐디아민Hydrochloric acid N-2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl-N'-methyl-2-nitro-1,1-ethenediamine

염화수소를 0.16g 당량 함유하는 메틸화된 공업용 주정 74도 오.피.(200㎖)에 N-[2-[[[5-(디메틸아미노)메틸-2-푸라닐]메틸]티오]에틸-N'-메틸-2-니트로-1,1-에텐디아민(50g, 0.16몰)을 용해하였다. 이 용액에 아세트산에틸(200㎖)를 천천히 가하고 결정화된 염산을 여과해서 메틸화된 공업용 주정 74도 오. 피.(50㎖)와 아세트산에틸(50㎖)의 혼합물로 세척한 다음 섭씨 50도에서 건조시켰다. 이렇게 함으로써 얻어진 생성물은 혼백색의 고체(50g)이었다.Methylated industrial spirit containing 0.16 g equivalents of hydrogen chloride at 74 degrees P. (200 mL) to N- [2-[[[5- (dimethylamino) methyl-2-furanyl] methyl] thio] ethyl-N '-Methyl-2-nitro-1,1-ethenediamine (50 g, 0.16 mol) was dissolved. Ethyl acetate (200 mL) was slowly added to this solution, and the crystallized hydrochloric acid was filtered to methylate industrial alcohol 74 degrees. Washed with a mixture of P. (50 mL) and ethyl acetate (50 mL) and dried at 50 degrees Celsius. The product thus obtained was a whitish solid (50 g).

융점 ; 섭씨 133-134도Melting point; 133-134 degrees celsius

[실시예 33]Example 33

[제약 조성물]Pharmaceutical Composition

Figure kpo00038
Figure kpo00038

* 직접 압축할수 있는 형태의 녹말로서 A.E. Staley Mfg. Co. (London) Limited, Orpington, Kent.의 제품이다.* A.E. starch that can be directly compressed. Staley Mfg. Co. (London) Limited, Orpington, Kent.

이 약품을 250㎛의 체를 통해서 거른 다음 4종류의 분말들을 즉시 분쇄기안에서 혼합하고 정제기(tabetting amchine)내의 지름이 8.5㎜인 펀치 사이에서 압축하였다.The drug was filtered through a 250 μm sieve and then the four powders were immediately mixed in a mill and compressed between punches with a diameter of 8.5 mm in a tabetting amchine.

Figure kpo00039
Figure kpo00039

활성성분을 주사용 증류수와 혼합하면서 잘 용해시킨 다음 용액의 pH가 5가 될 때까지 염산을 천천히 가했다. 이 용액에 질소를 살포하고 공극크기가 1.35㎛인 박막거르게(membrane filter)를 통해서 여과하여 정제시킨 다음 2㎖의 유리 앰푸울에 (각각 2.2㎖씩) 채워넣었다. 이 앰푸울들을 질소분위기중에서 밀봉한 다음 섭씨 121도에서 30분동안 오오토클레이브안에서 멸균시켰다.The active ingredient was dissolved well while mixing with distilled water for injection, and then hydrochloric acid was added slowly until the solution had a pH of 5. Nitrogen was sparged in this solution, filtered through a membrane filter with a pore size of 1.35 μm, and then purified. Then, 2 mL of glass ampoules (2.2 mL each) were charged. The ampoules were sealed in a nitrogen atmosphere and then sterilized in an autoclave for 30 minutes at 121 degrees Celsius.

Figure kpo00040
Figure kpo00040

** 큐티나 에이치알은 경화된 아주까리 기름의 미세품(微細品)으로서 런던 시폰 프로덕트 리밋티드의 제품이다.Cutina H.R is a fine product of cured castor oil, manufactured by London Chiffon Products Limited.

활성성분과 무수젖당 그리고 큐티나 에이치알의 대부분을 서로 혼합한 다음에 이 혼합물을 나머지 큐티나 에이치알의 10% 용액과 함께 메틸화된 공업용 주정 74도 오피중에서 혼합하여 습윤화시켰다. 습윤화된 물질을 구멍크기가 1.2㎜인 체에 통과시켜 입상(粒狀)으로 만들고 섭씨 50도에서 유동층 건조기로 건조시켰다. 그럼 다음 이 과립들을 구멍크기가 0.85㎜인 체로 거르고 스테아르산 마그네숨과 배합한 후에 지름이 12.5㎜인 펀치가 있는 정제기상에서 적어도 10㎏의 경도(쉘레윈지 시험기)로 압축하였다.The active ingredient, anhydrous lactose, and most of the cutie and HL were mixed with each other and then the mixture was wetted by mixing in a methylated industrial spirit 74 ° C. with 10% solution of the remaining cutie or HL. The wetted material was granulated by passing through a sieve having a pore size of 1.2 mm and dried in a fluid bed dryer at 50 degrees Celsius. The granules were then filtered through a sieve of 0.85 mm pore size and blended with magnesium stearate and then compressed to a hardness of at least 10 kg (Schelewinge tester) on a tablet machine with a punch of 12.5 mm diameter.

Figure kpo00041
Figure kpo00041

약간의 증류수를 교반하면서 활성성분을 용해하고 이때 용액의 pH가 5.0으로 될 때까지 단계적으로 염산을 가했다. 솔비톨용액과 향미 그리고 나머지 증류수를 이 용액에 가한 다음 pH를 다시 5로 조정하였다. 이 시럽을 적당한 셀롤로오스 여과판을 통햇 여과시켜 정제하였다.The active ingredient was dissolved while stirring with some distilled water, and hydrochloric acid was added stepwise until the pH of the solution reached 5.0. Sorbitol solution, flavor and remaining distilled water were added to this solution and the pH was adjusted back to 5. This syrup was purified by filtration through a suitable cellulose filter plate.

Figure kpo00042
Figure kpo00042

활성성분을 250㎛의 그 물체로 거르고 다른 분말과 함께 배합하였다. 이 분말을 적당한 충전기상에서 입자번호 3의 단단한 젤라틴 캡슈울에 충전시켰다.The active ingredient was filtered through the object of 250 μm and combined with other powders. This powder was filled into a hard gelatin capsule of particle number 3 on a suitable charger.

Figure kpo00043
Figure kpo00043

활성성분을 구멍크기가 150㎛인 체로 거른 다음 고전 단기내에서 백색의 연질파라핀과 함께 균일하게 배합시켰다.The active ingredient was filtered through a sieve having a pore size of 150 μm and then uniformly combined with white soft paraffin in the high-short run.

Figure kpo00044
Figure kpo00044

활성성분을 구멍크기가 150㎛인 체로 거르고 섭씨 65도에서 세토마크로골 유화연고와 잘 배합하였다.The active ingredient was filtered through a sieve having a pore size of 150 μm and well blended with cetomacrogol emulsified ointment at 65 degrees Celsius.

섭씨 65도에서 클로로크레졸을 물에 용해시키고 이 용액을 상기 유성약제 혼합물과 섞었다. 생성도니 에멀션을 계속 교반하면서 냉각시켜 크림을 제조하였다. 활성 성분은 본 발명의 화합물로서 특히 실시예 10과 15의 화합물이나 본 발명에 의한 다음 화합물이 사용될수도 있다.Chlorocresol was dissolved in water at 65 degrees Celsius and the solution was mixed with the oil-based drug mixture. The resulting dough emulsion was cooled with continued stirring to prepare a cream. The active ingredient may be used as the compound of the present invention, in particular the compounds of Examples 10 and 15, but the following compounds according to the present invention.

구조식(Ⅰ)의 화합물들은 히스타민에 의해서 유발된 위산분비의 억제물로 작용한다는 사실이 발견되었다. 이것은 1958년에 출간된 영국 약학회지 13권 54페이지에 기술된 엠. 엔. 고쉬와 에이치. 오. 쉴드의 방법을 변형해서 쥐를 대상으로 시험하므로써 증명되었다. 무게 150g 정도되는 암쥐를 하룻밤 굶기고 음료수 대신에 8%의 설탕을 함유하는 생리식염수를 주었다. 그런 다음 25% W/V 의 우레탄용액(0,5㎖/100g)으로 1회 복강내 주사하여 마취시키고 기관과 경정맥에 카뉴울을 장치하였다. 복벽 중앙을 절개해서 위를 노출시키고 결합조직을 절단해서 간과 비장에서 위를 분리시켰다. 위저부에 소공을 만들어서 이 위를 5%의 포도당 용액으로 세척하였다. 그런 다음 식도에 고무관을 삽관시키고 이 식도와 미주신경을 고무관위에서 절단했다. 위의 유문부에 소공을 만든다음, 커다란 퍼어스펙스 카뉴울을 위 저부의 소공을 통해서 위에 장치하되, 카뉴울의 유입단부가 유문부의 소공을 통해서 위를 통과해 나가는 식으로 장치하였다. 이러한 형태의 카뉴울은 위의 유효부피를 감소시키고 점막위를 흐르는 관류액이 난류(亂流)하도록 한다. 다음단계로, 위저부의 소공을 통해서 배수카뉴울을 삽입하였다. 두 개의 카뉴울의 결찰사로 묶어서 위주변에 고정시키되 주혈관은 피하도록 하였다. 체벽에 자상(刺傷)을 만들어서 이곳을 통해 카뉴울을 통과시켰다. 식도와 유문부의 카뉴울을 통하여 5%의 포도당 용액을 섭씨 39도에서 1.5㎖/분의 속도로 위에 채워넣었다. 유출액이 미세유출 pH 전극(micro-flow pH electrode, 액체의 유출량이 미세할 때 그 액체의 pH를 측정하는 전극) 위로 흐르게 하고 pH 밑와 평판기록계(flat bed recorder)로 기록하였다. 위에서 분비되는 산의 기초방출량을 관류용출액의 pH를 측정해서 검사하고 최저투여량의 히스타민을 정맥내로 지속주입하여 산의 분비를 증가시켰다. 이러한 조작은 위산의 분비가 안정한 고평부(plateau)를 이루게 하며 관류용 출액의 pH는 이러한상태가 얻어졌을 때 결정된다. 이제, 시험화합물을 쥐에 정맥내주사하고 관류용출액의 pH 변화값을 측정항 위산분비의 변화를 검사하였다. 관류용출액의 pH 변화값으로부터, 기초박출량과 히스타민에 의해서 자극된 고평부값 사이의 산분비 차를 수소 이온농도 물/1로 계산하였다. 또한 관류 용출액 pH 차로부터 시험화합물을 투여함으로서 야기된 산분비의 감소치를 수소이온농도 물/1의 변화로서 계산하였다. 이렇게 해서 얻어진 두 개의 계수로부터 시험화합물을 투여함으로서 야기된 산분비의 감소%를 계산할수 있다.It was found that the compounds of formula (I) act as inhibitors of gastric acid secretion induced by histamine. This is described in the British Journal of Pharmacy, Volume 13, page 54, published in 1958. yen. Gauche and H. Five. This was demonstrated by modifying the shield's method and testing it on rats. Rats weighing about 150 g were starved overnight and given saline containing 8% sugar instead of drinking water. Then, anesthesia was injected once intraperitoneally with 25% W / V urethane solution (0,5ml / 100g), and cannulas were installed in the trachea and jugular vein. The abdominal wall was cut open to expose the stomach and the connective tissue was cut to separate the stomach from the liver and spleen. A small hole was made in the bottom of the stomach and the stomach was washed with 5% glucose solution. Then, a rubber tube was inserted into the esophagus and the esophagus and the vagus nerve were cut on the rubber tube. After making a pore in the upper pyloric region, a large Perspex canopy was placed on top of the lower pores above, with the inlet end of the canyon wool passing through the pores of the pyloric section. This type of canewool reduces the effective volume of the stomach and allows turbulent flow of the perfusion fluid on the mucosa. In the next step, drainage canes were inserted through the pores of the upper base. Two canine wool ligatures were tied and fixed around the gastric vessels. It made a stab on the wall and passed through Canueul. A 5% glucose solution was charged over the esophagus and pylori at the rate of 1.5 ml / min at 39 degrees Celsius. The effluent was allowed to flow over a micro-flow pH electrode (electrode for measuring the pH of the liquid when the flow rate of the liquid was fine) and recorded below the pH and with a flat bed recorder. The basal release of acid secreted from the stomach was examined by measuring the pH of the perfusion eluate, and the lowest dose of histamine was continuously injected intravenously to increase acid secretion. This operation results in a stable plateau of gastric acid secretion and the pH of the perfusion extract is determined when this condition is obtained. Now, the test compound was injected intravenously into rats, and the change in gastric acid secretion was measured by measuring the pH change value of the perfusion eluate. From the pH change value of the perfusion eluate, the acid content difference between the base ejection amount and the high plateau value stimulated by histamine was calculated as hydrogen ion concentration water / 1. In addition, the decrease in acid secretion caused by administration of the test compound from the perfusion eluate pH difference was calculated as the change in hydrogen ion concentration water / 1. From the two coefficients thus obtained, the percent reduction in acid release caused by administration of the test compound can be calculated.

시험화합물을 쥐 한 마리에 1회 투여량만큼 투여해서 산분비를 억제하는데 대한 ED50값을 3회 이상 측정하되 매 측정마다 적어도 4마리의 쥐를 대상으로 반복시험하였다. 얻어진 결과로 최소제곱법인 표준 방법에 의해서 ED50값을 계산하였다. 얻어진 ED50의 값은 다음과 같다.The test compound was administered to one rat at a dose of three or more ED 50 values for inhibiting acid secretion, and at least four rats were repeated for each measurement. As a result, the ED 50 value was calculated by the standard method which is the least square method. The value of ED 50 obtained is as follows.

Figure kpo00045
Figure kpo00045

Claims (1)

본문에 상술한 바와같이, 아래의 일반식(Ⅱ)의 화합물을 일반식(Ⅲ)의 화합물과 반응시켜서 필요에 따라 최종 생성물을 약학적으로 허용된 염으로 분리시키거나 또는 그러나 염을 다른 염으로 전환시킬수 있는 일반식(Ⅰ)의 아미노알킬푸란 유도체의 제조방법.As detailed herein, the compound of formula (II) below may be reacted with a compound of formula (III) to separate the final product into a pharmaceutically acceptable salt as Process for preparing aminoalkylfuran derivatives of general formula (I) which can be converted.
Figure kpo00046
Figure kpo00046
이 식에서 R1과 R2는 동일하거나 상이한 것으로서 수소, 저급알킬, 시클로알킬, 저급알케닐, 아랄킬이거나 또는 산소원자나
Figure kpo00047
(R4는 수소나 저급알킬)가 중간에 결합된 저급알킬을 나타낸다. 또는 R1과 R2는 이들이 결합된 질소원자와 함께, 산소와
Figure kpo00048
중에서 선택된 이들 이중원자를 함유하는 헤테로고리를 형성할수도 있다.
Wherein R 1 and R 2 are the same or different and are hydrogen, lower alkyl, cycloalkyl, lower alkenyl, aralkyl or oxygen atom
Figure kpo00047
(R 4 represents hydrogen or lower alkyl) in which intermediate alkyl is bonded. Or R 1 and R 2 together with the nitrogen atom to which they are attached,
Figure kpo00048
It is also possible to form heterocycles containing these double atoms selected from among them.
R3는 수소, 저급알킬, 저급알케닐, 또는 알콕시 알킬이고,R 3 is hydrogen, lower alkyl, lower alkenyl, or alkoxy alkyl, X는 -CH2-, 산소 또는 유황이며X is -CH 2- , oxygen or sulfur Y는 =S, =O, =NR5또는 =CHR6이고,Y is = S, = O, = NR 5 or = CHR 6 , Alk는 곧은사슬 또는 분기(分岐) 사슬형태를 이루는 C1-C6의 알킬렌이며,Alk is a C 1 -C 6 alkylene which forms a straight or branched chain, R5는 수소, 니트로, 시아노, 저급알킬, 아릴, 알킬술포닐, 또는 아릴술포닐이고,R 5 is hydrogen, nitro, cyano, lower alkyl, aryl, alkylsulfonyl, or arylsulfonyl, R6는 니트로, 아릴술포닐 또는 알킬술포닐이며, m은 2-4의 정수이고,R 6 is nitro, arylsulfonyl or alkylsulfonyl, m is an integer from 2-4, n은 1 또는 2이나 X나 S나 -CH2-인 경우에 n은 0, 1 또는 2이다.n is 0, 1 or 2 when n is 1 or 2 or X or S or -CH 2- .
Figure kpo00049
Figure kpo00049
이 식에서 A는 수소이고 B는 수소 또는
Figure kpo00050
기[P는 분리기(基),
Where A is hydrogen and B is hydrogen or
Figure kpo00050
P is a separator,
Figure kpo00051
는 =NR5또는 -CHR6]이며 또는 A와 B 모두가 =CS이다.
Figure kpo00051
Is = NR 5 or -CHR 6 ] or both A and B are = CS.
Figure kpo00052
Figure kpo00052
이 식에서 Z는 수소이고 Z'는 수소 또는
Figure kpo00053
기이며 또는 Z와 Z' 모두가 =CO나 =CS이다.
Where Z is hydrogen and Z 'is hydrogen or
Figure kpo00053
Or Z and Z 'are both = CO and = CS.
KR7701808A 1976-08-04 1977-08-04 Preparation for pharmacologically active compounds KR810000355B1 (en)

Priority Applications (53)

Application Number Priority Date Filing Date Title
GB32465/76A GB1565966A (en) 1976-08-04 1976-08-04 Aminoalkyl furan derivatives
CY1277A CY1077A (en) 1976-08-04 1977-07-22 Aminoalkyl furan derivatives
FI772264A FI72318C (en) 1976-08-04 1977-07-22 FOERFARANDE FOER FRAMSTAELLNING AV SELEKTIVT PAO HISTAMINRESEPTORER VERKANDE N- / 2 - /// 5- (DIMETHYLAMINO) METHYL-2-FURANYL / METHYL / THIO / EECL-N'-METHYL-2-NITRO-1,1-ETENDIAMINE.
GB28187/78A GB1565967A (en) 1976-08-04 1977-07-22 Aminoalkyl furan derivatives
IE1536/77A IE45456B1 (en) 1976-08-04 1977-07-25 Aminoalkyl furan derivatives
US05/818,762 US4128658A (en) 1976-08-04 1977-07-25 Aminoalkyl furan derivatives
SE7708521A SE437373B (en) 1976-08-04 1977-07-25 PROCEDURE FOR PREPARING AN AMINOAL COOLING RANGE DERIVATIVE WITH THERAPEUTIC EFFECT
DK337977A DK148258C (en) 1976-08-04 1977-07-26 ANALOGY PROCEDURE FOR THE PREPARATION OF AN AMINOAL COOLING RANGE
NZ184759A NZ184759A (en) 1976-08-04 1977-07-27 Aminoalkyl-furan derivatives and pharmaceutical compositions
NZ191383A NZ191383A (en) 1976-08-04 1977-07-27 N-(2-mercaptoethyl)-2-nitro -1, 1 - ethene di - amines
DE2760097A DE2760097C2 (en) 1976-08-04 1977-07-28
DE2734070A DE2734070C2 (en) 1976-08-04 1977-07-28 Aminoalkylfuran derivatives, processes for their preparation and pharmaceuticals containing these compounds
DE2759959A DE2759959C2 (en) 1976-08-04 1977-07-28
CH938077A CH642072A5 (en) 1976-08-04 1977-07-29 Process for the preparation of aminoalkylfuran derivatives
CA283,694A CA1099268A (en) 1976-08-04 1977-07-29 Aminoalkyl-furanylalkyl-urea derivatives
PT66874A PT66874B (en) 1976-08-04 1977-08-01 Process for the preparation of new aminoalquil furan derivatives
AU27519/77A AU515628B2 (en) 1976-08-04 1977-08-01 Pharmacologically active aminoalkyl furans
BE179834A BE857388A (en) 1976-08-04 1977-08-02 NEW AMINO-ALCOYL-FURANS INHIBITORS OF HISTAMINE H2 RECEPTORS, THEIR PREPARATION AND THEIR USE
PH20057A PH13540A (en) 1976-08-04 1977-08-02 Aminoalkyl furan derivatives
YU1911/77A YU40006B (en) 1976-08-04 1977-08-03 Process for obtaining a new aminoalkyl-furane derivative
LU77911A LU77911A1 (en) 1976-08-04 1977-08-03 METHODS FOR THE PREPARATION OF NEW DERIVATIVES OF AMINO-ALCOYL-FURANS, EXERCISING A SELECTIVE ACTION ON HISTAMINE RECEPTORS
ES461334A ES461334A1 (en) 1976-08-04 1977-08-03 A procedure for the preparation of aminoalquilfurans. (Machine-translation by Google Translate, not legally binding)
IT50551/77A IT1126759B (en) 1976-08-04 1977-08-03 AMINO ALKYLFURANIC DERIVATIVE, PROCEDURES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
NLAANVRAGE7708601,A NL178320C (en) 1976-08-04 1977-08-03 PROCEDURE FOR PREPARING A COMPOUND WITH HISTAMINO-HŸ2 BLOCKING ACTIVITY AND FOR PREPARING PHARMACEUTICAL PREPARATIONS CONTAINING THIS COMPOUND.
JP52093722A JPS5840956B2 (en) 1976-08-04 1977-08-04 Aminoalkylfuran derivatives, their production methods and pharmaceutical compositions containing them
KR7701808A KR810000355B1 (en) 1977-05-13 1977-08-04 Preparation for pharmacologically active compounds
FR7724021A FR2360587B1 (en) 1976-08-04 1977-08-04 NEW AMINO-ALCOYL-FURAN DERIVATIVES USEFUL AS MEDICINES
AT0574077A AT375931B (en) 1976-08-04 1977-08-04 METHOD FOR PRODUCING NEW AMINOALKYLFURANDERIVATIVES
CH1229/84A CH651560A5 (en) 1977-05-13 1978-01-01 Aminoalkylfuran derivatives, and drugs containing these compounds
FR7814251A FR2384753B1 (en) 1976-08-04 1978-05-12 NEW THIOLS AND THEIR PREPARATION PROCESS
FR7814250A FR2384765B1 (en) 1976-08-04 1978-05-12 AMINO-SUBSTITUTED DERIVATIVES OF FURANNE AND PROCESS FOR THEIR PREPARATION
ES470836A ES470836A1 (en) 1976-08-04 1978-06-15 A procedure for the preparation of aminoalquilfurans (Machine-translation by Google Translate, not legally binding)
US05/951,025 US4279819A (en) 1976-08-04 1978-10-13 Aminoalkyl furan derivatives
US05/951,024 US4169855A (en) 1976-08-04 1978-10-13 N'-derivatives of n-(2-mercapto-ethyl)-2-nitro-1,1-ethenediamine
US05/951,026 US4255440A (en) 1976-08-04 1978-10-13 Furan derivatives having selective action on histamine receptors
JP3601580A JPS55153761A (en) 1976-08-04 1980-03-21 Thiols
JP3601680A JPS55153779A (en) 1976-08-04 1980-03-21 Novel amines
AT0322880A AT381937B (en) 1976-08-04 1980-06-18 METHOD FOR PRODUCING NEW AMINOALKYLFURANE DERIVATIVES AND THEIR TAUTOMERIC, DIASTEREOISOMERIC OR. OPTICAL ENANTIOMERS
KE3080A KE3080A (en) 1976-08-04 1980-08-30 Aminoalkyl furan derivatives
HK557/80A HK55780A (en) 1976-08-04 1980-10-02 Aminoalkyl furan derivatives
MY172/81A MY8100172A (en) 1976-08-04 1981-12-30 Aminoalkyl furan derivatives
FI821570A FI80687C (en) 1976-08-04 1982-05-05 2 - /// 5- (Dimethylamino) methyl-2-furanyl / methyl / thio / ethanamine
NLAANVRAGE8202659,A NL184219C (en) 1976-08-04 1982-07-01 METHOD FOR PREPARING AN INHIBITORY MEDICINAL PRODUCT ON HISTAMINE HŸ2 RECEPTORS STIMULATED STORAGE OF STOMATIC ACID; THERAPEUTIC ARTICLE AND METHOD FOR PREPARING MEDICINAL COMPOUNDS WITH THE SAID EFFECT.
CH509282A CH641176A5 (en) 1976-08-04 1982-08-27 Process for preparing aminoalkylfuran derivatives
YU2000/82A YU40088B (en) 1976-08-04 1982-09-03 Process for obtaining a new aminoalkyl furane derivative
DK427282A DK149813C (en) 1976-08-04 1982-09-24 AMINOALKYL REFERENCE DERIVATIVES USED AS INTERMEDIATES IN THE PREPARATION OF OTHER AMINOALKYL REFERENCE DERIVATIVES
DK427182A DK149812C (en) 1976-08-04 1982-09-24 ANALOGY PROCEDURE FOR THE PREPARATION OF AMINOAL COOLING RANGE DERIVATIVES
SE8205533A SE454882B (en) 1976-08-04 1982-09-28 PROCEDURE FOR THE PREPARATION OF AMINOAL COOLING RANGE DERIVATIVES WITH THERAPEUTIC EFFECT
SE8205962A SE8205962L (en) 1977-05-13 1982-10-20 Multilayer coating for metal-cutting tool - has alternate layers of Gp=IV metal carbide or nitride and Gp=VI metal nitride, carbide, boride or silicide
SE8206061A SE8206061D0 (en) 1977-05-13 1982-10-26 APPARATUS AND SET FOR PRODUCING GLASS FIBERS
SE8206556A SE454883B (en) 1976-08-04 1982-11-17 AMINOALKYL REFERENCE DERIVATIVES FOR USING INTERMEDIATES IN THE PREPARATION OF AMINOALKYL REFERENCE DERIVATIVES WITH THERAPEUTIC EFFECT
DK416384A DK149952C (en) 1976-08-04 1984-08-30 ANALOGY PROCEDURE FOR THE PREPARATION OF AN AMINOAL COOLING RANGE
IT48437/85A IT1221058B (en) 1976-08-04 1985-08-01 AMINE COMPOUNDS AS INTERMEDIATES IN THE PRODUCTION OF SELECTIVE AGENTS ON HISTAMINE RECEPTORS AND PROCEDURES FOR THE PRODUCTION OF THESE AMINE COMPOUNDS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2018777 1977-05-13
KR7701808A KR810000355B1 (en) 1977-05-13 1977-08-04 Preparation for pharmacologically active compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019810000272A Division KR810000356B1 (en) 1981-01-29 1981-01-29 Preparation for pharmacologically active compounds

Publications (1)

Publication Number Publication Date
KR810000355B1 true KR810000355B1 (en) 1981-04-22

Family

ID=26254517

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7701808A KR810000355B1 (en) 1976-08-04 1977-08-04 Preparation for pharmacologically active compounds

Country Status (2)

Country Link
KR (1) KR810000355B1 (en)
SE (1) SE8206061D0 (en)

Also Published As

Publication number Publication date
SE8206061L (en) 1982-10-26
SE8206061D0 (en) 1982-10-26

Similar Documents

Publication Publication Date Title
US4128658A (en) Aminoalkyl furan derivatives
SU1400508A3 (en) Method of producing derivatives of arylthiazole
US4239769A (en) Pharmacologically active compounds
US4098898A (en) Imidazolyl alkylguanidine compounds
JPH0220639B2 (en)
IE53274B1 (en) Chemical compounds derived from cyclobutene
NO170883B (en) PROCEDURE FOR PREPARING 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE DERIVATIVES
NZ190623A (en) Substituted 2-aminothiazoles and pharmaceutical compositions containing them
US4465841A (en) Imidazolylphenyl amidines
WO1999062892A1 (en) Aminoazole compounds
HU179492B (en) Process for producing 1,2,4-thiadiasole derivatives
SE447731B (en) SPIRO-POLYCYCLIC IMIDAZOLIDE INDION DERIVATIVES
EP0549796A1 (en) Diphenylpiperazine derivative and drug for circulatory organ containing the same
US4522943A (en) Chemical compounds
US4169855A (en) N'-derivatives of n-(2-mercapto-ethyl)-2-nitro-1,1-ethenediamine
KR810000355B1 (en) Preparation for pharmacologically active compounds
KR810000356B1 (en) Preparation for pharmacologically active compounds
CA2787860A1 (en) Substituted 2-imidazolidones and analogs and their use against cancer
US4503051A (en) Substituted 3-cyclobutene-1,2-diones, pharmaceutical compositions thereof and methods of use
US5021429A (en) Pharmacologically active aminoalkylphenyl compounds and their use
SE454882B (en) PROCEDURE FOR THE PREPARATION OF AMINOAL COOLING RANGE DERIVATIVES WITH THERAPEUTIC EFFECT
US4772704A (en) 2,5-disubstituted-4(3H)-pyrimidones having histamine H2 -receptor antagonist activity
CS241141B2 (en) Method of ethendiamine and guanidine derivatives production
US4546188A (en) Substituted 1,2-diaminocyclobutene-3,4-diones
JPS6058236B2 (en) Novel aminoalkylfuran derivatives, methods for their production and pharmaceutical compositions containing them